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Development of non-invasive methods for obtaining intact fetal cells would allow 
accurate prenatal diagnosis for aneuploidy and single gene disorders without the 
attendant risks associated with amniocentesis, chorion villus biopsy and fetal blood 
sampling.  Currently available methods are limited by the very low number of fetal 
cells enriched from maternal blood, which could be due to fetal cell loss during the 
density gradient centrifugation.  
 
This thesis investigates differentially expressed cell membrane proteins of first 
trimester fetal nucleated red blood cells (FNRBCs) and adult anucleate red blood 
cells (AARBCs).  Unique membrane proteins would be potential antigens for the 
development of monoclonal antibodies to separate FNRBCs from AARBCs. 
 
 Surface-enhanced laser desorption/ionization-time of flight mass spectrometry 
(SELDI-TOF-MS) was first used to screen the unique membrane proteins on 
FNRBCs.  Three unique membrane protein peaks were detected using immobilized 
metal affinity capture (IMAC) chips pre-treated with iron.  Subsequent analysis 
however revealed that these proteins were unsuitable candidates due to their 
intracellular localisation. 
 
Sodium dodecylsulphate polyacrylamide-gel electrophoresis (SDS-PAGE) and 
matrix-assisted laser desorption/ionization–time of flight/time of flight (MALDI-
TOF/TOF) tandem mass spectrometry were used to identify and characterise the 
different membrane proteins.  These data showed that spectrin (alpha and beta 
 viii
chain), actin (beta and gamma), and ankyrin were membrane proteins common to 
both FNRBCs and AARBCs.  N-ethylmaleimide-sensitive factor attachment protein 
alpha was unique to FNRBCs.  Erythrocyte membrane protein band 3, bands 4.1, 4.2, 
p55, flotillin 1 and 2, tropomodulin 1, aldolase A, glyceraldehydes-3-phosphate 
dehydrogenase and band 7.2 were membrane proteins unique to AARBCs.  Several 
putative membrane proteins (derived from functional domains) were also identified to 
be unique to FNRBCs and to AARBCs.  Of all the identified membrane proteins 
unique to FNRBCs or AARBCs, none of the unique FNRBC membrane proteins 
contained extracellular domains.  Interestingly, the unique AARBC membrane 
protein—band 3—contained extracellular domains.  If further experiments such as 
western blot could confirm that band 3 is absent in FNRBC membranes, monoclonal 
antibodies to band 3 extracellular domains could potentially be used to separate 
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Chapter 1: Introduction 
1.1 Overview 
Without prenatal diagnosis, 1 in 50 babies are born with serious physical or 
mental handicap, and as many as 1 in 30 with some form of congenital 
malformation (Harper, 1998).  These may be due to structural or chromosomal 
abnormalities, or single gene disorders.  The diagnosis of aneuploidy and 
monogenic disorders requires invasive testing by amniocentesis, chorion villus 
biopsy or fetal blood sampling.  These tests carry a procedure-related risk of 
miscarriage of 1-4% (Tabor et al., 1986; Canadian Collaborative CVS-
Amniocentesis Clinical Trial Group, 1989; Rhoads et al., 1989; MRC Working 
Party, 1991; Buscaglia et al., 1996; Wald et al., 1998).   
 
In contrast to monogenic conditions which are largely confined to certain ethnic 
groups or clustered within families, over 90% of the structural or chromosomal 
abnormalities arise in pregnancies with no specific risk factors.  Thus, while 
prenatal diagnosis for single gene disorders is concentrated on at-risk 
populations, low-risk populations are offered universal screening for structural 
anomalies and aneuploidy.  Whereas second trimester screening for structural 
malformations by ultrasonography may at the same time be diagnostic, current 
prenatal screening for chromosomal abnormalities using biochemical and 
sonographic markers for aneuploidy is more an antenatal risk-estimation exercise 
(Chitty, 1998).   
 
The diagnosis of aneuploidy and single gene disorders depends upon recovery of 
fetal cells and fetal DNA (deoxyribonucleic acid), but the hazard of fetal loss 
associated with current invasive methods limits the uptake of these procedures 
by women identified at increased risk by screening tests (Chitty, 1998).  
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Observations that cell-free fetal DNA and intact fetal cells can enter and circulate 
within maternal blood have raised the possibility of non-invasive access to fetal 
genetic material that would allow the prenatal diagnosis of chromosomal and 
monogenic disorders (Lo et al., 1990; Walknowska et al., 1969).   
 
Use of circulating fetal DNA for genetic diagnosis has progressed from an idea to 
clinical application in a very short time (Lo et al., 1998a) mainly because of the 
significant quantity of fetal DNA within maternal plasma and serum (Lo et al., 
1998b) compared with the rarity of intact fetal cells within maternal blood (Bianchi 
et al., 1997).  However, the usefulness of fetal DNA in prenatal genetic diagnosis 
is limited to a few paternally-inherited monogenic conditions whereas recovery of 
intact fetal cells would allow accurate genetic diagnoses of all aneuploidies and 
single gene disorders.   
 
Clinical application has been limited by the lack of a fetal-cell specific marker, and 
by the very low frequency of fetal cells circulating within maternal blood (Hamada 
et al., 1993; Bianchi et al., 1997).  Fetal nucleated red blood cells are the 
favoured target cells at present because they are the predominant nucleated cell 
type in the first and early second trimester of pregnancy, they are mononuclear 
and suitable for chromosomal fluorescence in situ hybridisation (cFISH), their 
limited lifespan makes them unlikely to persist across pregnancies (Pearson, 
1967) and unlike trophoblasts, which demonstrate confined placental mosaicism 
in 1% of cases (Hahnemann & Vejerslev, 1997), these cells reveal the 
representative fetal genotype.  Recent evidence suggests that ε-globin is the 
ideal fetal cell marker for non-invasive prenatal diagnosis using fetal cells derived 
from maternal blood (Choolani et al., 2001; Choolani et al., 2003; Ho et al., 2003; 
Mavrou et al., 2003).   
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Enriching these rare fetal cells has proved the greater challenge: there are only 1 
fetal nucleated cell per 107 maternal nucleated cells (Bianchi et al., 1997), and 
five hundred-fold less if compared with maternal anucleate red blood cells.  
Current enrichment protocols incorporate a magnetically-activated cell sorting 
(MACS) or fluorescence activated cell sorting (FACS) step to deplete or select 
target cell groups.  In either case, density gradient centrifugation is used as the 
first step to deplete maternal anucleate red blood cells.  It has been shown that 
almost 70% of target fetal erythroblasts settle in the pellet after density gradient 
centrifugation (Choolani et al., 2003).  This proportion of fetal cell loss is 
unacceptable when the target cell type is so rare in the first place; this level of 
loss at the very first enrichment step would jeopardise any potential clinical 
application of non-invasive prenatal diagnosis using fetal erythroblasts enriched 
from maternal blood.   
 
Fetal primitive erythroblasts (target fetal nucleated red blood cell type) are a 
poorly studied cell type due to the limited access to these cells, which circulate 
only in the first trimester of human pregnancy.  There is no information in the 
literature on the membrane proteins of fetal nucleated red blood cells (FNRBCs) 
that could help identify unique surface antigens differentially present on adult 
anucleate red blood cells (AARBCs), or other adult blood cell types.  
Immunocytochemistry of known red blood cell surface antigens reveal no 
difference between fetal primitive erythroblasts and adult anucleate red blood 
cells (Choolani et al., 2003; unpublished data, Rare Event Detection Group, 
NUS).   
 
Recent developments in novel proteomics strategies (Mann et al., 2001; Wu & 
Yates III, 2003; Seibert et al., 2004) allow the examination of whole membrane 
proteomes (Low et al., 2002), such that the membrane proteins of FNRBCs and 
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AARBCs could be compared to identify any unique differences. Using matrix 
assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF/MS), Low et al., (2002) demonstrated that it is now possible to generate 
detailed information on the membrane proteins of AARBCs.  In this thesis, I 
explore the possibility of using a proteomics strategy to identify membrane 
proteins differentially expressed on adult anucleate erythrocytes and fetal 
primitive erythroblasts.   
 
1.2 Current methods of fetal genetic screening and prenatal 
diagnosis  
Identification of fetuses that are structurally, chromosomally or genetically 
abnormal involves non-invasive screening, and diagnostic confirmation.  
Screening tests are designed to be non-invasive, safe, sensitive and applicable to 
a low-risk population; many prenatal screening tests however may have high 
false-positive rates.  In contrast, diagnostic tests are accurate but may be 
invasive.   
 
Structural malformations can be diagnosed non-invasively using ultrasonography.  
Since most structural abnormalities occur in the low-risk population, routine 
screening scans are offered to all pregnant women in the Singapore between 18-
22 weeks. 
 
Currently, the diagnosis of monogenic and chromosomal disorders requires 
invasive testing by amniocentesis, chorion villus biopsy or fetal blood sampling.  
These tests carry a small but definite risk of procedure-related fetal loss.  As 
such, non-invasive screening tests have been devised to identify a ‘high-risk’ 
population for targeted diagnostic invasive testing.  My work focuses on one facet 
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of the development of a non-invasive technology aimed at replacing invasive 
testing, the discussion below concentrates on chromosomal and monogenic 
disorders. 
 
1.2.1 Screening for chromosomal disorders 
Trisomy 21 (Down syndrome), which affects 1.3/1000 livebirths (Cuckle et al., 
1991), is the commonest aneuploidy that carries a significant risk of long-term 
morbidity and mental handicap.  Trisomies 13 and 18 are usually lethal in utero or 
within the first year of life.  Sex chromosome anomalies and structural re-
arrangements are less frequent and as a group less likely to cause severe mental 
deficit.  Thus, most antenatal screening programmes have been designed to 
detect Down syndrome.   
 
The incidence of Down syndrome increases with advancing maternal age but 
age-based screening detects only about 30% of pregnancies with Down 
syndrome (Chitty, 1998; Wald et al., 1998) because more than 70% of affected 
neonates are born to mothers under 35 years of age, usually classified as ‘low-
risk’.  The sensitivity of detection of Down syndrome has been improved by the 
development of biochemical and nuchal translucency (NT) screening.  
Information from these tests is analysed together with the maternal age to 
determine the woman’s individual risk of having a baby with Down syndrome.  It 
is known that, if available, about 80% of pregnant women would choose to have a 
screening test for Down syndrome and 90% of those with affected fetuses would 
terminate the pregnancy (Wald et al., 1998).   
 
Biochemical screening in the second trimester includes hormonal markers such 
as α-fetoprotein (AFP), unconjugated oestriol (uE3), free β-subunit of human 
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chorionic gonadotropin (β-hCG) and dimeric inhibin-A.  At a false-positive rate of 
5%, second trimester screening has a detection rate of 58-75% (Wald et al., 
1998).  Recently, two biochemical markers, free β-hCG and pregnancy 
associated plasma protein A (PAPP−A), have also been introduced for use in the 
first trimester (10-14 weeks) (Wald et al., 1998).  Szabo & Gellen (1990) reported 
the ultrasound observation of an increased nuchal fold thickness in first trimester 
fetuses with Down syndrome.  Extrapolation of the results obtained by Snijders et 
al. (1998) demonstrated that at a false-positive rate of 5%, NT screening detected 
77% of fetuses with Down syndrome.  Since first and second trimester serum 
screening and nuchal translucency assessment are independent measures of the 
risk of a Down syndrome pregnancy, adjusting the a priori risk of maternal age, 
recent efforts have attempted to combine first and second trimester serum 
screening into the “Integrated Test” (Wald et al., 1999) and to perform first 
trimester serum screening at the same time as a nuchal translucency scan as 
part of a single assessment (Brizot et al., 1995; Spencer et al., 1999; Spencer et 
al., 2000).  The “Combined Test” of NT together with first trimester serum 
screening is rapidly becoming the Gold Standard antenatal screening test for 
Down syndrome.  Non-invasive prenatal diagnosis using fetal cells derived from 
maternal blood ideally should also be performed in the first trimester to 
complement this prenatal screening strategy. 
 
1.2.2 Screening for genetic diseases 
Missed or late diagnoses make estimations of the incidence of genetic disease at 
birth less accurate, but it has been suggested that it may be as high as 1.7% 
(Polani, 1973).  Of the many thousand genetic diseases described to date (Online 
Mendelian Inheritance in Man, OMIM, www.ncbi.nlm.nih.gov/Omim/), only a few 
warrant more than a family history as a method of prenatal screening and most 
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are autosomal recessive conditions.  These include cystic fibrosis amongst 
Caucasians, Canavan and Tay-Sachs diseases within the Ashkenazi (and 
American) Jewish population, Sickle cell disease in individuals of African descent 
and the thalassaemias in Mediterranean, Middle East and Asian people.  In 
Singapore, both α- and β-thalassaemia are important monogenic disorders that 
warrant invasive prenatal diagnosis. 
 
1.2.3 Diagnosis of chromosomal and genetic disorders 
In contrast to screening tests, diagnostic tests for these conditions require 
invasive testing by amniocentesis, chorion villus sampling (CVS) or fetal blood or 
tissue sampling.  The method used depends upon: the gestational age, the 
condition being investigated, tests already performed, the expertise available, the 
risks of the procedure and parental preference.  Evidence suggests that if the 
risks of amniocentesis and CVS were equal, women would prefer earlier testing 
(Lippmann et al., 1985; McGovern et al., 1986; Abramsky & Rodeck, 1991).  This 
attitude is consistent with their preference for first trimester prenatal diagnosis 
and the rising popularity of nuchal translucency assessment over second 
trimester serum screening.   
 
1.2.3.1 Invasive procedures for diagnosis of chromosomal and genetic disorders  
Amniocentesis. This procedure is usually performed between 15-17 weeks.  
Under continuous ultrasound guidance, a 22-gauge needle is introduced into the 
amniotic cavity through an aseptically prepared area on the maternal abdomen 
and an amniotic fluid sample withdrawn.   
 
Chorion Villus Sampling. Chorion villus sampling is usually performed in one of 
two approaches between 10-13 weeks.  The older transcervical approach has 
been replaced by the more current transabdominal CVS, which is similar to 
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amniocentesis in that a needle is inserted through the maternal abdomen into the 
long axis of the placenta.  Unlike amniocentesis however, trophoblast tissue 
rather than amniotic fluid is drawn for karyotype analysis. 
 
Fetal Blood Sampling. Samples of fetal blood can be obtained by inserting a 22-
gauge needle, under continuous ultrasound guidance, through an aseptically 
prepared area of the maternal abdomen into the umbilical or fetal intrahepatic 
vein.  The umbilical vein is usually accessed at the placental insertion site where 
it is least mobile.  The procedure is usually performed after 20 weeks. 
 
Currently, all invasive procedures are performed under continuous ultrasound 
visualisation of the needle tip.  Despite this, there is a procedure-related risk of 
miscarriage of 1-4% (Tabor et al., 1986; Canadian Collaborative CVS-
Amniocentesis Clinical Trial Group, 1989; Rhoads et al., 1989; MRC Working 
Party, 1991; Buscaglia et al., 1996; Wald et al., 1998).  As many as 1 in 2 
couples decline invasive testing because of its attendant risks (Kocun et al., 
2000); amongst those that undergo testing, the risk of fetal loss causes weeks of 
anxiety and worse, sadness and guilt when it does occur.  Thus, the Holy Grail of 
prenatal diagnosis is non-invasive testing for chromosomal and monogenic 
disorders.   
 
1.2.4 Preference for non-invasive and early prenatal diagnosis 
Most pregnant women accept routine ultrasound screening for structural 
malformations (99.5%; Bricker et al., 2000) whereas about 20% of pregnant 
women decline Down syndrome screening and another 20% of screen-positive 
mothers decline invasive diagnostic testing (Wald et al., 1998), suggesting that 
women prefer non-invasive diagnostic tests.  There is less information available 
on women’s preferences regards the timing of prenatal diagnosis but there is 
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some evidence that they want testing as early in pregnancy as possible (Mulvey 
& Wallace, 2000).  Despite criticisms that a significant proportion of Down 
syndrome fetuses will miscarry beyond the first trimester, nuchal translucency 
screening is gaining popularity over second trimester biochemical tests because 
it can be performed at an earlier gestational age.  Furthermore, if invasive tests 
were indicated, screening in the first trimester would allow parents to choose 
immediate testing by CVS, offer them greater privacy at the time of the diagnosis 
and give them more time to make decisions about further testing or termination of 
the pregnancy.  The ideal screening test for aneuploidy and monogenic diseases 
should be non-invasive, diagnostic and performed in the first trimester.  Diagnosis 
of aneuploidy and single gene disorders requires access to fetal chromosomes 
and DNA.  Fetal cells are known to cross the placenta into the maternal 
circulation (Walknowska et al., 1969).  Isolation of these cells from maternal 
blood would allow the non-invasive prenatal screening and diagnosis of 
chromosomal and monogenic disorders (Bianchi, 1999; Adinolfi & Sherlock, 
2001).   
 
1.3 Non-invasive prenatal diagnosis of chromosomal and 
single gene disorders  
Diagnosis of fetal chromosomal and monogenic diseases requires access to fetal 
cells and/or fetal DNA.  Demonstration that fetal cells (Walknowska et al., 1969) 
and fetal DNA (Lo et al., 1990) can be obtained from maternal blood, and that 
chorionic cells that shed into the maternal cervix can also be retrieved (Shettles, 
1971), has raised the possibility of obtaining fetal genetic material for prenatal 
diagnosis without the need for invasive testing.  
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1.3.1 Transcervical sampling of fetal cells 
Fetal cells that pass into the maternal endocervical canal have been investigated 
as a source of genetic material for non-invasive prenatal diagnosis (Griffith-Jones 
et al., 1992; Adinolfi & Sherlock, 2001).  Poor recovery of fetal cells (Overton et 
al., 1996), contamination by foreign genetic material (Daryani et al., 1997), and 
considerable variation in the composition and quality of recovered material (Miller 
et al., 1999) limit its applicability for non-invasive prenatal diagnosis.   
 
1.3.2 Fetal DNA in maternal blood 
There is relatively much more cell-free fetal DNA in maternal blood than intact 
fetal cells (Lo et al., 1998b), but the usefulness of cell-free fetal DNA is limited to 
paternally-inherited fetal conditions for which the mother is not a carrier.  
Amplification of Y-chromosome sequences in pregnant women carrying male 
fetuses demonstrated the potential of circulating cell-free fetal DNA for non-
invasive prenatal diagnosis (Lo et al., 1997).  The relatively high fetal DNA in 
maternal plasma and serum has permitted the non-invasive prenatal diagnosis of 
several conditions, including fetal Rhesus (Rh) D status (Lo et al., 1998a), 
myotonic dystrophy (Amicucci et al., 2000), achondroplasia (Saito et al., 2000) 
and chromosomal translocations (Chen et al., 2001).  Studies by several groups 
showed that prenatal diagnosis of fetal RhD status using fetal DNA at the 
beginning of second trimester is possible (Lo et al., 1998a; Faas et al., 1998; 
Bischoff et al., 1999; Zhong et al., 2000) and its high accuracy detection has lead 
into the clinical application.  The main limitation in all these examples is that the 
fetal genes or mutations detected were paternally inherited and genetically 
different from corresponding sequences in the mother.  This precludes the use of 
this technology for the prenatal diagnosis of fetal aneuploidy, by far the 
commonest reason for invasive fetal testing.   
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1.3.3 Fetal cells in maternal blood 
In 1893, Schmorl identified trophoblast sprouts in the lungs of a woman who died 
of eclampsia (Schmorl, 1893).  Although similar observations have been 
confirmed (Attwood & Park, 1961), the definitive proof that fetal cells circulate in 
maternal blood only came when lymphocytes bearing the Y-chromosome were 
detected in the peripheral blood of mothers carrying male fetuses (Walknowska 
et al., 1969).  Herzenberg and his co-workers subsequently used FACS to detect 
and isolate fetal cells in the late 1970s and early 1980s (Herzenberg et al., 1979; 
Iverson et al., 1981).  Convincing evidence of the existence of fetal cells in 
maternal blood finally came in 1990 with application of molecular methods to 
detect unique amplified fetal DNA sequences from cellular components of the 
blood of pregnant women (Bianchi et al., 1990; Lo et al., 1989, 1990; 
Camaschella et al., 1990).  Currently, research in this area focuses not on 
whether these cells are present in maternal blood but instead aims to understand 
their biological role and effect in the mother and how to isolate and use these for 
non-invasive prenatal diagnosis.   
 
1.3.3.1 Prevalence of fetal cells in maternal blood 
Our best estimate suggests there are 1.2 fetal cells/ ml of maternal blood (Bianchi 
et al., 1997), but in fact the true prevalence of fetal cells in maternal blood 
remains unknown.  Earlier evaluations of the prevalence of fetal cells in maternal 
blood using methods such as polymerase chain reaction (PCR) and cFISH 
suggested these cells were much rarer; the approximates ranged between 10−4 
(Hamada et al., 1993) to 10−8 (Price et al., 1991).  It is difficult to reconcile these 
differences in the observed frequencies of fetal cells in maternal blood.  It is likely 
that the true frequency of fetal cells in maternal blood will be calculable only after 
all the problems of enrichment, identification and diagnosis have been resolved.  
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1.3.3.2 Candidate target cells for non-invasive prenatal diagnosis 
Trophoblasts.  The first fetal cell type documented to cross into the maternal 
circulation (Schmorl, 1893), trophoblasts are theoretically the most attractive 
candidates for fetal cell isolation.  Their intimate contact with maternal blood and 
the continuous remodelling occurring at the junction between fetal and maternal 
tissues, especially in the first trimester, is likely to result in the shedding of large 
numbers of trophoblast cells into the maternal circulation (Gänshirt et al., 1995).  
Trophoblasts are terminally differentiated and syncytiotrophoblast cells have a 
unique morphology readily recognised microscopically.  However, even if it 
trophoblast-specific monoclonal antibodies could be developed for their 
enrichment, their use for non-invasive prenatal diagnosis presents several 
difficulties:  
(a) trophoblast deportation into the maternal circulation does not appear to be a 
phenomenon common to all pregnancies (Sargent et al., 1994), 
(b) when it does occur, the cells are rapidly cleared by the pulmonary circulation 
(Attwood & Park, 1960), 
(c) their extraembryonic origin as part of the placenta implies that trophoblast 
cells are likely to exhibit confined chromosomal mosaicism in 1% of cases 
sampled (Hahnemann & Vejerslev, 1997), and 
(d) syncytiotrophoblast cells, which are multinucleate, do not give accurate 
results when chromosomes are analysed by cFISH.   
 
Leukocytes.  The first conclusive evidence that fetal cells circulate in maternal 
peripheral blood was provided by Walknowska et al. (1969) who demonstrated 
the presence of a Y chromosome in mitogen-stimulated lymphocytes obtained 
from the venous blood of pregnant women bearing male fetuses.  Ten years later, 
Herzenberg et al. (1979) enriched fetal lymphocytes from maternal blood by 
fluorescence activated cell sorting.  Studies of fetal white cells in the maternal 
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circulation have been limited by the lack of monoclonal antibodies directed 
against unique fetal leukocyte antigens.  One of the earlier attractions of fetal 
leukocytes was their ability to proliferate in vitro.  It is interesting that this 
propensity for fetal white blood cells to proliferate is now regarded as a 
disadvantage (since it is thought that they can proliferate in vivo and persist in 
maternal blood and organs), and has limited the development of this cell type for 
use in non-invasive prenatal diagnosis.  Schröder et al. (1974) and Ciaranfi et al. 
(1977) demonstrated that fetal leukocytes could persist in the maternal blood for 
up to one and seven years, respectively.  Bianchi et al. (1996) extended those 
findings by documenting not only haemopoietic stem cells and lymphoid/myeloid 
progenitors (CD34 and/or CD38 positive) but also fetal T lymphocytes (CD3 
positive) that had persisted for six years in one woman.  There is concern that 
enriched leukocytes may be the vestiges of previous pregnancies and not 
represent fetal genetic status in the current pregnancy.  Thus, the cell type 
chosen for non-invasive prenatal diagnosis should have unique cell surface 
markers to facilitate enrichment in all pregnancies, be short lived within the 
mother, and have no or only limited capacity to proliferate in vivo.   
 
Erythroblasts.  The search for a fetal cell target that has a limited life span 
(Pearson, 1967) and can be distinguished morphologically from its counterparts 
in maternal blood, led to the selection of the fetal nucleated erythrocyte (NRBC; 
erythroblast).  Other advantages of this cell type that have made it the target cell 
of choice for most investigators include the following: they are consistently 
present in maternal blood during pregnancy (Parano et al., 2001), they carry a 
representative complement of fetal genes, are short-lived, and have limited 
proliferative capacity making them unlikely to persist across pregnancies.  
Furthermore, NRBCs are the abundant fetal cell type in first and early second 
trimester fetal blood (Thomas & Yoffey, 1962), are mononucleated (Kelemen et 
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al., 1979) and carry developmentally-specific markers such as fetal and 
embryonic haemoglobins (Choolani et al., 2001; Choolani et al., 2003; Ho et al., 
2003).   
 
However, there are two caveats: 
(1) It was hoped that the availability of antibodies such as CD71 and CD36 
that target immature erythroid cells would enrich these rare fetal 
erythroblasts from maternal blood (Bianchi et al., 1990), but in fact the 
majority of NRBCs enriched were maternal in origin (Slunga-Tallberg et 
al., 1995).   
(2) Use of fetal erythroblasts derived from maternal blood for non-invasive 
prenatal diagnosis involves three steps: enrichment, fetal cell 
identification, and genetic diagnosis.  Downstream processing of fetal cell 
identification and genetic diagnosis (second and third steps) can now be 
performed satisfactorily (Choolani et al., 2001), but there is a need to 
identify surface antigens that are differentially expressed on target fetal 
NRBCs (Choolani et al., 2003).  Either the presence, or absence, of 
specific surface antigens is needed to allow the development of an 
enrichment strategy that could isolate these rare fetal erythroblasts.   
 
1.3.4 Clinical trials of non-invasive prenatal diagnosis and the place of fetal cells 
derived from maternal blood 
Results of the only clinical trial evaluating the accuracy of prenatal diagnosis 
using fetal cells in maternal blood have recently been published (Bianchi et al., 
2002).  The NIFTY (National Institutes of Health Fetal Cell Study) trial is a phase 
II non-intervention clinical investigation funded by the National Institute of Child 
Health and Human Development that began in 1994.  The study found that the 
detection rate of finding at least one aneuploidy cell in cases of fetal aneuploidy 
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was 74.4% (95% CI: 76.0%, 99.0%), with a false-positive rate estimated to be 
between 0.6% and 4.1%.  
 
Another larger trial is currently underway at the Columbia University Health 
Sciences, New York.  The FASTER trial (First And Second Trimester Evaluation 
of Risk for aneuploidy) is an open-label, non-randomised, interventional study 
involving 11 centres, that aims to recruit 62,000 pregnant women and evaluate 
the efficacy of first and second trimester non-invasive screening methods for 
Down syndrome and other aneuploidies (http://clinicaltrials.info.nih.gov/).  The 
screening modalities under investigation include maternal age, fetal NT 
measurement, and first and second trimester serum screening.  Screen-positive 
patients (risk ≥1 in 380) are offered amniocentesis at 15 weeks.  Those that 
accept invasive testing will have a tube of maternal blood taken for the 
enrichment and analysis of fetal NRBCs.   
 
The current view is that fetal cells derived from maternal blood could be used as 
a screening tool, alone or (more likely) in combination with other modalities such 
as biochemical tests and nuchal translucency scans.  The low sensitivity for 
aneuploidy detection in the NIFTY trial supports this hypothesis.  However, two 
changes in the current state of the art would allow enriched fetal cells to be used 
for screening and, more importantly, diagnosis. These include specific 
identification of the fetal origin of target cells, and the effective and reliable 
enrichment of fetal erythroblasts from first trimester maternal blood.  The former 





1.4 Enrichment of fetal erythroblasts from maternal blood 
1.4.1 State of the art 
Fetal cells are rare in maternal blood: a variety of strategies have been attempted 
to enrich them from maternal blood.  These include density gradient 
centrifugation (Oosterwijk et al., 1996; Sitar et al., 1997; Sekizawa et al., 1999), 
MACS (Ganshirt-Ahlert et al., 1992, 1993; Busch et al., 1994), FACS 
(Herzenberg et al., 1979; Iverson et al., 1981; Bianchi et al., 1990; Price et al., 
1991; Wachtel et al., 1991; Tse et al., 1994; Lewis et al., 1996; Sohda et al., 
1997), immunomagnetic bead separation (Bianchi et al., 1996; Wessman et al., 
1992), ferrofluid suspension with magnet (Steele et al., 1996; Martin et al., 1997), 
avidin-conjugated columns with biotinylated antibodies (Hall et al., 1994), 
micromanipulation of individual cells (Takabayashi et al., 1995, Sekizawa et al., 
1996a,b, 1998; Watanabe et al., 1998), selective lysis of maternal AARBCs using 
ammonium chloride (Boyer et al., 1976; De Graaf et al., 1999; Voullaire et al., 
2001; Choolani et al., 2003), carbonic anhydrase inhibition (Saunders et al., 
1997), and charged flow separation (Wachtel et al., 1996, 1998).  That so many 
strategies have been attempted over the past quarter century suggests that none 
is as yet successful. 
 
The most commonly followed enrichment procedure includes density gradient 
centrifugation followed by MACS or FACS.  In either case, surface specific 
monoclonal antibodies (MAb) are used to sort out the cells of interest.  In MACS, 
positive selection of FNRBCs are carried out using magnetic beads conjugated 
with monoclonal antibodies such as transferrin receptor (CD71), the 
thrombospondin receptor (CD36), and glycophorin A (GPA) (Bianchi et al.1990, 
1994; Troeger et al., 1999; Choolani et al., 2003).  A negative selection strategy 
would comprise depletion of CD45-positive mononuclear cells (Mavrou et al., 
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1998; Hromadnikova et al., 2002; Choolani et al., 2003).  FACS utilises 
fluorescence tagged antibodies to separate the cells of interest (Ma et al., 1996; 
Sitar et al., 1999; Sekizawa et al., 1999), but the positive and negative selection 
strategies remain the same.   
 
The National Institute of Child Health and Human Development (NICHD) Fetal 
Cell Isolation Study revealed that target cell recovery and fetal cell detection were 
better using MACS than with FACS (Bianchi et al., 2002).  Lack of target cells for 
further FISH analysis was more problematic for centres using FACS (49% of 
cases) than centres using MACS (2% of cases). Significantly, more nuclei with Y 
signals or X and Y signals (when fetus was male) were detected among cases 
sorted by MACS as compared to FACS. 
 
Whichever immunoseparation strategy is used, MACS or FACS, the first step 
involves maternal anucleate red blood cell depletion by density gradient 
centrifugation.  The commonly used density mediums are Ficoll (Oosterwijk et al., 
1998; Sitar et al., 1999; Martel-Petit et al., 2001) and Percoll (Sekizawa et al., 
1999; Smits et al., 2000; Choolani et al., 2003).  Unfortunately, a majority of the 
rare FNRBCs have been shown to pellet down along with anucleate erythrocytes 
during density gradient centrifugation (68.3% with Ficoll 1119) (Choolani et al., 
2003).  This loss is unacceptable when the cells of interest are so rare to begin 
with; losing half the number of target cells at the very first enrichment step is a 
major obstacle to the clinical application of non-invasive prenatal diagnosis using 
fetal erythroblasts derived from maternal blood.   
 
1.4.2 Replacing density gradient centrifugation with an immunosorting strategy 
Three parameters influence the detection of rare events: the frequency of the 
event of interest, the signal-to-noise ratio and the nature of the difference 
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between signal and noise i.e. qualitative or quantitative.  Little can be done to 
alter the frequency of fetal erythroblasts in maternal blood so strategies to 
recover them must focus on enhancing the signal or on diminishing the 
background noise.  Density gradient centrifugation diminishes the background 
maternal AARBC noise.  The trouble is that it also leads to the loss of a 
significant proportion of the very few target rare fetal erythroblasts.  Post-density 
gradient centrifugation processing by MACS/FACS can remain the same, but a 
strategy needs to be developed that separates FNRBCs from maternal AARBCs 
without the use of density gradient centrifugation.  If an antigen were found that 
was differentially expressed on FNRBCs, but not on AARBCs, a positive 
selection strategy could be developed to isolate these FNRBCs.  Ideally however, 
finding a red blood cell antigen present on maternal AARBCs, but absent on 
FNRBCs, would allow immunosorting with MACS to selectively deplete the 
unwanted maternal anucleate erythrocytes.   
 
To date, no surface antigen unique to FNRBCs, in particular to first trimester 
primitive erythroblasts, are known (Choolani et al., 2003).  I hypothesised that a 
broad comparison of the membrane protein profile of fetal nucleated red blood 
cells (after removing the nucleus in vitro) with that of adult anucleate erythrocytes 
(obtained from non-pregnant individuals), would allow the discovery of unique 
differentially expressed surface antigens.   
 
1.5 Adult anucleate RBCs and first trimester FNRBCs 
1.5.1 Genealogy of erythroid cells 
Nucleated red cell precursors, called normoblasts, are distinguished from other 
primitive cells by their denser nuclear chromatin and lack of cytoplasmic granules, 
and in later stages, by the appearance of haemoglobin within the cell cytoplasm. 
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Based on morphology with Wright’s staining, the sequence of cell mitoses and 
maturation is divided into three phases: early, intermediate, and late cell 
maturation. Early maturation forms, the pronormoblasts and basophilic 
normoblasts, are large cells (300 to 800 fL) with slightly clumped nuclear 
chromatin that is heavier than that of white cells at a corresponding stage of 
maturation (Kapoff et al., 1981). Nuclei are relatively indistinct, and the cytoplasm 
is medium to dark blue and does not contain recognizable granules or organelles. 
 
At intermediate stages of maturation, normoblasts are smaller.  They have a 
compact nucleus and haemoglobin within the cytoplasm, giving their typical blue-
green colour.  These are the polychromatic normoblasts.  Later in maturation, the 
nucleus continues to decrease in size and eventually becomes a dense, 
structureless mass. The cytoplasm is predominantly pink because of the 
increased haemoglobin content, and these cells are referred to as eosinophilic or 
orthochromatic normoblasts (Hillman et al., 1996). 
 
The sequence is complete when the pyknotic nucleus is finally extruded from the 
cell, leaving a marrow reticulocyte, the immediate precursor of the circulating 
adult erythrocyte.  By the time the nucleus is lost, the red cell contains about two-
thirds of its eventual haemoglobin content (Papayannopoulou et al., 1972).  The 
cell volume of 150-180 fL is still considerably larger than that of circulating mature 
erythrocyte, and the blue tinge in cytoplasm indicates the presence of ribonucleic 
acid (RNA).  This, together with the residual mitochondria supports the synthesis 
of the remaining one-third of the haemoglobin within the mature erythrocyte.  The 
reticulocyte stays within the marrow, while haemoglobinisation is continued with 
the progressive decline in the content of RNA and mitochondria.  Gradual 
reduction in cell size ensures that its volume approaches that of a mature cell, 
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which can penetrate the sinusoidal wall and enter the circulation (Goldwasser, 
1975).   
 
During the process of enucleation and maturation of erythrocytes, proteins such 
as spectrin and glycophorin stay behind in the nascent reticulocyte.  Most of the 
other surface glycoproteins such as transferrin receptors (Pan et al., 1983; 
Johnstone et al., 1987; Darnell et al., 1990) are lost in the fragment that contains 
the nucleus.  This suggests that structural changes that take place during the 
maturation of the red blood cell is accompanied with significant changes in its 
structural proteins as well.  Given this, it is highly likely that as yet undiscovered 
differences must exist in the cell surface proteome between adult anucleate 
erythrocytes and fetal nucleated red blood cells.   
 
1.5.2 Membrane composition of adult anucleate red blood cells 
The limiting barrier separating the red cell cytoplasm and its external environment 
is a phospholipid bilayer.  Phospholipid molecules are packed together tightly 
with their polar ends facing the aqueous phase on either side of the membrane. 
The external surface is relatively rich in phosphatidylcholine, sphingomyelin, and 
glycolipid; the inner portion of the membrane contains mostly phosphatidylserine, 
phosphatidylethanolamine, and phosphatidylinositol.  Cholesterol is present in a 
1:1 molar ratio with the phospholipids and is in rapid exchange with the 
unesterified cholesterol of the plasma.  The cholesterol content of the membrane 
depends on the concentrations of free plasma cholesterol and bile acids and 
activity of the esterifying enzyme, lecithin-cholesterol acyltransferase (LCAT) 
(Hillman et al., 1996).  The mature anucleate RBC membrane is composed of 
50% proteins, 40% lipid and 10% carbohydrate (Pallister, 1994). 
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Erythrocyte membranes, when solubilised in sodium dodecylsulphate (SDS) and 
subjected to polyacrylamide-gel electrophoresis (PAGE), separate into a series of 
polypeptide bands with molecular masses between 15-250 kD (Fairbanks et al., 


















Figure 1.1 SDS-polyacrylamide gel of the polypeptides of erythrocyte ghosts. 
Bands 1 and 2 (spectrin), band 3, bands 2.1-2.2 (ankyrin), band 4.1 and band 5 
(actin).  
 
(Adpated from James Darnell, Harvey Lodish, David Baltimore (1990) Molecular 











The three main groups of adult anucleate red blood cell membrane proteins 
include: (a) integral proteins, (b) peripheral proteins and (c) glycosyl-
phosphatidylinositol (GPI) anchored proteins. 
 
Integral proteins.  Integral proteins comprise up to 80% of all red cell membrane 
proteins, and are embedded in the membrane matrix spanning the entire bilayer. 
These proteins are characterised by at least two hydrophilic domains composed 
mainly of polar amino acids, and by at least one hydrophobic domain composed 
mostly of apolar amino acids.  The hydrophilic sections of the proteins are in 
contact with the surrounding water phases—the extracellular domain is usually 
glycosylated (Steck & Dawson, 1974), whereas the cytoplasmic domain is usually 
phosphorylated (Johnson et al., 1982).  Only relatively small portions of integral 
protein molecules are exposed to the inner and outer aqueous phases (Pallister, 
1994).  
 
Important integral proteins tightly bound to the cytoskeleton architecture include 
band 3, and the glycophorins (Table 1.1).  Band 3 acts as the anion transport and 
gas exchange channel (Bruce et al., 2003), which consists of N-terminal 
cytoplasmic domain and C-terminal membrane domain.  Structural models predict 
that the membrane domain consists of 12 to 14 transmembrane helices, and the 
longest, fourth loop is N-glycosylated and its single lactosamine-rich glycan chain 
carries over half of the red cell ABO blood group epitopes (Jarolim et al., 1998).  
Band 3 also carries the antigens of the Diego blood group system (Poole, 2000). 
Glycophorins are associated with the MNS blood group system (a complex blood 
group system which currently comprises 43 antigens such as M, N, S and s) 
(Poole, 2000).  About 60% of the glycophorin molecule is made up of 
carbohydrate (oligosaccharide) chains.  These are attached to the outer end of 
the molecule and serve to provide a negative charge to the surface of the red 
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cell, an important characteristic for preventing cell agglutination (Marchesi et al., 
1976).  Various serological characters of the erythrocyte membrane are located 
on glycophorin molecules: glycophorin A and B carry blood group MNS 
determinants, the T antigens, receptors for influenza viruses, malaria parasites, 
Coli bacteria, as well as binding sites for lectins (e.g. wheat germ agglutinin 
(WGA) and phytohemagglutinin (PHA)).  Glycophorin C is responsible for the 
blood group Gerbich phenotype (Anstee et al., 1984).  Other major integral 
proteins consist of glucose transporter (band 4.5), Rh polypeptides, Rh 
glycoproteins, and band 7 (stomatin) (Wang & Morrow, 2000).  
 
Table1.1 Major integral proteins of the human red blood cell membrane and their 
abundance 
 (Adapted from Tanner MJA & Anstee DJ (1993) Red Cell Membrane and Red 
Cell Antigens. London: Bailliere Tindall Publications.) 
Protein Synonyms Abundance (copies/cell) 
Band 3 Anion transporter, AE1 1.2x106




Glycophorin B SGP δ, Ss sialoglycoprotein 2.5x105
Glycophorin C SGP β, sialoglycoprotein D 5-12x104
 
Peripheral proteins.  Peripheral proteins are located on the cytoplasmic surface of 
the membrane.  They are bound loosely to the membrane, and can be readily 
removed in low ionic strength medium, in the presence of chelating agents, or 
under alkaline conditions.  This group is represented by the proteins of bands 1, 
2, 2.1, 2.2, 2.3, 4.1, 4.2, 4.9, 5, and 6 (Steck, 1974). 
 
Spectrin (band 1 and band 2) is the major constituent of the membrane skeleton; 
it accounts for 25% of the total red cell membrane proteins.  The spectrin fraction 
consists of two fibrous proteins that can be resolved on SDS-PAGE into two 
closely adjacent bands, band 1 (α-chain) and band 2 (β-chain); the respective 
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molecular masses are 240 and 220 kDa.  Two α-β helices are linked end-to-end 
to form a single tetramer, which has binding sites for several other proteins 
including other spectrin molecules (Branton et al., 1981; Bennet, 1985; Byers et 
al., 1985; Marchesi, 1985; Shen et al., 1986). 
 
Ankyrin (band 2.1) is a peripheral membrane protein with a molecular mass of 
210 kDa.  Band 2.2 and band 2.3 proteins are probably ankyrin analogues.  
Syndein (band 2.3) is a globular spectrin-binding protein of molecular weight of 
150 kDa, which belongs to the family closely related to ankyrin (Yu & Goodman, 
1979).  
 
Band 4.1 is a globular protein with a molecular mass in the range of 78 to 82 kDa.  
Band 4.2 (palladin, 72 kDa) is found in the erythrocyte membrane as a homo-
tetramer closely associated with band 3 protein (Cohen et al., 1992).  Band 4.9 
(Dematin) is an actin-bundling protein, which contains at least two actin-binding 
sites, one in the headpiece domain, and another in the amino-terminal portion 
(Rana et al., 1993; Azim et al., 1995). 
 
Actin (band 5) oligomers of 10-15 units are essential components of the 
membrane skeleton and the molecular mass of this protein is approximately 43 
kDa.  
 
Band-6 protein is a glyceraldehyde-3-phosphate dehydrogenase (G3PD) with a 
pivotal function in erythrocyte metabolism.  Immunostaining demonstrated that 
G3PD is preferentially associated with the plasma membrane of AARBCs, and 
approximately 10% of G3PD exists in the cytoplasmic fraction of AARBCs 
(Rogalski et al., 1989).    
 
 25
GPI-anchored proteins.  GPI-anchored membrane proteins are a class of 
membrane proteins that attach to the outer surface of the cell membrane through 
a glycosyl-phosphatidylinositol unit.  This glycolipid anchor is composed of 
phosphatidylinositol, phosphatidylethanolamine, one non-acetylated glucosamine 
and three mannose residues; the anchor unit is connected to the C-terminal 
amino acid of the protein via an amide bond.  This complex molecule is attached 
to the cell membrane by the fatty acid residues of the phosphatidylinositol moiety 
embedded in the outer leaflet of the bilayer (Rosse, 1990; Kinoshita et al., 1995).  
 
GPI-anchored membrane proteins of human red blood cells include complement 
control proteins (decay accelerating factor, membrane inhibitor of reactive lysis 
(CD59), and C8 binding protein), immune control proteins (LFA-3 and CD16, the 
major Fc receptor), and various enzymes (acetylcholinesterase, alkaline 
phosphatase, and 5’-nucleotidase) (Pratt et al., 1993; Rosse, 1990).  
Furthermore, it has been shown that antigens of several different blood group 
systems, Cromer, Dombrock, Cartwright, and John Milton Hagen (JMH), are 
located on GPI-linked membrane proteins (Telen et al., 1990). 
 
Current proteomics techniques such as two-dimensional gel electrophoresis 
(Jiang et al., 2003), matrix-assisted laser desorption ionisation-time of flight mass 
spectrometry (Low et al, 2002) and ion-trap mass spectrometry (Kakhniashvili et 
al, 2004), have enabled the detailed study of AARBCs membrane proteins, which 
have expanded the membrane protein database of AARBCs.  Minor surface 
proteins range in abundance from less than 1,000 copies/cell up to 50,000 
copies/cell are also found in AARBCs.  A list of known minor proteins together 
with information on their abundance and molecular weights is presented in Table 
1.2 (Tanner & Anstee, 1993). 
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Table 1.2 Minor proteins of the human red blood cell membrane 
Protein Abundance (x103 copies) Mr x103 (non-reducing 
conditions) 
CD 55 10-20 70 
CD 59 20-40 18-20 
AChE 3-10 160 
CD 58 3-8 55-70 
C8 binding protein Nk 55 
Dombrock Nk 46-58 
JMH Nk 76 
Kell 4-18 93 
Kx Nk 37 
Kidd 14 Nk 
CD 44 5-10 80 
CD 35 <1 190-280 
Duffy 10-12 35-45 
LW 2-5 37-47 
CD 47 10-50 47-52 
Lutheran 1-4 85/78 
Xga Nk 22-25/26.5-29 
Sc Nk 68 
OKa Nk 35-69 
12E7 1 32.5 
Nucleoside transporter 10 55 
 
Nk: not known. 
(Adapted from Tanner MJA & Anstee DJ (1993) Red Cell Membrane and Red 
Cell Antigens. London: Bailliere Tindall Publications.)  
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1.5.3 First trimester fetal primitive erythroblasts 
First trimester fetal blood contains two types of nucleated erythrocytes: primitive 
erythroblasts and definitive erythroblasts (Palis & Segel, 1998; Keller et al., 
1999).  Primitive erythroblasts derived from the yolk sac (Palis & Yoder, 2001) 
are large, and have a high cytoplasmic:nuclear ratio.  They are the prominent cell 
type until 12 weeks gestation.  In contrast, definitive erythroblasts, produced in 
the fetal liver and bone marrow, are smaller with a lower cytoplasmic:nuclear ratio 
and extrude their nuclei on maturation (Keller et al., 1999).  Primitive 
erythroblasts are target fetal cell type for non-invasive prenatal diagnosis as 
100% of these cells contain ε-globin, the ideal fetal cell identification marker 
(Choolani et al., 2001; Hogh et al., 2001; Choolani et al., 2003).   
 
No information is available about the membrane protein composition of FNRBCs.  
Limited immunophenotype studies demonstrated no significant difference in the 
surface antigens present on primitive erythroblasts and AARBCs.  CD71 
expression was weak/undetectable on primitive erythroblasts, and not suitable for 
immunosorting of the target nucleated fetal red blood cells (Choolani et al., 2003).  
In this thesis, I explore the membrane proteins present on fetal primitive 
erythroblasts (Figure 1.2), and compare these to the protein constituents of 



































Figure 1.2 First trimester fetal erythroblasts (9 weeks) (May-Grünwald-Giemsa 
staining). Primitive erythroblasts with three different types labeled according to 
Kelemen et al. (1979). Type I: large cells approximately 20 µm with an abundant 
polychromatic cytoplasm and large centrally located nuclei containing fine 
reticular chromatin. Type II: these cells are slightly smaller than type I, have a 
pink cytoplasm and a smaller off-centre nucleus containing denser nuclear 
chromatin. Type III: these cells contain abundant pink cytoplasm (haemoglobin) 
but their nuclei are eccentrically located, condensed and orthchromatic, and small 
pyknotic. Definitive erythroblasts (inset, arrow) are smaller cells with a large 
nucleus: cytoplasm ratio; they have a polychromatic cytoplasm and fine 
chromatin. 
 
(Reproduced with permission from Mahesh Choolani, PhD thesis, “Epsilon-globin 
to identify fetal cells isolated from maternal blood in the first trimester”, University 




1.6 Proteomics approach to interrogate cell membrane 
proteins 
Membrane protein analysis involves membrane protein extraction, resolution, and 
identification (Table 1.3).  Conventional gel-based approaches are now being 
augmented by protein profiling techniques such as surface-enhanced laser 
desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS), and 
more powerful protein sequencing methods such as MALDI-TOF and MALDI-
TOF/TOF.   
 
1.6.1 Plasma membrane protein extraction  
Extraction of relatively pure samples of plasma membrane protein is the critical 
step for subsequent membrane protein analysis.  Current methods require large 
samples (Casale et al., 1984), and specialised equipment (Hubbard et al., 1983).  
They generally fall into four main categories: (1) crude plasma membrane 
extraction, where cell nuclei are separated from cytoplasmic and membrane 
fractions, and crude plasma membrane subsequently extracted by ultracentrifuge 
(Simpson et al., 2000; Harvey et al., 2001; Blonder et al., 2002), (2) density-
based organelle separation, in which cell membranes were sequentially 
separated from other organelles by density gradients using sucrose or Percoll 
(Adam et al., 2003; Lehner et al., 2003), (3) sequential and detergent-based 
membrane extraction that sequentially removes and solublises membrane in the 
detergent (Lehner et al., 2003; Blonder et al., 2004), and (4) biotin-directed 
affinity purification (Goshe et al., 2003; Shin et al., 2003; Zhang et al., 2003; Zhao 
et al., 2004). 
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1.6.2 Membrane protein resolution and identification  
Membrane proteomic analysis employs either gel-based approaches, or 
“shotgun” chromatography methods (Wu & Yates III, 2003).   
 
Proteomic analysis of complex protein samples traditionally involves resolution of 
the proteins using two-dimensional gel electrophoresis (2D-gels) followed by the 
identification of resolved proteins by mass spectrometry (Santoni et al., 2000a, 
2000b). The ability of 2D-gels to resolve hundreds of proteins remains 
unchallenged, but the complexity of the experimental procedure and the large 
amount of starting material required makes it impractical for membrane 
proteomics studies where starting samples are in short supply.  Furthermore, 
many hydrophobic proteins are not readily soluble in non-detergent isoelectric 
focusing sample buffer; and those that dissolve are prone to precipitation at their 
isoelectric point.  In fact, many investigators have returned to couple one-
dimensional (1D) gel with mass spectrometry for protein identification (Simpson 
et al., 2000; Ferro et al., 2002; Galeva et al., 2002).  The commonly used mass 
spectrometry coupled with 1D or 2D gels is MALDI-TOF, or the recently 
developed MALDI-TOF/TOF tandem mass spectrometry (section 1.6.2.2).  
 
An alternative to the gel-based approach is ‘shotgun’ chromatography/mass 
spectrometry.  Proteins are first digested using proteases into complex peptide 
mixtures.  These are then analysed directly by liquid chromatography/mass 
spectrometry (LC/MS).  This approach is rapid and readily automated, but is 
costly, not readily available, and requires significant computing resources for data 
analysis.  As with 2D-gel based methods, the solubility of membrane proteins 




SELDI-TOF-MS is a recently developed technology that is suitable for use when 
the amount of protein available in the starting samples is small, as is the case for 
the membrane proteins extracted from fetal primitive erythroblasts.   
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       SELDI-TOF-MS 
 
1.6.2.1 SELDI-TOF-MS 
SELDI-TOF-MS (the basis of Ciphergen® ProteinChip® system) is different from 
other MS techniques in that it is used for protein profiling rather than protein 
identification.  Proteins in the range between 0-200 kDa can be profiled using this 
technology.  Crude protein extracts are spotted in a protein chip surface with 
definite protein chemistry, where selective adsorption of proteins takes place 
resulting in binding of only specific protein groups.   
 
When the laser is turned on, or “fired”, the sample is irradiated and the process of 
ionisation and desorption takes place.  Ionisation of the analyte results from an 
interplay between the laser energy, the EAM (energy absorbing molecule) and 
the analyte.  Laser energy excitation induces both protein ionisation and a 
change of state from the solid, crystalline phase into the gas phase.  After the 
laser beam is fired, two events happen: firstly, the analyte becomes charged; 
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secondly, the analyte is transformed into the gaseous phase.  Gaseous phase 
charged particles move rapidly (“fly”) away from a metal chip of the same charge 
upon the application of a voltage differential.  The voltage differential applies the 
same energy to all of the analytes in the sample, thus resulting in flight times that 
depend upon the mass of the analyte.  The ProteinChip reader records the time-
of -flight of the analyte, and from this measurement an accurate mass is derived.  
Ciphergen’s ProteinChip System is equipped with a ProteinChip Reader 
(Ciphergen) (series PBS ІІ) integrated with ProteinChip Software (Ciphergen ) to 
analyse proteins captured on the ProteinChip Arrays (Ciphergen).  The 
ProteinChip System detects and calculates the mass of compounds ranging from 
small molecules and peptides of less than 1000 Da to proteins of up to 250 kDa 
based on measured time-of-flight; it is most accurate for molecules of less than 
60 kDa (Figure 1.3). 
 
One distinct advantage of this system is that it requires only tiny amounts of 
sample (5-10 µg).  Its other major advantage is its ability to select for study only 
proteins with a pre-specified chemistry.  The system uses chip arrays with 
different chemical properties to capture special groups of proteins to analyse.  
Commonly used ProteinChips include normal phase (NP20), reverse phase (H4), 
strong anion-exchange (SAX2), weak cation-exchange (WCX2), and immobilised 
affinity capture (IMAC3) chips.  NP20 chips bind hydrophilic proteins, and H4 
chips are suitable for their hydrophobic counterparts.  SAX2 and WCX2 chips are 
used to analyse proteins that have negative and positive charges on the surface, 
respectively.  IMAC3 chips are used to capture proteins that bind divalent cationic 




Figure 1.3 Schematic representation of SELDI-TOF-MS mechanism (modified 
from www.ciphergen.com).  (1) Protein mixtures are loaded on ProteinChip 
(Ciphergen) with different surface chemistries.  (2) Specific proteins are captured 
and retained on the chip, and other proteins are washed away.  (3) The retained 
proteins are positively charged and transformed into the gaseous phase by the 
laser beam.  These then move rapidly away from the chip of the same positive 
charge.  The voltage differential applies the same energy to all of the proteins in 
the sample, thus resulting in flight times that depend upon the mass of the 
proteins. The ProteinChip reader records the time-of-flight of the proteins, and 





1.6.2.2 MALDI-TOF and MALDI-TOF/TOF 
Matrix-assisted laser desorption ionisation, developed by Karas & Hillenkamp 
(1988), is one of the two “soft ionisation” methods (the other is electrospray).  
Protonated molecules are mixed with a large excess of matrix material, spotted 
onto a metal substrate, and dried. 
 
To generate gas phase, protonated molecules and a large excess of matrix 
material are mixed and spotted onto a metal substrate and dried.  The resulting 
solid is then irradiated by nanosecond laser pulses, using nitrogen lasers with a 
wavelength of 337 nm.  The ions are accelerated to a fixed amount of kinetic 
energy and move rapidly in a flight tube.  Small ions having a higher velocity are 
recorded on a detector before the larger ones, producing the time-of-flight 
spectrum.  MALDI-TOF technology is a combination of MALDI and TOF in a 
mass spectrometer.  MALDI TOF/TOF allows the separation of a precursor ion 
from a multi-component sample in the first stage and separation of the precursor 
from its fragments in the second stage reflectron TOF. 
 
MALDI, coupled with TOF, provides protein identification when peptides mass 
information is submitted to the database.  On the other hand, MALDI-TOF/TOF 
acquires both peptide mass information and amino acid sequence information, 
thus being more sensitive and reliable than MALDI-TOF. 
 
Since proteins undergo fragmentation during MALDI resulting in broad peaks with 
lower sensitivity, this technique is mostly applied to the analysis of peptides. 
Hence protein mixtures should be fractionated (either using 1D or 2D gels) and 
digested before MALDI (Mann et al., 2001). 
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In the present study, SELDI-TOF-MS was used to profile membrane proteins of 
FNRBCs and AARBCs, and one-dimensional gel electrophoresis followed by 
MALDI-TOF/TOF tandem mass spectrometry for protein identification (Figure 
1.4).  Advantages and disadvantages of these techniques are listed in Table 1.4.  
 
Table 1.4 Properties of SELDI-TOF-MS and MALDI-TOF/TOF tandem mass 
spectrometry. 
 
 Advantages Disadvantages 
 
SELDI-TOF-MS 
a. Requires tiny amounts of 
protein sample; 
 
b. Protein mixtures can be 
directly loaded on the chip 
Only protein mass 
information is obtained, 








Coupled with database 
searching, protein identification 
could be obtained 
Before being loaded on the 
chip, protein mixtures need 
to be fractionated, and 
protein eluates need be 
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Figure 1.4 Gel-based analyses of membrane proteins. Four 
shown: (a) solubisation; (b) separation; (c) digestion/ex
identification (tandem mass spectrometry and database search.
 
 (c) Digestion/extraction(d) Identification 
 1st  MDatabase searchEnriched membrane sample2nd MSgeneral steps are 
traction; and (d) 
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1.7 Experimental aims and hypotheses 
Fetal nucleated red blood cells are the ideal fetal cell type for the non-invasive 
prenatal diagnosis of chromosomal aneuploidy and monogenic disorders.  
Enrichment, identification and diagnosis are the three key steps in this novel 
technology: issues of identification and diagnosis have been recently resolved 
(Choolani et al., 2001), but enrichment remains the ultimate challenge (Choolani 
et al., 2003).   
 
Investigators have been successful in enriching fetal cells especially from 
aneuploid pregnancies (Bianchi et al., 1997; Bischoff et al., 1998; Hromadnikova 
et al., 2002; Prieto et al., 2002), but in order for this technology to be used for 
diagnosis it should enrich fetal erythroblasts from all pregnancies.  Most 
pregnancies will be normal, and therefore in most cases the results would be 
normal and reassuring to the parents.   
 
Absence of any known surface antigen that is unique to either the FNRBC or 
AARBC is the major factor limiting reliable and reproducible recovery of fetal 
erythroblasts, and their use for non-invasive prenatal diagnosis.  Furthermore, 
surface membrane protein analyses of yolk sac derived primitive FNRBCs have 
been limited by the accessibility of this cell type for detailed study.  It is unclear if 
this cell type enucleates in vivo, or if it undergoes programmed cell death around 
14 weeks gestation with the nucleus in situ (Keller et al., 1999; Palis & Yoder, 
2001; Kingsley et al., 2004).   
 
Profiling the surface membrane proteins of FNRBC and AARBC would allow 
identification of differentially expressed surface antigens.  Proteomics 
technologies available today permit such profiling to be performed with accuracy.  
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Differentially expressed surface antigens could be exploited for positive selection 
strategies where unique antigens are expressed on the FNRBC surface, or for 
negative selection (depletion) strategies in cases when unique antigens are 
present on the adult anucleate red blood cell membrane surface. 
 
1.7.1 Hypotheses 
1. Membrane protein purification from first trimester fetal primitive erythroblasts 
is possible despite the small number of cells obtainable from this unique cell 
type present only during the first 14 weeks of human pregnancy.   
 
2. Membrane protein profiles of fetal nucleated red blood cells and adult 
anucleate erythrocytes differ. 
 
3. Unique surface antigen proteins that are differentially expressed between 
fetal nucleated red blood cells and adult anucleate erythrocytes can be 
identified.   
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Chapter 2: Materials & Methods 
2.1 Materials 
2.1.1 Human tissue samples 
2.1.1.1 Ethical approval for use of human samples 
Collection of adult peripheral blood and placental tissue at termination of 
pregnancy (TOP) for this research was approved by the Institutional Review 
Board, National University Hospital, Singapore.  All research participants gave 
written informed consent for the collection and use of human tissues. 
 
2.1.1.2 Peripheral blood from non-pregnant volunteers 
Peripheral blood samples (3 ml) were collected from healthy non-pregnant female 
volunteers. 
 
2.1.1.3 First trimester fetal nucleated red blood cells 
First trimester fetal nucleated red blood cells were extracted from tissues 
collected at elective termination of pregnancy.  Gestational ages were determined 
by ultrasound measurement of the crown rump length of the fetus; these ranged 
from 7 to 10 weeks. 
 
2.1.2 Reagents, solutions, protein standard marker and kits 
All reagents, solutions, markers and kits used in the experiments are listed below 
together with their source.   
 
2.1.2.1 Reagents 
Hank’s balanced salt solution (HBSS) without calcium and magnesium, trypsin 
(1:250), Hepes buffer solution (1M) and ethylenediaminetetraacetic acid (EDTA) 
(GIBCO, Invitrogen, Carlsbad, CA, USA); bovine serum albumin (BSA), Percoll 
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(Amersham Biosciences, Piscataway, NJ, USA); methanol (Fisher Scientific, 
Fairlawn, NJ, USA);  thiourea,  glycerol,  N-decyl-N, N-dimethyl-3-ammonio-1-
propane sulfonate (SB3-10), n-octylglucoside, Tris-carboxyethyl phosphine 
hydrochloride (TCEP), Trition X-100, potassium ferricyanide, sodium thiosulphate, 
iodo-acetamide, formic Acid, trifluoroacetic acid (TFA) and HPLC grade 
Acetonitrile (Sigma-Aldrich, St. Louis, MO, USA); urea, Tris base, sodium dodecyl 
sulphate and glacial acetic acid (BDH Merck, Whitehouse Station, NJ, USA);  
Complete Mini® protease inhibitor cocktail, Nonidet P-40 (NP40) (Roche 
diagnostics, Mannheim, Germany); fetal calf serum (Hyclone Perbio, Pierce 
Biotechnology, Rockford, IL, USA); modified sequencing grade trypsin (Promega, 
Southampton, UK); DTT (Sigma-Aldrich Fine chemicals, Oakville, Canada); 30% 
acrylamide/Bis solution 19:1 (5% C), TEMED and ammonium persulphate (Bio-
Rad laboratories, Hercules, CA, USA); 4700 Proteomics analyser calibration 
mixture (des-Arg-Bradykinin, Angiotensin I, Glu-Fibrinopeptide B, angiotensin I 
and adrenocorticotropic hormone (ACTH) (1-17 clip), ACTH (18-39 clip) and 
ACTH (7-38 clip)) (Applied Biosystems, Framigham, MA, USA).  
 
2.1.2.2 Water and Solutions 
Pure water (Milli-Q system, 18 MΩ/cm at 25˚C, with removal of organics) 
(Millipore, Bedford, MA, USA); TOP tissue digestion buffer (48.75 ml HBSS, 0.06 
g trypsin and 1.25 ml, 1M Hepes warmed to 37 ºC to dissolve trypsin and passed 
through 0.2 µm filter); HES buffer (20 mM Hepes, pH 7.4, containing 1 mM EDTA 
and 250 mM sucrose); 11.5M sodium chloride (NaCl); 20 mM, 50 mM and 100 
mM ammonium bicarbonate solution; 1x phosphate-buffered saline (PBS), 5x 
SDS/Glycine electrophoresis buffer (15.1 g Tris base, 72 g Glycine and 5 g SDS, 
NUMI, NUS); coomassie blue destaining solution (5% methanol, 7% acetic acid 
and 88% water); Sinapinic acid solution (50% acetonitrile, 0.5% TFA). 
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2.1.2.3 Protein standard marker 
Pre-stained SDS-PAGE standards (broad range) and Precision Plus Protein All 
blue® standards (Bio-Rad laboratories, Hercules, CA, USA). 
 
2.1.2.4 Kits 
RC® detergent compatible (DC) protein assay kit, Coomassie Brilliant blue R-250 
staining solution and Silver stain plus kit (Bio-Rad laboratories, Hercules, CA, 
USA), Wright’s stain set (Wescor, Logan, UT, USA). 
 
2.1.3 Hardware 
All specialised hardware used in the experiments is listed below with their source. 
2.1.3.1 Pipettes, centrifuge tubes, and filters 
Positive-pressure pipettes (Gilson, Villiers-le-Bel, France); Pipette-Aid motorised 
(BD Diagnostics, Franklin Lakes, NJ, USA); 1.5 ml conical-bottom polypropylene 
tubes, 0.2 µm filters and 70 µm cell strainers (BD Biosciences, Bedford, MA, 
USA); 1.5 polyallomer tubes (Beckman coulter, Fullerton, CA, USA). 
 
2.1.3.2 Blood collection tubes, needles, slides, coverslips, haemocytometer, 
coplin jars and Dounce homogeniser 
Vacutainer tubes and needles (BD Vacutainer systems, Oxford, UK); uncoated 
microscope slides, coverslips, Neubauer haemocytometer and coplin jars (BDH 
Merck, Whitehouse Station, NJ, USA); Dounce homogeniser (Wheaton Science, 
Millville, NJ, USA). 
 
2.1.3.3 Centrifuges 
Bench top centrifuge for 15- and 50 ml polypropylene tubes (Beckman GS-6R, 
Beckman coulter, Fullerton, CA, USA); bench top microcentrifuge for 0.5- and 1.5 
ml polypropylene tubes (Sanyo Gallenkamp PLC, Loughborough, UK); Savant 
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speedvac (Model SC110, Global Medical Instrumentation, Minnesota, USA); 
Beckman TL100 and L-80 ultracentrifuge (Beckman Coulter, Fullerton, CA, USA); 
cytocentrifuge (Shandon, Fisher Scientific, Hampton, NH, USA). 
 
2.1.3.4 Water bath and thermo bath 
Standard water bath (GFL, INNOV Solutions, Milan, Italy); ALB64 thermo bath 
(ESEL TechTra Inc, Korea). 
 
2.1.3.5 Sonicator 
Misonix sonicator (ultrasonic processor)-XL2020 (Misonix incorporated, 
Farmingdale, NY, USA). 
 
2.1.3.6 Electrophoresis system 
MP3 Electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA); 
Gibocobrl vertical gel electrophoresis apparatus Model V16-2 (Invitrogen, 
Carlsbad, CA, USA). 
 
2.1.3.7 Microscope and Spectrophotometers 
Microscope (Zeiss, Carl Zeiss, Oberkochen, Germany); Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, Ronkonkoma, NY, USA); Beckman 
DU 650 spectrophotometer (Beckman Coulter, Fullerton, CA, USA). 
 
2.1.3.8 SELDI-TOF-MS, MALDI-TOF/MS and MALDI-TOF/TOF tandem mass 
spectrometer 
Ciphergen ProteinChip SELDI-TOF-MS system (Ciphergen Biosystems, Fremont, 
CA, USA); Voyager-DE STR MALDI-TOF/MS system and 4700 Proteomics 
Analyser; MALDI-TOF/TOF tandem mass spectrometer (Applied Biosystems, 
Framigham, MA, USA). 
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2.1.3.9 Computer 
IBM X31 (IBM, Armonk, NY, USA). 
 
2.1.4 Computer software 
Ciphergen software (version 3.0, Ciphergen biosystems, Fremont, CA, USA); 
Auto MS-Fit software (Protein prospector; UCSF, San Francisco, CA, USA); GPS 
Explorer® software (Applied Biosystems, Framigham, MA, USA).  
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2.2 Methods 
2.2.1 Preparation of Percoll gradients 
Commercially available Percoll has a density of 1.130 g/ml.  Required Percoll 
gradients were prepared from this stock by mixing with 1.5M NaCl (ρ=1.058 g/ml) 
(Percoll Methodology and Applicants 2nd Edition, Amersham Pharmacia Biotech, 
Buckinghamshire, UK).  Percoll has a very low osmolality (<25 mOs/kg H2O) and 
can therefore form density gradients with iso-osmotic solutions (0.15M NaCl or 
0.25M sucrose) without significantly affecting the physiological conditions.  This is 
important for obtaining preparations of cells with intact morphology.  
 
To prepare 50 ml of Percoll at a specified density, the following were mixed 
together. 
5 ml 1.5M NaCl 
Percoll (1.130 g/ml), the volume of which was calculated as follows: 
 
 ρ − 0.1ρ’ − 0.9 
V0 = V                                  , where 
         ρ0 − 1 
 
V0 = volume of Percoll (1.130 g/ml) in ml 
V  = volume of the final working solution in ml (50 ml) 
ρ   = desired density of the final working solution in g/ml 
ρ0   = density of Percoll stock in g/ml (1.130 g/ml) 
ρ’    = density of 1.5M NaCl (1.058 g/ml) in g/ml 




2.2.2 Isolation of AARBCs from adult peripheral blood 
Adult blood samples were diluted 1:1 in PBS, and carefully layered over an equal 
volume of Ficoll (1077) in 15 ml polypropylene tubes.  Samples were centrifuged 
at 454 g for 30 min at room temperature.  Pelleted anucleate red blood cells were 
collected for use.  
 
2.2.3 Isolation of FNRBCs from placental tissue collected at termination of 
pregnancy  
Placental trophoblast tissue was washed several times with PBS, and the villi 
were collected by clean (non-sterile) dissection.  The villi were incubated with 45 
ml digestion buffer for 30 min at 37˚C with regular, vigorous shaking.  Cell 
suspension was transferred to a 50 ml polypropylene tube containing 5 ml fetal 
calf serum to stop enzyme activity, followed by filtration through a nylon cell 
strainer to remove any non-digested tissue.  Cell suspension was further 
centrifuged at 2,000 g for 10 min and cells were resuspended in 5 ml medium 
(PBS).  The suspension was carefully layered onto 5 ml of 40% Percoll solution 
(Percoll 1083), and centrifuged at 2,000 g for 20 min.  The supernatant was 
discarded, and the pellet containing FNRBCs was removed for storage at -80˚C. 
 
2.2.4 Nucleated red blood cell count 
10 µl of nucleated cell samples were diluted 1:1 with 3% glacial acetic acid, and 
10 µl of the mixture was loaded onto the Neubauer haemocytometer.  Nucleated 
cells were counted under the microscope.  At least 200 cells or four separate 
areas were examined and the average number of cells, N, per 1 mm2 (equivalent 
to 0.1 µl volume) determined and the concentration of nucleated cells in the 
original sample calculated (N x Dilution x 104 per ml).   
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2.2.5 Cytospin preparation 
104 fetal nucleated red blood cells were resuspended in 300 µl 0.5% BSA/PBS 
(w/v) and cytospun onto a slide at 500 rpm for 5 min using the cytocentrifuge.  
Cytospun slides were air dried and processed immediately. 
 
2.2.6 Wright’s staining 
Cells cytospun onto glass slides were Wright’s stained sequentially: immersed in 
methanol fix for 1.5 min, methylene blue stain solution for 1 min, eosin Y stain 
solution for 1 min, rinsed in water and air dried.   
 
2.2.7 AARBC membrane protein extraction 
Adult anucleate red blood cell membranes were prepared according to the 
protocol described by Hanahan and Ekholm (1974).  AARBCs (9x109 cells) were 
suspended in isotonic Tris-HCl buffer (pH 7.6) to a haematocrit of 50%.  The cell 
suspension was diluted 1:7 with 20 imOsM Tris-HCl buffer (pH 7.6) at 4˚C for 
hypotonic lysis. After 5 min, the lysed suspension was centrifuged at 20,000 g for 
40 min at 4˚C.  The pelleted membrane was suspended in the same buffer, and 
centrifuged again.  Washing was repeated five times.  After the final wash, the 
membrane was suspended in solubilisation buffer (5M urea, 50 mM Tris, 2M 
thiourea, 10% glycerol, 2.5% SB3-10 (w/v), 0.05% TritonX-100, 1% NP-40, 5 mM 
TCEP and 1x protease inhibitor cocktail).  The suspended membrane was 
sonicated in short bursts, 10 sec each, with an output force level 3, on ice, for 1 
min.  The membrane protein samples were analysed fresh, or stored in -80˚C. 
 
2.2.8 FNRBC membrane protein extraction 
To extract FNRBC membrane proteins by freeze-thawing followed by Dounce 
homogenisation, the protocol described by Simpson et al. (2000) was followed 
with minor modifications: FNRBCs (106 cells) were washed once each in PBS 
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and HES buffer (20 mM Hepes, pH 7.4, containing 1 mM EDTA and 250 mM 
sucrose) and resuspended in HES buffer (1 ml) containing 1x protease inhibitor 
cocktail (section 2.1.2.1). The cell suspension was frozen at -20˚C for atleast 12 
hrs and thawed completely before Dounce homogenisation (30 passes). Cell 
debris and nuclei were removed from the cell homogenate by centrifugation (900 
g for 10 min at 4˚C) to obtain post-nuclear supernatant (PNS). Plasma membrane 
proteins were recovered from the PNS by centrifugation at 100,000 g for 45 min 
at 4˚C, and resuspended in the solubilisation buffer (5M urea, 50 mM Tris, 2M 
thiourea, 10% glycerol, 2.5% SB3-10 (w/v), 0.05% TritonX-100, 1% NP40, 5 mM 
TCEP and 1x protease inhibitor cocktail).  The membrane protein samples were 
analysed fresh or stored at -80˚C.  
 
2.2.9 Protein quantification 
Protein concentrations of AARBC membrane proteins were determined using Bio-
Rad RC® DC protein assay kit (Principle of Lowry method) following the 
manufacturer’s instructions with slight modifications.  25 µl of BSA standards (0.2 
µg/µl, 0.6 µg/µl, 1 µg/µl and 1.4 µg/µl) or samples were mixed with RC® DC 
reagent I and II, then centrifuged at 13,000 rpm for 10 min.  Supernatants were 
discarded and pellets were dissolved in 127 µl of working reagent A (20 µl of 
reagent S to each ml reagent A), and 1 ml of reagent B was added to it.  After 15 
min, absorbance was read at 750 nm.  Protein concentrations were calculated 
from the equation deduced from the standard curve.  
 
Other methods used to measure FNRBC membrane protein concentration 
included the Bradford method, UV spectrophotometry and Nanodrop 
spectrometer micro-assay.  Bio-Rad Protein assay dye reagent concentrate was 
used for Bradford method, where 800 µl of diluted BSA standards (dissolved in 
the same buffer as that of protein sample) or protein samples were incubated with 
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200 µl of dye reagent for at least 5 min, and absorbance was read at 595 nm.  
Protein concentrations were calculated from the equation deduced from the 
standard curve.  In UV spectrophotometry (absorbance at 280 nm) and Nanodrop 
spectrophotometer micro-assay, absorbencies of samples were read directly 




2.2.10.1 SELDI-TOF-MS: preparation 
Ciphergen ProteinChips with different surface chemistries were used for SELDI-
TOF-MS membrane protein profiling: SAX2, WCX2, IMAC3, H4 and NP20 
proteinchips.  Prior to sample loading, SAX2 and WCX2 chips were equilibrated 
with 10 µl binding buffer (1x PBS/0.1% Triton-X100, pH 7.5 for SAX2 and 100 
mM ammonium acetate, pH 6.5 for WCX2).  Similarly, IMAC3 chips were 
chelated with Ni2+, Cu2+, Mg2+, Fe3+ and Mn2+ by adding 10 µl 100 mM NiSO4, 
CuSO4, MgSO4, FeCl3 and MnSO4, respectively.  After 30 min incubation, the 
chips were quickly rinsed with water to remove unbound metal.  For Cu2+ 
conjugation, the surface was washed with 50 mM sodium acetate (pH 4.0).  Chips 
were then equilibrated with 5 µl binding buffer (0.5 M NaCl in PBS) and all these 
chips were incubated with 5 µl of sample for 30 min in a humidity chamber.  The 
chips were washed twice with binding buffer and once in HPLC grade water, and 
air dried.  In contrast to ion-exchange and metal binding chip preparations, H4 
chips and NP20 chips were simply pre-washed using 5 µl of binding buffer (50% 
acetonitrile in PBS) and 5 µl of pure water, respectively.  Samples (5 µl) were 
incubated in these chips for 2-4 h.  Chips were then treated with sinapinic acid (3, 
5-dimethosy-4-hydroxycinnaic acid), and all chips were analysed with Ciphergen 
ProteinChip Reader (model PBSII). 
 
 49
2.2.10.2 SELDI-TOF-MS: analysis 
Chip arrays were analysed using the Ciphergen ProteinChip Reader (model 
PBSII).  Mass spectra of proteins were generated using 80 laser shots at 
intensities of 240-295 arbitrary units (AU).  Data for low molecular weight proteins 
(0-20 kDa) were acquired by focusing the laser at 10 kDa: detector intensity was 
set at 10, and the laser intensity at 240 AU.  Data for middle size proteins (20-60 
kDa) were acquired by focusing the laser at 30 kDa: detector intensity was set at 
10, and the laser intensity at 260 AU.  Data for high molecular weight proteins 
(100-250 kDa) were acquired by focusing the laser at 150 kDa: detector intensity 
was set at 10, and the laser intensity at 295 AU.  Mass-to-charge ratios (m/z) of 
each of the proteins captured on the array surface were determined according to 
externally calibrated standards (Ciphergen Biosystems): bovine insulin (5,733.6 
Da), human ubiquitin (8,564.8 Da), bovine cytochrome c (12,230.9 Da), equine 
myoglobin (16,951.5 Da), bovine β-lactoglobulin A (18,363.3 Da), horse-radish 
peroxidase (43,240 Da), chicken conalbumin (77,490 Da) and bovine IgG 
(147,300 Da).  Mass spectra obtained from the spectrometer were first processed 
using Ciphergen ProteinChip software version 3.0 for baseline subtraction, and 
automatic peak detection.  Baseline subtraction was performed on individual 
spectrum in isolation to eliminate any baseline signal caused by chemical noise.  
Peak detection identifies areas of the mass spectrum as peaks by comparing the 
signal to neighbouring troughs, or “valley depths”.  Signals that rise out of the 
“valley” and descend back into it are defined as peaks.   
 
External calibration provides a mass accuracy of within 0.1%, and for consistency 
samples were processed using SELDI-TOF-MS on the same day.  Fresh samples 
were used to optimise spectra, and deviations of up to 1% for 3,000-20,000 Da, 
2% for 20,000-60,000 Da, and 3% for more than 60,000 Da were considered 
acceptable for data analysis (personal communication, Ciphergen Biosystems, 
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Fremont, CA, USA).   
 
2.2.11 SDS-PAGE 
SDS-PAGE gels with different acrylamide concentrations ranging from 8 to 15% 
were used in the present study.  Gel compositions for the mini-size (8 cm) gels 
are described in Table 2.1.  Resolving gel mixture was prepared by mixing the 
reagents listed in Table 2.1 and loaded into the space between the glass plates.  
Once acrylamide is polymerised, protein standards and samples were loaded and 
electrophoresis was performed by applying a voltage of 90 V.  Enhanced 
resolution of high molecular weight (MW) protein bands was obtained by 
preparing a 16 cm 8% gel applying a voltage of 150 V.   
 




gel mixture Separating gel mixture 
  8% 10% 12% 15% 
H2O 1.75 ml 4.35 ml 3.75 ml 3.15 ml 2.25 ml 
4xTris(Upper/Lower) 625 µl 2.25 ml 2.25 ml 2.25 ml 2.25 ml 
30%AA 325 µl 2.4 ml 3 ml 3.6 ml 4.5 ml 
10%APS 30 µl 25 µl 25 µl 25 µl 25 µl 
TEMED 12 µl 12.5 µl 12.5 µl 12.5 µl 12.5 µl 
 
4x Lower Tris (1.6 M Tris, pH 8.8, 0.4% SDS) 
4x Upper Tris (0.5 M Tris, pH 6.8, 0.4% SDS) 
AA: acrylamide/Bis solution 
APS: ammonium persulfate 
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2.2.11.1 Gel staining after SDS-PAGE: Coomassie blue staining 
Coomassie blue staining gel was performed according to manufacturer’s 
instructions. After electrophoresis, gels were stained in coomassie blue stain 
solution for 20-30 min.  Destaining was carried out by placing gels in destaining 
solution overnight (12-15 h) with up to 4 changes of fresh destaining solution. 
 
2.2.11.2 Gel staining after SDS-PAGE: Silver staining 
Silver Stain Plus kits were used with modifications to manufacturer’s instructions.  
After electrophoresis, gels were fixed in fixative enhancer solution with 30 min 
followed by washing in deionised distilled water for 30 min; both with 
simultaneous gentle agitation.  Gels were stained in staining solution until desired 
staining intensity was reached, and then placed in 5% acetic acid to stop the 
reaction (minimum 15 min).  Final wash was in high purity water for 5 min before 
scanning.  
 
2.2.12 In-gel digestion for MALDI-TOF/MS and MALDI-TOF/TOF tandem mass 
spectrometry 
In-gel digestion was performed as follows.  Finely cut SDS-PAGE gel pieces were 
ground up, and transferred into a 600 µl PCR tube.  Destaining was performed by 
adding 1:1 ratio of 30 mM potassium ferricyanide and 100 mM sodium 
thiosulphate solution, and vortexing.  The mixture was then washed and 
dehydrated sequentially in 100 mM ammonium bicarbonate, 50 mM ammonium 
bicarbonate/50% (v/v) acetonitrile.  The sample was dried in a vacuum centrifuge.  
Dried sample was reduced by adding a fresh solution of 10 mM DTT in 100 mM 
ammonium bicarbonate (incubated at 57˚C for 60 min), and alkylated by using 55 
mM iodoacetamide solution in 100 mM ammonium bicarbonate (kept at room 
temperature for 60 min).  Further procedures included gel washing in 100 mM 
ammonium bicarbonate (thrice), dehydration in 100% acetonitrile (twice), re-
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swelling in 100 mM ammonium bicarbonate (once), dehydration in 100% 
acetonitrile (twice), and drying in a vacuum centrifuge (once).  Dried sample was 
re-swelled by adding digestion solution (12.5 ng/µl trypsin in 50 mM ammonium 
bicarbonate solution), and kept at 4˚C for 30 min. Excess digestion solution was 
removed, and 50 mM ammonium bicarbonate solution was added to the sample 
before incubation in a thermo bath at 37˚C (12-15 h).  After incubation, the 
solution was centrifuged at 6,000 rpm (10 min) and supernatant (“fraction A”) 
collected; to the pellet, 20 mM ammonium bicarbonate was added and spun at 
6,000 rpm (10 min) and the supernatant (“fraction B”) was collected; to the pellet, 
5% formic acid in 50% aqueous acetonitrile was added and centrifuged at 6,000 
rpm (10 min) and supernatant (“fraction C”) was collected.  All fractions (“A”, “B” 
and “C”) were pooled and dried in a vacuum centrifuge. 
 
2.2.13 MALDI-TOF analysis  
After in-gel digestion, the vacuum dried sample containing protein peptides was 
dissolved in 0.1% TFA and diluted in 50% acetonitrile.  0.4 µl of the extracted 
sample was dispensed onto a MALDI sample plate along with 0.4 µl of matrix 
solution consisting of 10 mg/ml α-cyano-4-hydroxycinnamic acid, 0.1% TFA, and 
50% acetonitrile.  Samples were allowed to dry at room temperature.  Mass 
spectrometric analysis was performed using Applied Biosystems Voyager-DE 
STR MALDI-TOF mass spectrometer with the following specifications.  MS 
automatic data acquisition was performed in delayed extraction, reflectron mode, 
with the parameters set as follows: accelerating voltage of 20,500 volts; grid 
voltage of 73.5%; grid wire of 0.01% and extraction time of 380 ns.  Laser 
intensity was set at 2700, with 100 shots per spectrum.  The mass range was set 
between 800-3500 Da.  The mixture of ACTH peptides (1296.6835 Da and 
2465.1989 Da (M+H+) ions) were set as internal calibration standards.  
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2.2.14 MALDI-TOF/TOF analysis 
Extracted peptides were resuspended in solution with 0.1% (v/v) TFA and 50% 
(v/v) acetonitrile.  0.5 µl of this peptide solution was mixed with an equal volume 
of matrix solution and spotted onto a MALDI target plate.  The matrix was a 
saturated solution of α–cyano-4-hydroxycinnamic acid (CHCA) in 0.1% (v/v) TFA 
and 50% (v/v) acetonitrile.  The sample was analysed on the MALDI-TOF/TOF 
4700 Proteomics Analyser (Applied Biosystems).  Calibration of the instrument 
was performed externally with [M+H]+ ions of calibration mixture (4700 Cal Mix).  
For MS analysis, the instrument was turned in a reflector mode with the laser 
intensity set at 5% higher than the threshold for ionisation.  MS spectra were 
obtained after accumulation of 5000 consecutive laser shots.  For MS/MS 
analysis, the laser intensity was set at 15% higher than the threshold for 
ionisation.  Nitrogen was used as collision gas and a medium CED pressure was 
selected (approximately 8x10-7 torr as measured by the Souce 2 pressure gauge).  
Data-dependent MS/MS analysis was performed in automatic mode, with the 
highest twenty peaks in MS selected for MS/MS from the most intense ion to the 
least intense.  
 
2.2.15 Protein database search using MS-Fit and MASCOT search engines 




MS-Fit is a peptide mass fingerprinting (PMF) tool developed by Karl Clauser and 
Peter Baker at UCSF Mass Spectrometry Facility.  The program tries to correlate 
user’s Mass Spectrometry (MS) data (parent masses only, not fragment masses) 
with a protein in a sequence database which best fits the data and thus suggest 
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the identity of the user's protein.  The input MS data should be generated by 
analysing the peptides produced by the enzymatic digestion of a user's protein.  
MS-Fit only gives the nearest fit of the protein in the data base and doesn’t 
identify the protein.  
 
MS-Fit performs best where both species and approximate intact protein 
molecular weight were known.  This could be directly linked to the lower 
sensitivity of the mass spectrometry machines available during the time the 
program was developed (a sensitivity of +/- 0.5 Da).  However to establish protein 
identity one need sequence support.  This support could be obtained from the 
combined use of MS/MS and PMF. I have not used MS-Tag option under the MS-
Fit platform (for MS/MS data), since MS-Tag cannot incorporate combined 
peptide mass and MS/MS sequence data for data base search.  
 
The Mowse (MOlecular Weight SEarch) score reported by MS-Fit is based on the 
scoring system described by Pappin (1993).  Masses in the theoretical digestion 
which match masses in the data set are divided into scoring matches and non-
scoring matches.  Scoring matches include unmodified peptides and acrylamide 
modified Cys and N-terminal Gln to pyroGlu and oxidation of Met in the presence 
of the unmodified peptide. Non-scoring matches include pyroGlu and oxidation of 
Met in the absence of the unmodified peptide, acetylated N-termini, 
phosphorylation of S, T and Y and single amino acid substitutions.  Unmatched 
masses are ignored.  The score for each matching mass is assigned as the 
appropriate normalised distribution frequency value.  In the case of multiple 
matching masses the scores are multiplied together.  The final product score is 




If scoring is not selected, MS-Fit uses a simple ranking system.  The results are 
sorted so that if multiple database entries are matched, more likely sequences 
are listed higher in the list.   All database entries matching the input data and 
parameters are ranked on the following basis:  
1. Database entries with the least number of unmatched masses are ranked 
higher.  
2. Among equivalent matches (those with the same rank) the results are sorted in 
order of increasing index number.  
 
A user interface for MS-Fit to search proteins could be found in the following web 
link: http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm.  I have used this for the 
PMF of my data in the later part of the thesis.  Data processing tools selected 
from Proteomics Solution 1® (Applied Biosystems) were used for baseline 
correction, noise removal and peak de-isotoping for MS-Fit data base search.   
 
2.2.15.2 MASCOT 
The other search engine I used was MASCOT.  This search engine was used for 
both PMF and MS/MS based sequence query.  MASCOT database sequence 
query, in which one or more peptide molecular masses are combined with 
sequence, composition and fragment ion data, is potentially the most powerful 
search of all.  MASCOT is based on Mowse.  The process of database search 
takes place in two stages.  The first stage of a Mowse search is to compare the 
calculated peptide masses for each entry in the sequence database with the set 
of experimental data.  Each of the calculated value which falls within a given 
mass tolerance of an experimental value is counted as a match.  A molecular 
weight range for the intact protein can be used as a pre-filter.  The second stage 
is to use empirically determined factors to assign a statistical weight to each 
individual peptide match.  MASCOT incorporates a probability based 
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implementation of the Mowse algorithm.  The Mowse algorithm is an excellent 
starting point because it accurately models the behaviour of a proteolytic enzyme.  
By casting the Mowse score into a probabilistic framework, we gain a number of 
additional benefits (Perkins et al., 1999).  The benefits include:  
1. A simple rule can be used to judge whether a result is significant or not.  
2. Different types of matching (peptide masses and fragment ions) can be 
combined in a single search.  
3. Scores from different searches and on different databases can be compared.  
4. Search parameters can be optimised more readily by iteration.  
Matches using mass values (either peptide masses or MS/MS fragment ion 
masses) are always handled on a probabilistic basis. The total score is the 
absolute probability that the observed match is a random event.  Reporting 
probabilities directly can be confusing.  Partly because they encompass a very 
wide range of magnitudes, and also because a "high" score is a "low" probability, 
which can be ambiguous.  For this reason, scores are reported as -10*LOG10(P), 
where P is the absolute probability. A probability of 10-20 thus becomes a score of 
200.  
 
Whether the best match is also a significant match depends on the size of the 
database (i.e. the significance level is higher if more sequences are searched) 
(Perkins et al., 1999).  This could be explained using this example, the calculated 
probability of matching, six out of ten peptide masses to a particular sequence 
might be 10-5.  This may sound like a promising result but, if the real database 
contains 106 sequences, several scores of this magnitude may be expected by 
chance.  A widely used significance threshold is that the probability of the 
observed event occurring by chance is less than one in twenty (p<0.05).  For a 
database of 106 entries, this would mean that significant matches were those with 
probabilities of less than 5x10-8 (i.e. 5x10-8x106 = 0.05).  
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2.2.15.3 Search parameters 
MS-Fit search parameters 
All searches were performed using a mass window between 1,000 Da and 
100,000 Da, and for sequences pertaining to Homo sapiens.  Mass tolerance was 
set at 50 parts per million (ppm), and minimum number of matched peptides was 
set at 4 (default value).  Search parameters allowed for oxidation of methionine, 
N-terminal acetylation, carboxy-amidomethylation of cysteine, and 
phosphorylation of serine, threonine and tyrosine.  For auto MS-Fit search, 
MALDI-TOF/MS results were submitted to Swiss-Prot and NCBI non-redundant 
protein databases to match the PMF. Manual MS-Fit was performed after 
AutoMS-Fit, to counter check the data.  
 
MASCOT search parameters 
For MASCOT PMF search, parameters were set as follows: database was 
chosen with NCBI nonredundant database and Swissprot, taxonomy was 
selected with Homo sapiens, protein mass was set at 0-250 kDa, and tryptic 
digest with a maximum number of one missed cleavage.  Peptide masses were 
stated to be monoisotopic. Methionine residues were assumed to be partially 
oxidized.  Additionally, the searches were carried out with carbamidomethylation 
of cysteine residues.  The mass tolerance was set as 50 ppm.  
 
For MASCOT sequence query search, parameters were set as follows: PMF data 
in combination with MS/MS spectra were submitted to the MASCOT database 
sequence query search engine using mass tolerance settings of 100 ppm for 
PMF and 0.2 Da for MS/MS data, and 1 missing cleavage site.  The protein mass 
set at 0-250 kDa. Taxonomy was chosen as Homo sapiens.  Peptide masses 
were stated to be monoisotopic, methionine residues assumed to be partially 
oxidised, and cysteine residues carbamidomethylated.  Fixed modification was 
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set as carbamidomethyl (C) and variable modification was set as oxidation (M).  
Trypsin autodigested peaks and keratin trypsin digested peaks were excluded 
from the submitted peaks.  De novo protein sequencing was carried out by the De 
novo Explorer Software of the 4700 Proteomics Analyser. 
 
2.2.16 Evaluation of search parameters and results 
Major algorithm for protein identification using database search in the present 
study was MASCOT, which applied probability-based protein identification.  
MASCOT database sequence query search engine, in which one or more peptide 
molecular masses are combined with sequence, composition and fragment ion 
data, is potentially the most powerful search of all.  
The advantages of this scoring include:  
1. A simple rule can be used to judge whether a result is significant or not. This is 
particularly useful in guarding against false positives. 
2. Scores can be compared with those from other types of search, such as 
sequence homology.  
3. Search parameters can be readily optimised by iteration (Perkins et al., 1999). 
 
Specifying the molecular mass of the intact protein in MASCOT is not normally 
necessary, because the score is a true probability of a random match by taking 
protein length into account.  If there are valid reasons to specify the protein 
molecular mass, simply restricting matches to database entries based on the 
calculated mass of the entire sequence is highly inadvisable, because many of 
the sequence database entries are for the least processed form of a protein 
(Perkins et al., 1999).  For example, the SWISS-PROT entry for bovine insulin, 
INS_BOVIN, is actually the sequence of the precursor protein including signal 
and connecting peptides.  This adds up to a molecular mass of 11,394 Da, so 
that a search based too tightly around an experimental measurement of the 
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molecular mass of this protein (5,734 Da) would fail to find a correct match.  
Therefore, in the MASCOT search mentioned in chapter 5, there was no 
restriction of molecular mass. 
 
With regard to the mass accuracy, literature review indicated that the 
performance of the number of identified spots was best at a mass tolerance of 50 
ppm (Mann & Wilm, 1994; Pappin et al., 1996; Chamrad et al, 2004).  While mass 
accuracy also depends on the machine condition, mass tolerance of 100 ppm as 
well as 50 ppm were employed for the search parameters.  However, mass 
tolerance was set at a specific value (i.e. either 50 ppm or 100 ppm) for all the 
samples in the same run to obtain the consistency.   
 
As far as the allowed missed cleavage sites were concerned, literature review 
indicated that the performance of search algorithms slightly improved if only one 
missed cleavage site was allowed (Chamrad et al, 2004).  Therefore, this 
parameter was applied in all searches performed in the present study. 
 
MASCOT clearly separated correct identifications and random matches by its 
search scores.  The criteria for a positive identification of proteins were set as 
p<0.05 (http://www.matrixscienc.com/help/scoring_help.html), which is applied for 
both peptide mass fingerprinting (for MALDI-TOF data) and sequence query (for 
MALDI-TOF/TOF data).  For MS-Fit search engine, there is no cut-off of 
probability based search scores.  Different researchers used different criteria for a 
positive identification.  The most stringent criteria seem to be the following: (1) at 
least 4 matching peptide masses; (2) 50 ppm or better mass accuracy; (3) MW of 
identical proteins should match estimated values obtained from gel image; (4) 
Mowse score of at least 1e+003; (5) Sequence coverage of at least 30%.  
However, most researchers only applied part of the criteria listed above (James 
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et al., 1994; Yates, 1998; Marcus et al., 2000; Low et al., 2002).  This issue will 
be discussed further in chapter 5. 
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Chapter 3: Optimisation of membrane protein 
extraction 
3.1 Introduction 
The present research focuses on the study of membrane proteins of primitive 
FNRBCs, and to compare these with those of adult anucleate RBCs.  The 
objective of this research is to identify unique, differentially expressed surface 
membrane proteins.  To date, there is no report that characterises the membrane 
proteins of primitive FNRBCs, although there have been some reports describing 
the immunohistochemical localisation of several surface proteins (Zheng et al., 
1997; Choolani et al., 2003) and use of antibodies against these proteins in the 
attempt of enrichment from maternal blood (section 1.5.3).  
 
This is the first investigation dedicated solely to the proteomics of FNRBC surface 
membrane proteins: from isolation of these FNRBCs from placental tissue 
obtained at termination of pregnancy, extraction of their membrane proteins, and 
profiling, detection and identification of membrane proteins unique to first 
trimester primitive FNRBCs. 
 
In cells, membrane proteins constitute 30% of cellular proteins, and regulate the 
exchange of information between the cell and its environment.  They have a role 
in cellular homeostasis, and fulfil several vital functions (Stryer et al., 1995; 
Santoni et al., 2000).  Membrane proteins are a heterogeneous mixture 
comprising integral membrane proteins and peripheral membrane proteins 
(Santoni et al., 2000). Integral membrane proteins are composed of both 
hydrophobic and hydrophilic regions.  Localisation of these proteins is readily 
performed, but study of their characteristics is more challenging.  Membrane 
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protein analysis is limited by their low abundance in cells, and low copy numbers 
of individual proteins. 
 
Earlier studies on the membrane protein extraction on different cell types have 
been carried out using large cell numbers: Adam et al. (2003) used 2x108 cells 
when applying a sucrose density gradient, and Lehner et al. (2003) used 3x108 
cells with biotin-directed affinity purification.  Extraction and quantitation of 
AARBC membrane protein are readily performed using standard protocols.  
Clearly however, such large cell numbers are not likely when fetal primitive 
erythroblasts are being harvested from the trophoblastic villi of tissue collected at 
termination of pregnancy (Choolani, 2002).  Furthermore, even (and especially) 
with satisfactory purification, fetal primitive erythroblasts will be mixed with fetal 
anucleate red blood cells.  Thus, a membrane extraction protocol needed to be 
developed that would be effective on small cell numbers (order of magnitude c. 
106), and one where the effect of admixture with other contaminating fetal cells 
could be controlled.  These proteins should be quantifiable, and comparable to 
membrane protein extracts obtained form adult anucleate RBCs.   
 
In this chapter, I explore hypothesis 1 (section 1.7.1), that: 
“Membrane protein purification from first trimester fetal primitive erythroblasts is 
possible despite the small number of cells obtainable from this unique cell type 
present only during the first 14 weeks of human pregnancy.”   
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3.2 Adult anucleate RBC membrane protein extraction 
Aim.  To extract membrane proteins from adult anucleate RBCs 
 
Investigation.  Peripheral blood samples were collected from healthy non-
pregnant female volunteers after obtaining informed consents as approved by the 
ethics committee (section 2.1.1.1).  The protocol described by Hanahan and 
Ekholm (1974) for the extraction of AARBC membrane proteins was followed 
(section 2.2.7). The protein content of membrane proteins prepared were 
quantified by Lowry method (section 2.2.9).  Proteins were separated by SDS-
PAGE, and were stained using either coomassie blue or silver stain (section 
2.2.11).  
 
Results.  Membrane pellets appeared colourless indicating removal of 
haemoglobin.  Quantification of membrane proteins by the Lowry method was 
satisfactory, and the amount of protein detected ranged between 1-2 mg/ml. 
SDS-PAGE of AARBC membrane proteins stained using coomassie blue is 





























Figure 3.1 SDS-PAGE (10%) of anucleate RBC membrane proteins (15 µg) 
stained with coomassie blue stain. 
 
Interpretation.  Recovery of protein bands on SDS-PAGE gel suggested that the 
protocol for AARBC membrane protein extraction was suitable for further study.  
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3.3 Isolation of FNRBCs and extraction of their membrane 
proteins 
3.3.1 Isolation of FNRBCs from placental trophoblast tissue  
Placental tissues collected from volunteers undergoing elective termination of 
pregnancy (section 2.1.1.1) were used to obtain FNRBCs following the protocol 
described in section 2.2.3.  FNRBCs isolated were counted, cytospun, and 
Wright’s stained (sections 2.2.4 to 2.2.6).  
 
Total numbers of FNRBCs isolated from one placental tissue sample varied from 
1x104-7x106 depending on the quality of tissue and the gestational age.  Purity of 
the preparation varied between 10% and 90% (Table 3.1).  Samples containing at 
least 70% of FNRBCs were considered satisfactorily pure, and used for 
membrane protein extraction.  Photomicrograph of a pure FNRBC sample is 












Figure 3.2 Wright’s stained primitive FNRBCs with high cytoplasmic:nuclear ratio 
(arrow A) and anucleate fetal RBCs (arrow B).  The purity of this sample was 









Tissue quality Number of 
FNRBCs 
Purity 
1 7 Fair 2.3x106 60% 
2 8 Fair 9.6x105 50% 
3 8 Fair 1.9x106 60% 
4 10 Fair 3.9x106 40% 
5 10 Poor 5.2x105 20% 
6 7 Fair 7x105 50% 
7 8 Good 8.5x105 90% 
8 8 Fair 7.3x105 70% 
9 8 Fair 1.5x106 80% 
10 8 Fair 106 70% 
11 8 Poor 3.4x105 30% 
12 10 Poor 3.4x105 10% 
13 10 Fair 3.5x106 50% 
14 10 Fair 1.6x105 40% 
15 9 Fair 3x104 50% 
16 8 Good 6x104 80% 
17 8 Fair 9x104 60% 
18 8 Poor 3x105 20% 
19 9 Good 1.3x106 80% 
20 8 Poor 6x105 40% 
21 8 Poor 3x105 30% 
22 9 Fair 2x105 60% 
23 9 Poor 6x104 30% 
24 10 Poor 8x104 10% 
25 9 Good 1.8x106 80% 
26 8 Fair 1.4x106 60% 
27 9 Fair 1.5x106 70% 
28 6 Poor 2x104 10% 
29 9 Good 1.5x106 80% 
30 8 Good 6.5x106 90% 
31 9 Good 3.6x106 80% 
32 8 Good 2.3x106 90% 
33 10 Poor 104 10% 
34 8 Fair 3.5x106 60% 
35 8 Good 3.8x105 90% 
36 9 Good 3x106 90% 
37 10 Fair 1.5x106 40% 
38 8 Fair 1.4x106 70% 
39 8 Poor 4x104 50% 
40 10 Fair 1.5x106 50% 
41 9 Fair 6x105 70% 
42 9 Good 3x106 80% 
43 9 Fair 4.2x106 70% 
44 9 Fair 1.9x106 50% 
45 8 Fair 106 70% 
46 10 Good 1.4x106 70% 
47 9 Good 3.3x106 90% 
48 10 Fair 6.9x105 50% 
49 9 Fair 1.4x106 70% 
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50 10 Good 6.3x105 70% 
51 8 Good 1.2x106 90% 
52 9 Good 3x105 90% 
53 10 Fair 2.4x105 50% 
54 10 Poor 1.5x105 10% 
55 10 Poor 2.5x105 10% 
56 7 Good 4.5x105 90% 
57 8 Fair 1.5x106 70% 
58 8 Fair 2.4x106 70% 
59 9 Fair 9x105 50% 
60 7 Poor 106 40% 
61 7 Poor 1.2x105 10% 
62 10 Fair 3.7x105 50% 
63 8 Poor 3x105 20% 
64 8 Good 1.9x106 90% 
65 10 Fair 1.6x106 50% 
66 8 Fair 2.5x106 80% 
67 10 Good  3.9x106 70% 
68 7 Good 2.6x106 90% 
69 9 Good 2.2x106 80% 
70 9 Poor 1.5x105 10% 
71 9 Fair 7x106 70% 
72 10 Poor 1.8x105 10% 
73 10 Poor 105 10% 
74 9 Fair 2.8x105 60% 
75 10 Poor 3.2x105 10% 
76 9 Fair 106 40% 
77 9 Good 4.4x106 90% 
78 10 Good 3x106 80% 
79 8 Fair 1.8x106 60% 
80 10 Good 2.1x106 80% 
81 8 Poor 3.3x105 10% 
82 8 Poor 1.5x106 20% 
 
 
3.3.2 FNRBC membrane protein extraction 
FNRBCs are nucleated cells containing haemoglobin in the cytoplasm.  No 
method has been specifically described for the extraction of their membrane 
proteins.  In view of the relatively small number of cells in the starting sample, 
several protocols were evaluated in order to optimise their cell membrane 
extraction.   
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3.3.2.1 Lysis of FNRBCs to remove their nuclei for membrane protein preparation 
Aim.  To lyse FNRBCs in order to separate their nuclei from membrane and 
cytoplasmic fractions using (a) 20 imosM Tris-HCl buffer (pH 7.6) and (b) 0.075M 
KCl.  This was attempted as a first step of membrane protein extraction. 
 
Investigation.  FNRBCs (106 cells) isolated as described in section 2.2.3 were 
suspended in 1 ml 20 imosM Tris-HCl buffer (pH 7.6), and incubated at 4˚C either 
for 5 min or 30 min.  After the incubation, the cell suspension was centrifuged at 
900 g for 10 min, and the pellet was resuspended in PBS.  The suspended cells 
were cytospun on the slides and Wright’s stained (sections 2.2.5 and 2.2.6). 
FNRBCs (106 cells) were suspended in 1ml 0.075M KCl and incubated at 37˚C 
either for 18 min or 30 min.  After the incubation, the cell suspension was 
centrifuged at 900 g for 10 min and the pellet was resuspended in PBS. The 
suspended cells were cytospun on the slides and Wright’s stained (sections 2.2.5 
and 2.2.6). 
 
Results.  (a) FNRBCs did not get completely lysed even after 30 min in hypotonic 
20 imosM Tris-HCl buffer.  Partially lysed FNRBCs with nuclei inside are shown in 
Figure 3.3 (arrows).  It should be noted that hypotonic lysis of AARBCs with 20 


















Figure 3.3 Nuclear pellet of FNRBCs after 20 imosM Tris-HCl lysis (30 min). 
Arrows indicate partially lysed FNRBCs.  
 
(b) Only partial lysis of FNRBCs was observed even after 30 min incubation in 
0.075 M KCl (Figure 3.4).  It should be noted that white blood cells which are also 
nucleated get lysed by 18 min (our personal observation during FISH 





















Figure 3.4 Nuclear pellet of FNRBC after 0.075M KCl lysis (30 min). Arrows 
indicate partially lysed FNRBCs.  
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Interpretation.   Neither of the two lysis solutions (20 imosM Tris-HCl and 0.075M 
KCl) were effective enough to completely lyse FNRBCs to separate their nuclei 
from membrane and cytoplasmic fractions.  As such, it was decided to Dounce 
homogenise the cells for further experiments.  
 
3.3.2.2 Dounce homogenisation-sucrose gradient centrifugation method  
Aim.  To determine whether Dounce homogenisation followed by sucrose 
gradient centrifugation can extract membrane proteins from FNRBCs. 
 
Investigation.  The procedure recommended in Ciphergen ProteinChip manual 
(section 2.1.3.8) was followed to lyse FNRBCs, and obtain their membrane 
proteins.  In brief, 5x106 FNRBCs were suspended in buffer A (10 mM Tris-HCl, 
pH 7.4, 10 mM NaCl, 1.5 mM MgCl2).  After Dounce homogenisation (30 passes), 
the cell suspension was centrifuged at 7,000 g for 20 min at 4˚C.  The 
supernatant (cytoplasmic fraction) was discarded and the membrane pellet was 
resuspended in 1 ml buffer A and layered over equal volume of 35% (w/v) 
sucrose solution and centrifuged at 18,000 g for 60 min at 4˚C in order to obtain 
an interface of plasma membrane proteins.  HL-60 cells (nucleated cells, 108) 
were processed in parallel to serve as a positive control.  These experiments 
were repeated for a few times to confirm my observations.  
 
Results.   A thin interface indicating the layer of plasma membrane was observed 
at sucrose gradient for HL-60 cell membrane protein preparation.  In contrast, no 
similar layer was found with FNRBC membrane protein extraction.  
 
Interpretation.  The absence of an interface after sucrose gradient centrifugation 
for FNRBC membrane protein preparation may be due either to the limited cell 
number used or to less effective lysis by Dounce homogenisation.  Unfortunately, 
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the maximum number of cells I could generally obtain from one placental tissue 
sample did not exceed 106 cells.  It was decided to try freeze-thawing FNRBCs 
before Dounce homogenisation to explore the possibility of complete lysis of cells 
and thus more recovery of membrane proteins.  This idea is based on the 
premise that crystallisation of water molecules, and subsequent thawing would 
make the plasma membrane more fragile and susceptible to mechanical shearing 
forces. 
 
3.3.2.3 Freeze-thawing-Dounce homogenisation method  
Aim.  To determine whether freeze-thawing followed by Dounce homogenisation 
could enhance extraction of membrane proteins from FNRBCs. 
 
Investigation.  To extract membrane proteins by freeze-thawing followed by 
Dounce homogenisation, the protocol described by Simpson et al. (2000) was 
followed with minor modifications (section 2.2.8).  Extracted membrane proteins 
were separated by SDS-PAGE, and stained with coomassie blue or silver stain 
(section 2.2.11).  
 
Results.  Membrane proteins separated by SDS-PAGE and stained using 
coomassie blue are shown in Figure 3.5.  The proteins were extracted from 
varying numbers of FNRBCs: membrane protein preparations from 6x105 and 
1.3x106 cells showed separated protein bands (lanes 4 and 6) whereas no such 
separation was seen for the sample prepared using 3x105 FNRBCs (lane 5).  For 
comparison, protein bands for AARBC membrane samples are also shown in the 
figure.   
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Figure 3.5 SDS-PAGE (8%) of AARBC and FNRBC membrane proteins stained 
using coomassie blue stain.  AARBC membrane proteins (lane 1-3, 15 µg each) 
and FNRBC membrane proteins (lanes 4-6; 6x105, 3x105 and 1.3x106 FNRBCs 
respectively were used to extract membrane proteins by freeze-thawing–Dounce 
homogenisation method). 
 
Interpretation.  Freeze-thawing-Dounce homogenisation proved suitable for the 
extraction of membrane proteins from FNRBCs.  This procedure was 
reproducible with membrane proteins extracted from as few as 6x105 FNRBCs; 
hence it was decided to follow this method for further experiments in my study. 
 
3.3.2.4 Biotinylation of surface membrane proteins for extraction  
While the freeze-thawing-Dounce homogenisation method was found suitable for 
the extraction of membrane proteins from FNRBCs, an attempt was also made to 
explore the possibility of extracting only surface membrane proteins by 
biotinylation (for profiling the cell surface proteome of FNRBCs).   
 
Aim.  To explore if biotinylation of surface proteins could be useful for extraction 















Investigation.  Biotinylation of surface membrane proteins and their separation 
using modified avidin columns was attempted following Shin et al. (2003) with 
minor modifications: 5x106 FNRBCs were washed in ice-cold PBS (pH 8.0) to 
remove contaminating proteins, if any.  The cells were suspended in 200 µl PBS 
(pH 8.0) and 0.1 mg of Sulfo-NHS-LC-Biotin was added for biotinylation at room 
temperature for 30 min.  Following biotinylation, the cells were washed in PBS,  
pelleted by centrifugation, and solubilised in PBS (pH 8.0) containing 2% NP-40. 
The cells were further disrupted by brief sonication (force level 3 for 1 min on ice). 
Solubilised biotinylated membrane proteins were purified on ImmunoPure 
immobilised monomeric avidin columns (Pierce, Upland, IN, USA).  1 ml-columns 
of immobilised monomeric avidin were extensively washed with PBS, and then 
with 2 mM D-biotin in PBS to block any non-reversible biotin binding sites.  The 
loosely bound biotin was removed from the reversible biotin binding sites by 
washing with 5 ml of 0.1M glycine (pH 2.8), and the columns were then 
extensively washed with PBS.  The solubilised-sonicated solution was passed 
through the immobilised monomeric avidin columns three times, after which the 
column was again extensively washed with PBS containing 1% NP-40.  The 
bound biotinylated proteins were eluted from the column with 5 mM D-biotin in 
PBS containing 1% NP-40.  Fractions containing eluted proteins were 
concentrated on Centricon YM-3 columns (Millipore Billerica, MA, USA).  
Biotinylated proteins were analysed by SDS-PAGE (section 2.2.11). 
 
HL-60 cells (109 cells) were also processed following the procedures described 
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Results.  SDS-PAGE gels stained with coomassie blue for the biotinylated 
membrane protein samples showed separated proteins bands for HL-60 















Figure 3.6 Coomassie blue stained SDS-PAGE gel for surface membrane 
proteins extracted by biotinylation method from HL-60 cells (109 cells) (lane 1) 
and FNRBCs (5x106 cells) (lane 2). No band was seen for FNRBC surface 
membrane protein preparation.  
 
Interpretation.  Protein bands on SDS-PAGE for biotinylated HL-60 preparation 
confirmed earlier reports by Shin et al. (2003) that extraction of surface proteins is 
possible by this method.  Absence of protein bands for the biotinylated FNRBC 
surface membrane protein preparation may be due to the smaller number of 
FNRBCs (5x106 cells) available (section 3.3.1; Table 3.1), compared with 109 HL-
60 cells used.  Thus, this biotinylation method was not thought satisfactory for 





















3.3.2.5 Protein quantification of membrane protein preparations 
Aim.  To estimate the protein content of membrane protein samples  
 
Investigation. Both biochemical (Lowry and Bradford methods) and 
spectrophotometric (UV and Nanodrop methods) techniques were tested for 
protein estimation (section 2.2.9).  Colourless AARBC membrane protein 
samples prepared (section 3.2) indicated their purity without haemoglobin 
contamination, and their protein contents were quantified by Lowry method 
(section 2.2.9).  Biochemical and spectrophotometric methods were also used to 
quantify FNRBC membrane protein preparations.  
 
Results.  The Lowry method was sensitive enough to measure the AARBC 
membrane protein concentrations as evident from the separated protein bands on 
SDS-PAGE gels using 5-15 µg protein extracts prepared.  In contrast, no protein 
bands was seen when “15 µg” FNRBC membrane protein preparations were run 











Figure 3.7 Coomassie blue stained SDS-PAGE (10%) for 15 µg of AARBC (lane 
1) and FNRBC membrane proteins (lane 2). No protein band was resolved for 
FNRBC membrane protein.  
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Interpretation.  Absence of protein bands for “15 µg” FNRBC membrane protein 
extract in SDS-PAGE gel suggested that both biochemical and 
spectrophotometric methods over-estimated the protein contents for these 
samples than the actual.  Over-estimation of protein content in case of FNRBC 
samples could be due to haemoglobin contamination as observed in the prepared 
sample.  An attempt was made to estimate the protein quantity of FNRBC 
membrane extracts by relative staining intensity compared with known amounts 
of AARBC membrane protein samples:  10 µg, 30 µg and 50 µg FNRBC 
membrane protein samples prepared from 2x105, 6x105 and 1x106 cells 
(respectively) showed varying intensity of staining in SDS-PAGE when stained 
with silver stain and thus, the amount of protein from 106 FNRBCs could be 
















Figure 3.8 SDS-PAGE (8%, 16 cm gel) analysis of AARBC and FNRBC 
membrane proteins using silver stain.  AARBC membrane protein (lane 1 and 2: 
10 µg and 5 µg) and FNRBC membrane protein (lanes 3: 10 µg, lane 4: 30 µg 




Adult anucleate RBC membrane proteins have been extensively studied for many 
years (section 1.5.2), and recent mass spectrophotometric techniques have even 
identified several new functional proteins (Low et al., 2002; Kakhniashvili et al., 
2004).  The extraction of good quality AARBC membrane proteins is simple, but 
these procedures are not applicable for FNRBC membrane protein extraction.   
 
Two different hypotonic cell lysis solutions (20 imosM Tris-HCl buffer and 0.075M 
KCl) were not adequately effective in completely separating nuclei from the 
membrane fractions.  Dounce homogenisation followed by sucrose centrifugation 
and biotinylation of surface membrane proteins were also ineffective strategies 
for membrane protein extraction from FNRBCs.  In most protocols, greater cell 
numbers are used to extract satisfactorily pure and adequate amounts of 
membrane proteins: at least 2x108 cells were used for sucrose gradient 
centrifugation (Adam et al., 2003; Lehner et al., 2003), and 3x108 cells were used 
for the biotinylation method for surface membrane protein preparation as 
described by Shin et al., (2003).  Low cell densities of FNRBCs isolated from 
each placental tissue sample (c. 106 cells) limited the use of these established 
methods of membrane protein purification.  Other methods, such as the 
sequential and detergent-based extraction method required c. 8x107 cells (Lehner 
et al., 2003), and were not tested. 
 
Interestingly, the freeze-thawing-Dounce homogenisation method was found to 
be the most suitable for extraction of membrane proteins from FNRBCs even as 
few as 6x105, and hence this method was used for subsequent experiments.  
Biochemical and spectrophotometric methods both over-estimated the protein 
concentration in FNRBCs membrane preparations most likely because of the 
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contaminating haemoglobin, which could not be avoided or circumvented.  It was 
possible however to estimate the concentration of FNRBC membrane protein 
preparations by their relative intensity of staining in SDS-PAGE gels, stained with 
either coomassie blue or silver stain with known quantities of anucleate RBC 
membrane proteins.  Membrane proteins extracted from 106 FNRBCs was 
estimated to be ≤ 5 µg of protein. 
 
Fetal primitive erythroblasts represent a unique, unusual and little studied human 
cell type.  These cells circulate in the human only in the fetal stage of life, and 
then only during the first trimester.  Little is known about the membrane and 
cytoplasmic properties of this cell type, and even less about manipulative 
processes that could be used to interrogate this cell type.  Not only are there 
fewer cells available for investigation, but also standard (and variations to the 
standard) methods are ineffective for adequately removing haemoglobin from 
within these cells.  It is probable that this is less likely due to an ineffective 
technique than to an inherent property of haemoglobin in primitive erythroblasts 
that appear to be associated with the plasma and nuclear membranes (Choolani, 
2002).  Despite these limitations, I am satisfied with the quality of FNRBC 
membrane proteins that were prepared by freeze-thawing-Dounce 
homogenisation.  Although the quantity of protein obtained is small, the samples 
were well visualised on SDS-PAGE, and suitable for further investigations such 
as SELDI-TOF-MS (chapter 4) and MALDI-TOF/TOF tandem mass spectrometry 
(chapter 5). 
 
Chapter 4: Detection of unique FNRBC 
membrane protein using SELDI-TOF-MS 
4.1 Introduction 
The primary aim of this project was to identify membrane proteins unique to either 
fetal primitive erythroblasts or adult anucleate red blood cells.  Membrane 
proteins have different chemistries and constitute 30% of all cellular proteins, and 
have varied chemistries (section 1.5.2).  Various protein purification and 
characterisation techniques have been used previously to identify membrane 
proteins from different cell types.  These techniques could be broadly classified 
into protein separation techniques such as 1-dimensional and 2-dimensional gel 
electrophoresis, and other liquid phase separations coupled with sophisticated 
MS techniques (Wu and Yates lll, 2003; Simpson et al., 2000; Satoni et al, 2000a, 
2000b; Ferro et al., 2002; Galeva et al., 2002).  Some of the inherent 
characteristics of membrane proteins such as their metal binding nature could 
help develop novel strategies for their enrichment and identification.  A more 
recent MS based technique is to profile proteins using SELDI-TOF-MS.  This 
technique is efficient in the selective enrichment of subclasses of proteins based 
on their chip binding characteristics (Table 4.1).  By studying the presence or 
absence (“on/off switch”) of the protein peaks in the Ciphergen protein profile, it is 
possible to study the difference in the protein patterns between two different 
samples (Section 1.6.2.1). Simultaneously, it is possible to look into several 
hundreds of proteins in a single spot in the ProteinChip array to identify unique 
proteins in samples.  
 
In this chapter, I explore hypothesis 2 (section 1.7.1) that: Membrane protein 
profiles of fetal nucleated red blood cells and adult anucleate erythrocytes differ.  
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4.2 Suitability of different chips for profiling FNRBC and 
AARBC membrane proteins.  
Aim.  To determine if ProteinChip arrays can be used for profiling membrane 
proteins.   
 
Investigation.  Several different ProteinChip array surfaces were used to identify 
the ideal ProteinChip array for profiling membrane proteins (Table 4.1).  
Differences in protein profiles are represented as unique peaks within the 
Ciphergen spectra of the respective cell type.  A protein peak with m/z value ‘X’ 
present in sample A and absent in sample B is taken as a unique protein peak 
within sample A, and vice versa.  Once profiling is completed the identification of 
these proteins peaks could be carried out either manually or with the help of 
Ciphergen ProteinChip software (version 3.0.1, Ciphergen Biosystems Inc, 
Fremont, California, USA).  Sample preparation for different ProteinChip arrays 
as well as optimised machine settings for data acquisition from SELDI-TOF-MS is 
described in section 2.2.10. 
 
Table 4.1 Property of different Ciphergen ProteinChip arrays 
Chip type Types of target proteins retained on the chip surface 
H4 
Hydrophobic proteins abundant in alanine, valine, leucine, isoleucine, 
phenylalanine, tryptophan, or tyrosine 
NP20 Hydrophilic proteins 
SAX2 
Proteins having negative charges on the surface, e.g., aspartic acid 
or glutamic acid 
WXC2 
Proteins having positive charges on the surface, e.g., lysine, arginine 
or histidine 
IMAC Proteins binding metal ions such as Cu, Fe, Ni, etc 
(Adapted from Ciphergen Manual, pp. 6-3) 
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The FNRBC results are compared with AARBC protein profiles corresponding to 
the following three mass ranges (1) 0-20 kDa, (2) 20-60 kDa and (3) 60-250 kDa.  
If present in both FNRBC and AARBC the peaks are considered common while if 
it is present in NRBC and absent in RBC it is considered unique to FNRBC cell 
type (and vice versa). 
 
Results.  This investigation revealed that it is possible to profile membrane 
proteins using ProteinChip arrays.  Membrane protein profiling demonstrated 
differences in the pattern of protein peaks present in FNRBC and AARBC cell 
types.  The membrane protein profile of FNRBC and AARBC on various 
ProteinChip arrays surfaces is shown in Figure 4.1.  Labelled peaks shown in the 
protein spectra were auto-detected as single charged peaks with a signal/noise 
ratio of more than 5; this ratio allowed the exclusion of ‘pseudo peaks’ when 
comparing different spectra.  
 
Interpretation.  It is possible to profile membrane proteins using Ciphergen 
ProteinChip arrays.  Importantly, both membrane protein similarities and 
membrane protein differences between FNRBC and AARBC could be 
demonstrated across the varied chip chemistries tested.  Similarities are 
important, as both cell types belong to the erythropoietic lineage and must share 
some surface characteristics.  Differences are more important, as it is these that 
this project is designed to study so that at least one difference could be identified 
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Figure 4.1 FNRBC and AARBC membrane protein profilin
SAX2, WCX2 and IMAC Cu2+, Mn2+, Ni3+, Mg2+, Fe3+ chip
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4.3 Protein profiling using NP20 and H4 ProteinChip arrays  
Aim.  To identify membrane protein peaks unique to hydrophobic and hydrophilic 
proteins amongst fetal primitive erythroblast and adult anucleate erythrocyte 
membrane proteins.  
 
Investigation.  FNRBC and AARBC membrane proteins were profiled on 
hydrophobic (H4) and hydrophilic (NP20) ProteinChip arrays.  Data acquisition 
was carried out on three different mass ranges as described in section 2.2.10. 
 
Results.  Some proteins were absent in AARBC samples, but only occasionally 
represented in FNBRC samples (Tables 4.2, 4.3).  These were disregarded for 
the purposes on this study, as I was interested in proteins that demonstrated the 
“on/off switch” pattern: where one protein is either present (100%) or absent 
(100%) on one cell type, and represented conversely on the other.  Only this 
pattern of surface antigen representation would be suitable for immunosorting 
during non-invasive prenatal diagnosis.   
 
Remarkably, there was considerable overlap in the cell membrane protein 
expression.  In fact, no differences were noted on the H4 chip spectra (Table 4.2).  
In all cases where there was some representation of a protein within FNRBC 
samples and absence of this protein peak within the AARBC spectra, the 
representation was only partial i.e. not 100% and not suitable for my purpose. 
 
The NP20 ProteinChip spectra did show a difference, but only one.  This only 
difference was found for protein peaks with MW ranging from 31,166.2-31,192.1 
Da, where these peaks were detected in 100% of FNRBC samples and were 
absent in 100% of AARBC samples (Table 4.3).  My concern was that these 
 84
specific peaks may only represent dimers of haemoglobin (Herbert et al., 2001), 
which was known to contaminate the FNRBC samples (section 3.4). 
 
Table 4.2 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using H4 chip. 
Peak range 
(Da) 
Peaks (Da) Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
3,000-20,000 8,963 1/2 0/2 
 15,181±75.4 1/2 1/2 
 15851.7 1/2 0/2 
20,000-60,000 31,190.9 1/2 0/2 
 47,092 1/2 0/2 
>60,000 63,554.7 1/2 0/2 
 79,807 1/2 0/2 
 95,984.5 1/2 0/2 
 145,297.1 1/2 0/2 
 185,077.45±2,891.95 1/2 1/2 
 
Table 4.3 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using NP20 chip. Peak with MW range 31,166.2-31,192.1 
Da was detected in both of FNRBC membrane protein samples, and it was 
absent in both of AARBC membrane protein samples.  
Peak range 
(Da) 
Peaks (Da) Ratio of FNRBC 
M protein 
Ratio of AARBC M 
protein 
3,000-20,000 10,052.55±82.45 1/2 1/2 
 15,201.95±85.85 2/2 1/2 
 16,047.85±43.75 2/2 1/2 
20,000-60,000 31,179.15±12.95 2/2 0/2 
 47,218.9 1/2 0/2 
>60,000 63,643.2 1/2 0/2 





Interpretation.  FNRBCs and AARBCs share many membrane protein similarities 
amongst their hydrophobic and hydrophilic proteins.  There was no major 
difference between the two cell type membrane protein profiles when evaluated 
using NP20 and H4 ProteinChip arrays, but one protein with MW ranging 
between 31,166.2-31,192.1 Da was found only in FNRBC samples on the NP20 
ProteinChip.  Although this protein meets my criteria of 100% differentially 
expressed proteins, one concern is that it represents dimers of haemoglobin that 
could not be completely removed from FNRBC membrane preparations (section 
3.4).   
 
4.4 Protein profiling using SAX2 and WCX2 ProteinChip 
arrays 
Aim.  To identify membrane protein peaks unique to anionic and cationic proteins 
amongst fetal primitive erythroblast and adult anucleate erythrocyte membrane 
proteins.  
 
Investigation.  FNRBC and AARBC membrane proteins were fractionated based 
on pI values, and profiled on anionic (SAX2) and cationic (WCX2) ProteinChip 
arrays.  Data acquisition was carried out on three different mass ranges as 
described in section 2.2.10. 
 
Results.  Unique, differentially expressed proteins were identified using the SAX2 
ProteinChip (Table 4.4), but the expression pattern on FNRBCs was only partial 
(50-75%).  These did not meet my set criteria.  Results from the WCX2 
ProteinChip were even less promising, and the only difference identified was the 
presence of three protein peaks that occurred more frequently in FNRBCs than in 
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AARBCs (over-representation, rather than over-expression or differential 
expression) (Table 4.5).   
 
Table 4.4 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using SAX2 chip 
Peak range 
(Da) 
Peaks (Da) Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
3,000-20,000 15,165.3±43.8 3/4 0/3 
 16,082.9±10.1 3/4 0/3 
20,000-60,000 48,162.85±459.05 3/4 0/3 
>60,000 63,481.8±1,108.7 3/4 0/3 
 79,715.65±669.95 2/4 1/3 
 
Table 4.5 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using WCX2 chip 
Peak range 
(Da) 
Peaks (Da) Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
3,000-20,000 15,174.3±21.5 3/5 1/3 
20,000-60,000 31,770.75±418.45 3/5 1/3 
>60,000 63,459.5±1,178.5 3/5 1/3 
 
Interpretation.  Membrane protein profiling studies using SAX2 and WCX2 
ProteinChip arrays showed over-representation of several proteins in FNRBC 
samples.  However, this expression difference was not absolute (100%), and 
would not be useful targets for non-invasive prenatal diagnosis.  These were not 







4.5 Protein profiling using IMAC ProteinChips arrays 
Aim:  To identify membrane proteins amongst fetal primitive erythroblast and 
adult anucleate erythrocytes that have unique metal binding properties. 
 
Investigation.  IMAC ProteinChip arrays were chelated with metal ions (Fe3+, 
Cu2+, Mn2+, Ni3+ and Mg2+. Following metal chelation both FNRBC and AARBC 
samples were applied to the ProteinChip arrays to identify unique metal binding 
membrane proteins present in each cell type.  
 
Results.  IMAC ProteinChip arrays were ideal for identifying unique, differentially 
expressed proteins within FNRBC membrane samples. Protein profiling using 
IMAC ProteinChips arrays showed unique proteins in many FNRBC samples 
tested (Tables 4.6 – 4.10),  and 5 protein peaks met my criteria: 100% present in 
FNRBC samples and 100% absent in AARBC samples.  Three of these were 
Fe3+ binding proteins (Figure 4.2; Table 4.6), and one each Cu2+ (Table 4.7) and 
Mg2+ binding proteins (Table 4.10).   
 
IMAC chips pre-treated with Cu2+ (Table 4.7), Mn2+ (Table 4.8), Ni3+ (Table 4.9) 
and Mg2+ (Table 4.10) ions were also used to profile proteins binding these 
chelated metal ions.  The unique FNRBC membrane protein peaks with MW in 
the range between 32,072.3-32,214.3 Da were detected in IMAC-Cu2+ 
ProteinChip array (Figure 4.3) and protein peaks with MW range 31,324.9-
32,155.9 Da were detected in IMAC-Mg2+ chip (Figure 4.3).  More representative 
membrane protein spectra are presented in Appendix A (Figures A4.1-A4.8). 
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Figure 4.2 (a-c) Representative protein mass spectra of AARBC memb
FNRBC membrane processed on IMAC-Fe3+ chip surface.  (a), (b)
showed three unique membrane proteins to FNRBC identified with MW
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Table 4.6 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using IMAC Fe3+ chip. Peaks with MW range 46,432.1-
48139.6 Da, 61,320.1-64,219.7 Da, and 76,384.8-79766 Da were detected in all 
the nine FNRBC membrane protein samples, and they were absent in all the 





Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
3,000-20,000 15,202.55±119.95 5/9 7/7 
30,488.75±313.95 7/9 0/7 
32,108±64 7/9 0/7 20,000-60,000 
47,286.15±853.45 9/9 0/7 
62,769.9±1,449.8 9/9 0/7 
78,075.4±1,690.6 9/9 0/7 >60,000 
94,396.25±1,146.55 6/9 2/7 
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                             (a)                                                   (b) 
Figure 4.3 Representative protein mass spectra of FNRBC an
membrane proteins processed on (a) IMAC-Cu2+ and (b) IMAC-Mg2+ ch
Unique FNRBC protein peaks with MW ranged 32,072.3-32,214.
31,324.9-32,155.9 Da were detected from IMAC-Cu2+ and IMAC-M







3 Da and 
g2+ chips, 
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Table 4.7 Ratio analysis of peaks detected from FNRBC and AARBC membrane 
protein sample spectra using IMAC Cu2+ chip. Peaks with MW range 32,072.3-
32,214.3 Da were detected in all the four FNRBC membrane protein samples, 




Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
5,934.25±1.55 2/4 0/3 
15,199.6±86.6 2/4 3/3 3,000-20,000 
16,025.75±83.75 4/4 1/3 
30,255.1±55.7 2/4 3/3 
31,172.6±42.5 2/4 1/3 
32,143.3±71 4/4 0/3 
20,000-60,000 
47,414.6±975.7 3/4 1/3 
62,140.35±1,536.55 4/4 2/3 
>60,000 
78,775.3±1,066.3 3/4 1/3 
 
 
Table 4.8 Ratio analyses of peaks detected from FNRBC and AARBC membrane 




Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
3,000-20,000 16,009.3±73.6 3/4 2/3 
31,780.55±496.35 4/4 1/3 
20,000-60,000 
48,453.7±202.1 2/4 0/3 
63,103.1±1,193 4/4 1/3 
>60,000 




Table 4.9 Ratio analysis of peaks detected from FNRBC and AARBC membrane 




Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
15,150.65±43.75 4/5 3/3 
3,000-20,000 
16,107.75±46.05 4/5 0/3 
31,723.25±487.05 4/5 1/3 
20,000-60,000 
47,535.55±713.55 3/5 1/3 
62,854.15±1,550.55 4/5 1/3 
>60,000 
78,347.35±1,746.75 3/5 1/3 
 
Table 4.10 Ratio analysis of peaks detected from FNRBC and AARBC 
membrane protein sample spectra using IMAC-Mg2+ chip. Peak with MW range 
31,324.9-32,155.9 was detected in all the six FNRBC membrane protein samples, 




Ratio of FNRBC 
M protein 
Ratio of AARBC 
M protein 
15,150.65±50.15 5/6 3/3 
3,000-20,000 
16,026.55±129.25 5/6 1/3 
31,740.4±415.5 6/6 0/3 
20,000-60,000 
47,960.05±288.35 3/6 0/3 
79,334.65±589.05 3/6 0/3 
>60,000 
95,070.75±1,185.65 3/6 1/3 
 
Interpretation.  Five protein peaks met my criteria: 100% present in FNRBC 
samples and 100% absent in AARBC samples.  Three of these were Fe3+ binding 
proteins (47.2 kDa, 62.7 kDa, 78 kDa), and one each Cu2+ and Mg2+ binding 
proteins.  These results are promising, as membrane proteins are known to have 
metal binding properties.  My concern with the proteins identified on the Cu2+ and 
Mg2+ binding chips is that they could represent dimers of haemoglobin that could 
not be completely removed from FNRBC membrane preparations (sections 4.3, 
3.4).  The three proteins identified using the Fe3+ binding chips were the best 
targets for further purification and characterisation.   
 92
4.6 Conclusion 
Principal findings of this SELDI-based membrane protein profiling study are the 
identification of unique, differentially expressed FNRBC proteins, especially those 
with Fe3+ binding properties identified using IMAC3 ProteinChips.   
 
Owing to their fetal origin, and the presence of nuclei in FNRBCs, I expected their 
membrane protein profile to be unique when compared with anucleate adult 
RBCs.  Membrane proteins demonstrate varied chemistries (e.g. hydrophobicity 
and hydrophilic properties) and often have high molecular weights with complex 
surface moieties.  No one technique would satisfactorily interrogate all these 
proteins, but a high-throughput technique such as SELDI allows a standardised 
comparison of many proteins simultaneously.  This is the first study that exploits 
this advantage of SELDI protein profiling to compare similarities and differences 
the membrane proteome of two different cell types.      
 
Membrane protein extraction in the present study appears superior to cell lysates 
(Cazares et al., 2002; Shiwa et al., 2003) or homogenate tissue lysates (Yang et 
al., 2004; Moody et al., 2004) to be loaded on the ProteinChip arrays.  This 
strategy reduces the complexity of the sample, and enriches proteins of interest 
by pre-fractionation based upon specific chemistries.  In addition, both AARBCs 
and FNRBCs contain large amount of haemoglobin, which will affect other 
proteins binding to the ProteinChip arrays if whole cell lysates are loaded on the 
chip. Enriching membrane proteins through fractionation from the whole lysates 
avoided this problem. 
 
SELDI profiling allows us to examine several hundred protein subclasses on a 
single protein spot. The current investigations on membrane protein profiles 
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showed the presence of a large number of proteins in each subclass (based on 
type of ProteinChip array) in the molecular weight range between 10 kDa and 40 
kDa, but peaks were fewer for proteins more than 50 kDa.  This could be due to 
the limitations of the mass spectrometer to carry out efficient resolution of these 
proteins, or possibly the copy number of these high molecular weight proteins is 
below the detection threshold of the mass spectrometer.   
 
The hydrophobic and hydrophilic membrane protein profiles from both FNRBC 
and AARBC were largely identical, except for one unique, differentially expressed 
protein peak of 31.2 kDa.  As for similar protein peaks present on the copper and 
magnesium binding chips, I suspect these are dimers of haemoglobin as FNRBC 
membrane samples were not completely clear of haemoglobin contamination 
(section 3.4).   
 
IMAC-Fe3+ ProteinChip arrays detected three distinguishing peaks unique to 
FNRBCs.  Membrane proteins are known to have metal binding properties: 
protein-metal interaction studies indicate that the low dielectric constant of protein 
cavities seems to favour the exchange reaction between protein ligands and the 
metal-bound water (Dudev & Lim, 2000).  Erythrocyte membranes have 
membrane transport systems for the exchange of metal ions.  They relate to the 
bioenergetics of the erythrocyte cell, and the regulation of enzyme activity on 
important metabolite pathways (glycolysis, pentosephosphate pathway) (Gahr et 
al, 1991; Bernhardt et al, 1988).  The amino acid histidine present in proteins 
forms complexes with transitional metal ions such as Cu2+, Mg2+, Ni2+, and Fe3+.  
Thus it is possible that unique FNRBC membrane proteins detected by the IMAC 
Fe3+ chip may play an active role in the regulation of metabolic enzyme activity.  
Their identity, however, is not known.   
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The advantage of SELDI is to study many proteins simultaneously, but its 
disadvantage is that at present we cannot characterise or identify any one of 
those multitudes of proteins.  To do that, I proceeded with conventional SDS-
PAGE gel electrophoresis and tandem MALDI-TOF/TOF mass spectrometry to 
identify and characterise individual unique bands corresponding to either FNRBC 







Chapter 5: Membrane protein identification 
using SDS-PAGE, MALDI-TOF, MALDI-
TOF/TOF and database search 
5.1 Introduction 
SELDI-TOF-MS data indicated the presence of several unique FNRBC 
membrane protein peaks in MW ranges of 46-49 kDa, 61-65 kDa and 76-80 kDa 
(Chapter 4).  The identity of these proteins cannot be established using SELDI-
TOF.  Protein identification is possible using other techniques such as gel 
electrophoresis (SDS-PAGE) followed by MS based identification (PMF and more 
sensitive MS/MS sequencing techniques).  
 
For the identification of candidate proteins, we used several techniques starting 
with (1) SDS-PAGE to separate different proteins based on MW, followed by (2) 
in-gel digestion of selected protein bands, and (3) identification of proteins using 
MALDI-TOF/TOF tandem mass spectrometry.  
 
SDS-PAGE could resolve only a limited number of protein bands while hundreds 
of proteins exist within the cell membrane, and it is likely that each protein band 
may contain more than one protein; hence MALDI-TOF/TOF tandem mass 
spectrometry was used.  For maximum sensitivity, SDS-PAGE was stained using 
silver stain compatible to MS which was up to 50-fold more sensitive than 
Coomassie blue staining for detecting proteins. 
 
MS-based protein identification was carried out in two steps.  Firstly, MALDI-
TOF/MS technique was used to analyse selected AARBC membrane protein 
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bands from a SDS-PAGE.  This preliminary study was carried out to confirm our 
experimental settings including membrane extraction procedures and protein 
identification by comparing our results with earlier investigations on erythrocyte 
membrane proteome (Low et al, 2002; Kakhniashvili et al, 2004).  Next, we used 
the more sensitive technique of MALDI-TOF/TOF tandem mass spectrometry to 
confirm the identity of the proteins.  Coupled with database searching, this is a 
powerful technique for protein identification.    
 
In addition to the identification of membrane proteins from AARBC and FNRBC, I 
also investigated their subcellular location.  Comparing the membrane proteins 
identified revealed differences in membrane protein composition of the two cell 
types.  In this chapter, I explore hypothesis 3 (section 1.7.1), that: Unique surface 
antigen proteins that are differentially expressed between fetal nucleated red 
blood cells and adult anucleate erythrocytes can be identified. 
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5.2 AARBC membrane protein identification using MALDI-
TOF/MS  
Aim. To validate our membrane extraction, protein separation protocols and MS 
identification of proteins based on published reports on erythrocyte membrane 
proteome analysis.  
 
Investigation.  Purified membrane proteins isolated from plasma membrane 
fractions were subjected to gel based electrophoretic separation (section 2.2.10).  
Two gel bands Ra and Rb from SDS-PAGE gel (Figure 5.1) were excised and 
proteins were eluted and subjected to alkylation and reduction prior to 
identification using MALDI-TOF/MS (section 2.2.13).   
Results.  The AARBC membrane proteins resolved in SDS-PAGE are shown 
Figure 5.1.  Protein bands with MW greater than 100 kDa appeared to stack in 
the upper part of the gel.   
 
Peptide mass fingerprinting using MALDI-TOF/MS (section 2.2.14) followed by 
MASCOT search (section 2.2.15.2) identified Ra as Erythrocyte band 7 integral 
membrane protein (Stomatin) (Protein 7.2b) and Rb as Glyceraldehyde 3-
phosphate dehydrogenase (Table 5.1).  These results were significant as the p 








































































1 AARBC membrane protein bands (lanes 1-6) in SDS-PAGE gel (8%, 
l). 10 µg of sample was loaded into each lane. Two protein bands (Ra 
ere exercised out for MALDI-TOF analysis and Swiss-Prot or NCBInr 
search.  
 manual MS-Fit searches (section 2.2.15.1) were also performed for 
ass fingerprinting, and the results are presented in Table 5.2.  In the 
arch (section 2.2.16, criteria 1-5), identical proteins were identified as 
d using the MASCOT search i.e. Stomatin (Protein 7.2b) and Arginase 
entified from bands Ra and Rb, respectively.  However, if only four 
MS-Fit search were used (section 2.2.16, criteria 1-4), as that followed 
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by Low et al. (2002), more proteins were identified (Table 5.2); these proteins 
have previously been reported in anucleate RBCs by Low et al. (2002). 
 
Table 5.1 MALDI-TOF MASCOT search summary for band Ra and Rb 





Accession No. Protein Description MW (Da) 
Ra P27105
Erythrocyte band 7 integral 
membrane protein (Stomatin) 
(Protein 7.2b)
31751
Rb P04406 Glyceraldehyde 3-phosphate dehydrogenase 36070
 
 
Table 5.2 MALDI-TOF MS-Fit search summary for band Ra and Rb (mass 







































































Mass spectra for bands Ra and Rb are shown in Figures 5.2 and 5.3 respectively.  
Matched peptide peaks were highlighted with an arrow for MASCOT search 
results.  In addition, sequence coverage of Ra and Rb are also presented in 
Figures 5.4 and 5.5, respectively. 
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Figure 5.2 MALDI-TOF/MS spectrum of peptides digested from band Ra.  Peaks 
matching Erythrocyte band 7 integral membrane protein (Stomatin) (Protein 7.2b) 
are labelled with arrows (m/z 1392.69; 1601.91; 1572.79; 1929.99; 915.54; 




















Figure 5.3 MALDI-TOF/MS spectrum of peptides digested from band Rb. Peaks 
matching Glyceraldehyde 3-phosphate dehydrogenase are labelled with arrows 
(m/z 805.42; 1613.89; 2041.01; 1833.88; 1411.77; 869.50; 1530.77; 1763.76; 
















































      
    51 MCIKIIKEYE RAIIFRLGRI LQGGAKGPGL FFILPCTDSF IKVDMRTISF  
1 AEKRHTRDSE AQRLPDSFKD SPSKGLGPCG WILVAFSFLF TVITFPISIW  
   101 DIPPQEILTK DSVTISVDGV VYYRVQNATL AVANITNADS ATRLLAQTTL  
   151 RNVLGTKNLS QILSDREEIA HNMQSTLDDA TDAWGIKVER VEIKDVKLPV  
   201 QLQRAMAAEA EASREARAKV IAAEGEMNAS RALKEASMVI TESPAALQLR  
   251 YLQTLTTIAA EKNSTIVFPL PIDMLQGIIG AKHSHLG 
 
(b) 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
     8 - 19     1392.69  1391.68  1391.67     0.01     1  DSEAQRLPDSFK   
    97 - 110    1601.91  1600.90  1600.87     0.03     0  TISFDIPPQEILTK   
   111 - 124    1572.79  1571.78  1571.78     0.00     0  DSVTISVDGVVYYR   
   125 - 143    1929.99  1928.98  1928.99    -0.01     0  VQNATLAVANITNADSATR   
   144 - 151     915.54   914.54   914.55    -0.02     0  LLAQTTLR   
   198 - 204     853.50   852.49   852.52    -0.03     0  LPVQLQR   
   205 - 214    1006.45  1005.45  1005.45    -0.01     0  AMAAEAEASR   
   220 - 231    1247.60  1246.59  1246.60    -0.01     0  VIAAEGEMNASR   
   220 - 231    1263.64  1262.63  1262.59     0.04     0  VIAAEGEMNASR  Oxidation (M)  
   235 - 250    1715.89  1714.89  1714.89    -0.01     0  EASMVITESPAALQLR   
   251 - 262    1351.71  1350.71  1350.74    -0.03     0  YLQTLTTIAAEK   
 
Figure 5.4 Sequence coverage of tryptic digested peptides from band Ra, 
identified as Erythrocyte band 7 integral membrane protein (Stomatin) (Protein 
7.2b) by MASCOT searching.  (a) Complete amino acid sequence of identified 
protein, matched peptides were shown in bold italic.  Sequence coverage was 
43%.  (b) Illustrated mass value, mass tolerance and number of missed cleavage 





     
    51 THGKFHGTVK AENGKLVING NPITIFQERD PSKIKWGDAG AEYVVESTGV  
1 GKVKVGVNGF GRIGRLVTRA AFNSGKVDIV AINDPFIDLN YMVYMFQYDS  
   101 FTTMEKAGAH LQGGAKRVII SAPSADAPMF VMGVNHEKYD NSLKIISNAS  
   151 CTTNCLAPLA KVIHDNFGIV EGLMTTVHAI TATQKTVDGP SGKLWRDGRG  
   201 ALQNIIPAST GAAKAVGKVI PELNGKLTGM AFRVPTANVS VVDLTCRLEK  
   251 PAKYDDIKKV VKQASEGPLK GILGYTEHQV VSSDFNSDTH SSTFDAGAGI  
   301 ALNDHFVKLI SWYDNEFGYS NRVVDLMAHM ASKE 
 
(b) 
    Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
     5 - 12      805.42   804.41   804.42    -0.01     0  VGVNGFGR   
    66 - 79     1613.89  1612.88  1612.89    -0.01     0  LVINGNPITIFQER   
    66 - 83     2041.01  2040.01  2040.10    -0.09     1  LVINGNPITIFQERDPSK   
   145 - 161    1833.88  1832.87  1832.91    -0.04     0  IISNASCTTNCLAPLAK   
   200 - 214    1411.77  1410.77  1410.78    -0.02     0  GALQNIIPASTGAAK   
   219 - 226     869.50   868.49   868.50    -0.01     0  VIPELNGK   
   234 - 247    1530.77  1529.77  1529.79    -0.02     0  VPTANVSVVDLTCR   
   309 - 322    1763.76  1762.76  1762.80    -0.04     0  LISWYDNEFGYSNR   
   323 - 334    1330.65  1329.64  1329.64    -0.00     1  VVDLMAHMASKE   
 
Figure 5.5 Sequence coverage of tryptic digested peptides from band Rb, 
identified as Glyceraldehyde 3-phosphate dehydrogenase by MASCOT searching. 
(a) Complete amino acid sequence of identified protein, matched peptides were 
shown in bold italic.  Sequence coverage was 31%.  (b) Illustrated mass value, 
mass tolerance and number of missed cleavage site of each matched peptide. 
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Interpretation. The membrane proteins identified were similar to those reported in 
AARBC membrane proteins by Low et al. (2002), who also used SDS-PAGE and 
MALDI-TOF/MS.  This indicates that the experimental protocols followed by me 
were suitable for mass spectrometric studies, and I chose to use the more 
sensitive MALDI TOF/TOF tandem mass spectrometry with MASCOT protein 
identification searches for the rest of my work. 
 
5.3 Identification of FNRBC and AARBC membrane 
proteins by SDS-PAGE, MALDI-TOF/TOF Tandem MS and 
database search 
 
Aim.  To identify unique surface membrane proteins in AARBC and FNRBC cell 
types using MALDI-TOF/TOF Tandem MS.   
 
Investigation.  AARBC and FNRBC membrane proteins were extracted following 
the protocols described (sections 2.2.7 and 2.2.8), and the proteins were 
separated using SDS-PAGE (section 2.2.10).  All distinct bands on SDS-PAGE 
gels (Figures 5.7 and 5.10) for both these preparations were excised and proteins 
eluted.  MALDI-TOF/TOF Tandem MS was used for the identification of these 
proteins (section 2.2.14)  
 
A flow chart representing the steps for identification of proteins from AARBC and 




























Figure 5.6 Flowchart to represent the workflow used for the identification of 
membrane proteins in this study.  
 
Digested peptides were analysed using MALDI-TOF/TOF tandem mass 
spectrometry followed by sequence query of MASCOT search.  The strategy for 
the MASCOT sequence query search is described over the next few pages using 
band 3 and ankyrin (Protein band R5 in Figure 5.7; MW 75-100 kDa) as 
examples, Table 5.3.  Details of the rest of the bands in Figure 5.7 are tabulated 









Table 5.3 (A) – (E1-E8) are data that relate to the MASCOT database search 
engine. 
(A): probability based Mowse score; 
 
(B1 and B2):  sequence coverage of band 3 and ankyrin respectively; 
 
(C1 and C2): matched peptides sorted by residue number for band 3 and ankyrin, 
respectively; 
 
(D): MS spectra for band 3 and ankyrin; 
 
(         ): Labelled peaks of band 3 matched peptides subjected to MS/MS 
analysis to confirm the identity of band 3; 
 
(         ): Labelled peaks of ankyrin matched peptides subjected to MS/MS 
analysis to confirm the identity of ankyrin; 
 
(E1-E8): MS/MS analysis of 949.46 Da, 1054.48 Da, 1466.79 Da, 1490.76 Da, 
1876.99 Da (band 3), and 942.55 Da, 1080.51 Da, 1323.70 Da (ankyrin) peptides 
fragments are illustrated.  
 
The Mowse score for band 3 and ankyrin from all of the mass spectrometric data 
was 212 and 175, respectively.    
 
 
(A) Probability Based Mowse Score. Score is -10*Log(P), where P is the 
probability that the observed match is a random event. Protein scores greater 









(B1) Band 3 Sequence Coverage: 15%, matched peptides shown in Bold. 
 
     1 MEELQDDYED MMEENLEQEE YEDPDIPESQ MEEPAAHDTE ATATDYHTTS  
    51 HPGTHKVYVE LQELVMDEKN QELRWMEAAR WVQLEENLGE NGAWGRPHLS  
   101 HLTFWSLLEL RRVFTKGTVL LDLQETSLAG VANQLLDRFI FEDQIRPQDR  
   151 EELLRALLLK HSHAGELEAL GGVKPAVLTR SGDPSQPLLP QHSSLETQLF  
   201 SGILEKI PPDSEATLVL VGRADFLEQP VLGFVRLQEA   CEQGDGGTEG HSP
   251 AELEAVELPV PIRFLFVLLG PEAPHIDYTQ LGRAAATLMS ERVFRIDAYM  
   301 AQSRGELLHS LEGFLDCSLV LPPTDAPSEQ ALLSLVPVQR ELLRRRYQSS  
   351 PAKPDSSFYK GLDLNGGPDD PLQQTGQLFG GLVRDIRRRY PYYLSDITDA  
   401 FSPQVLAAVI FIYFAALSPA ITFGGLLGEK TRNQMGVSEL LISTAVQGIL  
   451 FALLGAQPLL VVGFSGPLLV FEEAFFSFCE TNGLEYIVGR VWIGFWLILL  
   501 VVLVVAFEGS FLVRFISRYT QEIFSFLISL IFIYETFSKL IKIFQDHPLQ  
   551 KTYNYNVLMV PKPQGPLPNT ALLSLVLMAG TFFFAMMLRK FKNSSYFPGK  
   601 LRRVIGDFGV PISILIMVLV DFFIQDTYTQ KLSVPDGFKV SNSSARGWVI  
   651 HPLGLRSEFP IWMMFASALP ALLVFILIFL ESQITTLIVS KPERKMVKGS  
   701 GFHLDLLLVV GMGGVAALFG MPWLSATTVR SVTHANALTV MGKASTPGAA  
   751 AQIQEVKEQR ISGLLVAVLV GLSILMEPIL SRIPLAVLFG IFLYMGVTSL  
   801 SGIQLFDRIL LLFKPPKYHP DVPYVKRVKT WRMHLFTGIQ IICLAVLWVV  
   851 KSTPASLALP FVLILTVPLR RVLLPLIFRN VELQCLDADD AKATFDEEEG  
   901 RDEYDEVAMP V 
 
(B2) Ankyrin Sequence Coverage: 12%, matched peptides shown in Bold. 
      
     1 MPYSVGFREA DAATSFLRAA RSGNLDKALD HLRNGVDINT CNQKGNTALH  
    51 IAALAGQDEV VRELVNYGAN VNAQSQKGFT PLYMAAQENH LEVVKFLLEN  
   101 GANQNVATED GFTPLAVALQ QGHENVVAHL INYGTKGKVR LPALHIAARN  
   151 DDTRTAAVLL QNDPNPDVLS KTGFTPLHIA AHYENLNVAQ LLLNRGASVN  
   201 FTPQNGITPL HIASRRGNVI MVRLLLDRGA QIETKTKDEL TPLHCAARNG  
   251 HVRISEILLD HGAPIQAKTK NGLSPIHMAA QGDHLDCVRL LLQYDAEIDD  
   301 ITLDHLTPLH VAAHCGHHRV AKVLLDKGAK PNSRALNGFT PLHIACKKNH  
   351 VRVMELLLK  T GASIDAVTES GLTPLHVASF MGHLPIVKNL LQRGASPNVS 
   401 NVKVETPLHM AARAGHTEVA KYLLQNKAKV NAKAKDDQTP LHCAARIGHT  
   451 NMVKLLLENN ANPNLATTAG HTPLHIAARE GHVETVLALL EKEASQACMT  
   501 KKGFTPLHVA AKYGKVRVAE LLLERDAHPN AAGKNGLTPL HVAVHHNNLD  
   551 IVKLLLPRGG SPHSPAWNGY TPLHIAAKQN QVEVARSLLQ YGGSANAESV  
   601 QGVTPLHLAA QEGHAEMVAL LLSKQANGNL GNKSGLTPLH LVAQEGHVPV  
   651 ADVLIKHGVM VDATTRMGYT PLHVASHYGN IKLVKFLLQH QADVNAKTKL  
   701 GYSPLHQAAQ QGHTDIVTLL LKNGASPNEV SSDGTTPLAI AKRLGYISVT  
   751 DVLKVVTDET SFVLVSDKHR MSFPETVDEI LDVSEDEGTA HITIMGEELI  
   801 SFKAERRDSR DVDEEKELLD FVPKLDQVVE SPAIPRIPCA MPETVVIRSE  
   851 EQEQASKEYD EDSLIPSSPA TETSDNISPV ASPVHTGFLV SFMVDARGGS  
   901 MRGSRHNGLR VVIPPRTCAA PTRITCRLVK PQKLSTPPPL AEEEGLASRI  
   951 IALGPTGAQF LSPVIVEIPH FASHGRGDRE LVVLRSENGS VWKEHRSRYG  
  1001 ESYLDQILNG MDEELGSLEE LEKKRVCRII TTDFPLYFVI MSRLCQDYDI  
  1051 IGPEGGSLKS KLVPLVQATF PENAVTKRVK LALQAQPVPD ELVTKLLGNQ  
  1101 ATFSPIVTVE PRRRKFHRPI GLRIPLPPSW TDNPR SLRLLCS  DSGEG DTT
  1151 VIGGTDQAQW EDITGTTKLV YANECANFTT NVSARFWLSD CPRTAEAVNF  
  1201 ATLLYKELTA VPYMAKFVIF AKMNDPREGR LRCYCMTDDK VDKTLEQHEN  
  1251 FVEVARSRDI EVLEGMSLFA ELSGNLVPVK KAAQQRSFHF QSFRENRLAM  
  1301 PVKVRDSSRE PGGSLSFLRK AMKYEDTQHI LCHLNITMPP CAKGSGAEDR  
  1351 TPTPLALR YSILSESTPG SLSGTEQAEM KMAVISEHLG LSWAELAREL   RR
  1401 QFSVEDINRI RVENPNSLLE QSVALLNLWV IREGQNANME NLYTALQSID  
  1451 RGEIVNMLEG SGRQSRNLKP DRRHTDRDYS LSPSQMNGYS SLQDELLSPA  
  1501 SLGCALSSPL RADQYWNEVA VLDAIPLAAT EHDTMLEMSD MQVWSAGLTP  
  1551 SLVTAEDSSL ECSKAEDSDA TGHEWKLEGA LSEEPRGPEL GSLELVEDDT  
  1601 VDSDATNGLI DLLEQEEGQR SEEKLPGSKR QDDATGAGQD SENEVSLVSG  
  1651 HQRGQARITH SPTVSQVTER SQDRLQDWDA DGSIVSYLQD AAQGSWQEEV  
  1701 TQGPHSFQGT STMTEGLEPG GSQEYEKVLV SVSEHTWTEQ PEAESSQADR  
  1751 DRRQQGQEEQ VQEAKNTFTQ VVQGNEFQNI PGEQVTEEQF TDEQGNIVTK  
  1801 KIIRKVVRQI DLSSADAAQE HEEVTVEGPL EDPSELEVDI DYFMKHSKDH  





(C1) Band 3 matched peptides sorted by residue number 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
   220 - 233    1466.79  1465.78  1465.81    -0.04     0  IPPDSEATLVLVGR (No match) 
   220 - 233    1466.79  1465.78  1465.81    -0.04     0  IPPDSEATLVLVGR (Ions score 26) 
   234 - 246    1490.76  1489.76  1489.79    -0.04     0  ADFLEQPVLGFVR (No match) 
   234 - 246    1490.76  1489.76  1489.79    -0.04     0  ADFLEQPVLGFVR (Ions score 33) 
   247 - 263    1876.99  1875.99  1876.03    -0.04     0  LQEAAELEAVELPVPIR (Ions score 26) 
   247 - 263    1876.99  1875.99  1876.03    -0.04     0  LQEAAELEAVELPVPIR Oxidation (M) (No match) 
   284 - 292     949.46   948.45   948.47    -0.02     0  AAATLMSER (Ions score 38) 
   284 - 292     949.46   948.45   948.47    -0.02     0  AAATLMSER (No match) 
   284 - 292     965.45   964.44   964.46    -0.02     0  AAATLMSER (No match) 
   284 - 295    1351.66  1350.65  1350.71    -0.06     1  AAATLMSERVFR (No match) 
   296 - 304    1054.48  1053.47  1053.49    -0.02     0  IDAYMAQSR (No match) 
   296 - 304    1054.48  1053.47  1053.49    -0.02     0  IDAYMAQSR (Ions score 34) 
   296 - 304    1070.47  1069.46  1069.49    -0.03     0  IDAYMAQSR (No match) 
   347 - 360    1604.77  1603.76  1603.75     0.01     0  YQSSPAKPDSSFYK (No match) 
   593 - 600     899.42   898.41   898.42    -0.01     0  NSSYFPGK (No match) 
   632 - 639     862.45   861.44   861.46    -0.02     0  LSVPDGFK (No match) 
   731 - 743    1328.67  1327.66  1327.69    -0.03     0  SVTHANALTVMGK (No match) 
   818 - 826    1117.54  1116.53  1116.56    -0.03     0  YHPDVPYVK (No match) 
   872 - 879     970.63   969.62   969.64    -0.01     0  VLLPLIFR (No match) 
   893 - 911    2201.88  2200.87  2200.91    -0.04     1  ATFDEEEGRDEYDEVAMPV (No match) 
   893 - 911    2201.88  2200.87  2200.91    -0.04     1  ATFDEEEGRDEYDEVAMPV (No match) 








(C2) Ankyrin matched peptides sorted by residue number 
 
Start - End   Observed  Mr(expt) Mr(calc)   Delta   Miss Sequence 
     2 - 8       825.38   824.38   824.42    -0.04     0  PYSVGFR (No match) 
     9 - 18     1080.51  1079.50  1079.52    -0.02     0  EADAATSFLR (Ions score 27) 
   155 - 171    1794.87  1793.86  1793.95    -0.09     0  TAAVLLQNDPNPDVLSK (No match) 
   254 - 268    1604.77  1603.76  1603.89    -0.13     0  ISEILLDHGAPIQAK (No match) 
   349 - 359    1351.66  1350.65  1350.78    -0.13     1  NHVRVMELLLK (No match) 
   353 - 359     845.50   844.49   844.51    -0.02     0  VMELLLK (No match) 
   404 - 413    1124.57  1123.56  1123.58    -0.02     0  VETPLHMAAR (No match) 
   447 - 454     899.42   898.41   898.47    -0.06     0  IGHTNMVK (No match) 
   518 - 525     942.55   941.54   941.55    -0.02     0  VAELLLER (Ions score 36) 
   518 - 525     942.55   941.54   941.55    -0.02     0  VAELLLER (No match) 
   526 - 534     880.43   879.42   879.42     0.00     0  DAHPNAAGK (No match) 
   657 - 666    1086.52  1085.51  1085.53    -0.02     0  HGVMVDATTR (No match) 
   744 - 754    1207.66  1206.65  1206.69    -0.03     0  LGYISVTDVLK (No match) 
   825 - 836    1323.70  1322.69  1322.72    -0.03     0  LDQVVESPAIPR (No match) 
   825 - 836    1323.70  1322.69  1322.72    -0.03     0  LDQVVESPAIPR (Ions score 39) 
   986 - 996    1328.67  1327.66  1327.63     0.03     1  SENGSVWKEHR (No match) 
  1096 - 1112   1841.97  1840.96  1841.00    -0.04     0  LLGNQATFSPIVTVEPR (No match) 
  1124 - 1135   1392.69  1391.68  1391.72    -0.04     0  IPLPPSWTDNPR (No match) 
  1186 - 1193   1080.51  1079.50  1079.49     0.01     0  FWLSDCPR (No match) 
  1310 - 1319   1062.54  1061.53  1061.55    -0.02     0  EPGGSLSFLR (No match) 
  1353 - 1360    868.51   867.50   867.52    -0.02     0  TPTPLALR (No match) 
  1399 - 1409   1349.64  1348.63  1348.66    -0.03     0  ELQFSVEDINR (No match) 
  1464 - 1472   1113.57  1112.56  1112.61    -0.05     1  QSRNLKPDR (No match) 
  1565 - 1576   1345.69  1344.68  1344.56     0.13     0  AEDSDATGHEWK (No match) 

























































































































































































































































































































































































































 (D) MS spectrum:  labelled peaks are band 3 matched peptides subjected to MS/MS analysis to confirm the identity of band 3, and                          






(E1) MS/MS spectrum of the 9-amino acid peptide AAATLMSER [(M+H)+ m/z 
949.46], generated by digestion with trypsin.  Only b-, y- and a-type fragment ions 





(E2) MS/MS spectrum of the 9-amino acid peptide IDAYMAQSR [(M+H)+ m/z 
1054.48], generated by digestion with trypsin.  Only b-, y- and a-type fragment 







(E3) MS/MS spectrum of the 14-amino acid peptide IPPDSEATLVLVGR [(M+H)+ 
m/z 1466.79], generated by digestion with trypsin.  Only y-type fragment ions are 






(E4) MS/MS spectrum of the 13-amino acid peptide ADFLEQPVLGFVR [(M+H)+ 
m/z 1490.76], generated by digestion with trypsin.  No basic amino acid is 
present at either N- or the C- terminus of the peptide, and as a result both b- and 












(E5) MS/MS spectrum of the 17-amino acid peptide LQEAAELEAVELPVPIR 
[(M+H)+ m/z 1876.99], generated by digestion with trypsin.  No basic amino acid 
is present at either N- or the C- terminus of the peptide, and as a result both b- 






(E6) MS/MS spectrum of the 8-amino acid peptide VAELLLER [(M+H)+ m/z 
942.55], generated by digestion with trypsin.  No basic amino acid is present at 
either N- or the C- terminus of the peptide, and as a result both b- and y-type 










(E7) MS/MS spectrum of the 10-amino acid peptide EADAATSFLR [(M+H)+ m/z 
1080.51 Da], generated by digestion with trypsin.  Only b-, y- and a-type fragment 





(E8) MS/MS spectrum of the 12-amino acid peptide LDQVVESPAIPR [(M+H)+ 
m/z 1323.70], generated by digestion with trypsin.  Only y-type fragment ions are 









Results.  Membrane proteins of both AARBC and FNRBC identified using the 
above strategy are described below.  
 
• AARBC membrane protein identification   
All the distinct bands were excised from SDS-PAGE (Figure 5.7), and were 
subjected to MALDI-TOF/TOF analysis.  In-gel digestion was performed on 31 
protein bands (Figure 5.7: R1-R31).   
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Figure 5.7 AARBC membrane protein bands resolved in SDS-PAGE (8%, 16 cm 
gel) using silver stain for MALDI-TOF/TOF.  10 µg of protein was loaded to lanes 
1-6.  31 distinct bands (arrows) were excised separately (bands from all 6 lanes 
for each R-number were pooled), and subjected to in-gel digestion for MALDI-
TOF/TOF analysis.  
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A total of 114 distinct proteins were identified using MALDI-TOF/TOF and 
MASCOT database search from 31 bands.  Data obtained from MALDI analysis 
are presented in Appendix B (Table B5.1).  The number of peptides identified, the 
protein sequence coverage and the MS/MS ion score gave an indication of the 
accuracy of identification.  Furthermore, only proteins with statistically significant 
MASCOT score results (p < 0.05) are tabulated in Table B5.1.   
 
Identification of low MW proteins from the high MW region of the gel could be due 
to either post-translational modification that could alter the MW, or the formation 
of dimers/trimers/tetramers and polymers (Herbert et al., 2001; Vitorino et al., 
2004). In order to increase the specificity of identification, low MW proteins 
identified from high MW region were not included in Table B5.1.  The only 
exception to this was the globin chain, which was reported by Herbert et al. (2001) 
to form dimers, trimers and tetramers in SDS-PAGE gels.  In contrast, it is 
reasonable to expect high MW proteins in the low MW region due to degradation 
of high MW proteins in SDS-PAGE (Low et al., 2002).  All high MW proteins 
identified in low MW regions were included in subsequent analysis.   
 
The 114 distinct AARBC proteins were classified into 55 categories (Table 5.4). 
These proteins were also categorised according to their subcellular location into 4 
major groups: (1) membrane proteins, (2) membrane associated proteins, (3) 
cytoplasmic and nuclear proteins, and (4) location uncharacterised proteins.  It is 
known that many of the proteins identified here can exist in multiple cell locations, 
but only those that are known to have some association with cellular membranes 
have been included in Table 5.4.  Only those proteins with their properties 




 Table 5.4 Classification of identified proteins from AARBC membrane pellet 
fraction. (p) Denotes putative subcellular location deduced from functional 
domains, or literature evidence. 
 
Protein Classification Identified from bands 
Subcellular 
location 
Spectrin alpha chain; spectrin beta chain R1, R2, R3 Membrane 
Erythrocyte membrane protein band 3 R1, R3, R4, 
R5, R7, R8, 




Ankyrin; ankyrin repeat domain; similar to 
hypothetical protein DKFZp434A171; 
KIAA1561 protein 
R2, R3, R5, 




Erythrocyte membrane protein 4.1 R6 Membrane 
Erythrocyte membrane protein band 4.2 R6, R7 Membrane  
Erythrocyte membrane protein p55 R11, R13 Membrane  
Flotillin; flotillin 1 and 2 R14, R15 Membrane 
Actin gamma and beta; actin binding 
protein ABP620; ACTB protein; Similar to 
FKSG30 
R16, R3 Membrane 
Tropomodulin 1 R17 Membrane  
Aldolase A R18 Membrane 
Glyceraldehyde-3-phosphate 
dehydrogenase; uracil DNA glycosylase 
R20, R21 Membrane 











Dystrophin Dp4271 isoform R2 Membrane (p)  














IGHG1 protein; Unknown (protein for MGC: 
20691); unnamed protein product 
(gi34526063, gi34527739, gi34527430, 
gi21757082); Chain H, crystal structure of 
the intact human Igg B12 with broad and 
potent activity against primary Hiv-1 
isolates: a template for Hiv vaccine design 
R12, R13 Membrane (p) 
Domain: IGc, IGv 





Hypothetical protein FLJ12649 R19 Membrane (p) 
Domain: 
COG5373 
Nebulin-related anchoring protein; nebulin; 
Hypothetical protein (gi30268247 and  
gi30348693) 
R1, R2, R4, 








Kinesin family member 27; KIF27B; 
KIF27C ; unnamed protein product 
(gi14042584); myosin, heavy polypeptide 
14; KIAA2034 protein; unnamed protein 
product (gi10436039); Chromosome 6 open 
reading frame 60 





Trabeculin-alpha; trabeculin-beta R2, R3, R24 Membrane 
associated 




Filamin A interacting protein 1 R2, R7, R8 Membrane 
associated 
Envoplakin; Hypothetical protein KIAA0568; 
195 kDa cornified envelope precursor; 
periplakin 
R3, R24, R15 Membrane 
associated 
Microfilament and actin cross-linker protein 
isoform a, b 
R3 Membrane 
associated 
KIAA0465 protein; microtubule-actin 
crosslinking factor 1 
R3 Membrane 
associated 
Pericentrin B R3, R11, R24 Membrane 
associated 




Dynein, axonemal, heavy polypeptide 8 R6 Membrane 
associated 
Rho-associated, coiled-coil containing 
protein kinase 2; KIAA0619 protein 
R10, R11 Membrane 
associated 
Unknown (protein for MGC: 75105); 
annexin A4; protein PP4-X; annexin IV 
R22 Membrane 
associated 
Cilliary rootlet coiled-coil, rootletin; 
KIAA0445 protein 




KIAA1275 protein; Hypothetical protein 
(gi30268231) 





Caspase recruitment domain protein 10 R2 Cytoplasm  






Asp (abnormal spindle)-like, microcephaly 
associated 
R3 Cytoplasm and 
nuclear 
Unnamed protein product (gi7023190); 
hypothetical protein (gi31873894 and 
gi31874811); Grb10 interacting GYF protein 
2; KIAA0642 protein 
R18 Cytoplasm (p) 
Domain: GYF 
KIAA0565 protein R19 Cytoplasm (p) 
Domain: Smc, 
EzrA 




TruB pseudouridine (psi) synthase homolog R29 Cytoplasm 
Centromere protein F; CENP-F kinetochore 
protein  
R2 Nuclear  
Nuclear transcription factor, X-box binding 1 
isoform 1 
R3 Nuclear 
RAD50 homolog isoform 2; RAD50 
homologue hsRAD50; RAD50 homolog 
isoform 1; RAD 50 protein 





Poly (ADP-ribose) synthetase R11 Nuclear 
Multiple coiled-coil GABABR1-binding 
protein 
R13 Nuclear (p) 
Possible global transcription activator 
SNF2L1; global transcription activator 
homologous sequence 
R15 Nuclear 
Chromosome-associated protein-C R22 Nuclear and 
cytoplasm 

































Group 1: Membrane proteins within AARBCs 
Spectrin α-chain (erythrocyte membrane protein band 1) was identified from gel 
band R1, which was found as a thick band at about 250 kDa region. Spectrin β-
chain (erythrocyte membrane protein band 2) was identified from band R2 and 
R3.  Spectrin is the major constituent of the membrane skeleton; it accounts for 
approximately 25% of the total red membrane proteins (Bennet, 1985). 
 
Interestingly, degradation of ankyrin (erythrocyte membrane protein band 2.1) 
and band 3 which are high molecular weight proteins was observed.  This was 
evidenced by the presence of several lower MW bands with highly confident 
sequence query data that matched to the original high molecular weight proteins.  
Ankyrin was identified from band R2, R3, R5, R6, R8, R9, R10, R19 and R24. 
Erythrocyte membrane protein band 3 was identified from band R1, R3, R4, R5, 
R7, R8, R9, R10, R11, R17, R18, R19 and R21.  Initially degradation was 
suspected of using stored erythrocyte membrane protein sample (aliquots stored 
in -80ºC for two weeks to one month), however, later our observations indicated 
that even using freshly prepared erythrocyte membrane protein sample (Figure 
5.7) degradation still occurred. This phenomenon is in accordance with Low et al. 
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(2002) who found degradation of spectrin and band 3 in SDS-PAGE for AARBC 
membrane proteins. In the experiment reported by these authors, ankyrin was not 
identified in 1D gel.  
 
Erythrocyte membrane protein band 3 was identified from band R1 and R2 
around 150-250 kDa region; this phenomenon could be explained that lots of high 
MW proteins were not completely separated and stacked in the upper part of the 
gel. Similarly, hypothetical protein DKFZp434A171 (note “similar to hypothetical 
protein DKFZp434A171” is the name of the protein) was identified from band R15; 
and KIAA1561 protein was identified from band R24.  Both of these hypothetical 
proteins contain ankyrin repeats domain and were categorised into ankyrin family. 
 
Erythrocyte membrane protein band 4.1 was identified from band R6; and 
erythrocyte membrane protein band 4.2 was identified from band R6 and R7. 
Band 4.1 plays a key role in regulating membrane physical properties of 
mechanical stability and deformability by stabilizing spectrin-actin interaction.  It 
binds with a high affinity to glycophorin and with lower affinity to band 3 protein 
(Correas et al., 1986; Tang et al., 1998).  Band 4.2 (paladin) interacts with the 
cytoplasmic domain of band 3 anion transport protein (Korsgren et al., 1991; 
Risinger et al., 1992). 
 
Erythrocyte membrane protein p55 was identified from band R11 and R13.  It was 
established that the p55 protein is an obligate component of the protein 4.1-
glycophorin C complex, which regulates the stability and mechanical properties of 
the erythrocyte plasma membrane.  p55 is also a member of a growing family of 
signaling and cytoskeletal proteins termed membrane-associated guanylate 
kinase homologues (MAGUKs).  MAGUKs are multidomain proteins consisting of 
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either a single or three copies of the PDZ (PSD-95/Discs large/ZO-1) domain, an 
SH3 motif, and a guanylate kinaselike domain.  Recent studies have implicated 
MAGUKs in the clustering of ion channels, organization of cytoskeletal elements, 
cell signaling events, and regulation of cell proliferation and tumor-suppression 
pathways (Ruff et al., 1991; Metzenberg et al., 1992). 
 
Flotillin-1 and Flotillin-2 were identified from band R14 and R15. Both of them are 
caveolae-associated, integral membrane protein.  Caveolae are small domains 
on the inner cell membrane involved in vesicular trafficking and signal 
transduction.  Flotillin 1 may act as a scaffolding protein within caveolar 
membranes, functionally participating in formation of caveolae or caveolae-like 
vesicles (Zhang QH et al., 2000).  Flotillin 2 is thought to function in neuronal 
signalling (Schroeder et al., 1994; Hazarika et al., 1999).  
 
Actin (corresponding to erythrocyte membrane protein band 5) beta and gamma 
were identified from band R16.  Actins are highly conserved proteins that are 
involved in various types of cell motility and are ubiquitously expressed in all 
eukaryotic cells (Erba et al., 1988; Ohmori et al., 1992).  ACTB protein was 
identified from band R16.  The sequence coverage of this protein reached 50% 
and 20 peptides including 3 MS/MS peptides with amino acid sequence matched 
this protein, which highly supported the identification.  It is a calcium-regulated 
actin binding protein and belongs to actin family.  This protein is a monomer 
containing 2 EF-hand domains; it may contribute to the structure and 
reorganization of filopodia and pseudopodia accompanying cell movements 
(Fechheimer et al., 1991; Rivero et al., 1996).  Actin binding protein ABP620 
(identified from band R3) and protein similar to FKSG30 (identified from band 
R16) also contain actin domain, therefore were categorised into actin family.  
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Tropomodulin was identified from band R17.  This protein blocks the elongation 
and depolymerization of the actin filaments at the pointed end.  The Tmod/TM 
complex contributes to the formation of the short actin protofilament, which in turn 
defines the geometry of the membrane skeleton (Chu et al., 2000). 
 
Aldolase A was identified from band R18.  Aldolase A (fructose-bisphosphate 
aldolase) is a glycolytic enzyme that catalyzes the reversible conversion of 
fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate (Kishi et al., 1987; Kreuder et al., 1996). 
 
Glyceraldehyde-3-phosphate dehydrogenase (G3PD) (erythrocyte membrane 
protein band 6) was identified from band R20 and R21.  Glyceraldehyde-3-
phosphate dehydrogenase catalyzes an important energy-yielding step in 
carbohydrate metabolism, the reversible oxidative phosphorylation of 
glyceraldehyde-3-phosphate in the presence of inorganic phosphate and 
nicotinamide adenine dinucleotide (NAD).  The enzyme exists as a tetramer of 
identical chains (Beth et al., 1981; Rogalski et al., 1989).  Uracil DNA glycosylase 
was also identified from band R20.  It is the 37-kDa subunit of glyceraldehyde-3-
phosphate dehydrogenase (Meyer-Siegler et al., 1991). 
 
Erythrocyte membrane protein band 7.2 (stomatin) was identified from band R22 
to R26, and R30, which also indicated its degradation.  It is an integral membrane 
protein and is thought to regulate cation conductance (Unfried et al., 1995; 
Gallagher et al., 1995). 
 
Hypothetical protein (NCBI accession number gi31874640) was identified from 
band R2.  This protein contains COCG4942, APG6 and Smc domains. 
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COCG4942 domain corresponds to membrane-bound metallopeptidase.  APG6 
domain corresponds to autophagy protein Apg6 which plays a distinct role in the 
autophagic process by either associating with the membrane or in a retrieval step 
of the carboxypeptidase Y sorting pathway (Kametaka et al., 1998; Suzuki et al., 
2001).  SmC domain is chromosome segregation ATPase involved in cell division 
and chromosome partitioning (from PSI-BLAST NCBI website).  Therefore, 
subcellular location of this protein was deduced as membrane or cytoplasm.  
 
Dystrophin Dp4271 isoform was identified from band R2.  It contains actin-binding 
domain, spectrin repeats and many other domains.  Dystrophin is part of the            
dystrophin-glycoprotein complex (DGC), which bridges the inner cytoskeleton (F-
actin) and the extra-cellular matrix.  It is a membrane protein with the following 
function: actin-binding, zinc ion binding and calcium ion binding (Lee et al., 1991; 
Harper et al., 2002; Muntoni, et al., 2003; Flanigan et al., 2003; Le et al., 2003). 
 
Unnamed protein product (NCBI accession number gi34536017) was identified 
from band R10 and R15.  It contains Prominin, myosin_tail_1, DUF869, MAD, 
Smc, COG2344 and SbcC domains. The prominins are an emerging family of 
proteins that among the multispan membrane proteins display a novel topology. 
Mouse prominin and human prominin (mouse)-like 1 (PROML1) are predicted to 
contain five membrane spanning domains, with an N-terminal domain exposed to 
the extracellular space followed by four, alternating small cytoplasmic and large 
extracellular, loops and a cytoplasmic C-terminal domain.  The exact function of 
prominin is unknown although in humans defects in PROM1, the gene coding for 
prominin, cause retinal degeneration (Maw et al., 2000; Corbeil et al., 2001). 
MAD is a mitotic checkpoint protein.  This family consists of several eukaryotic 
mitotic checkpoint (Mitotic arrest deficient or MAD) proteins.  The mitotic spindle 
checkpoint monitors proper attachment of the bipolar spindle to the kinetochores 
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of aligned sister chromatids and causes a cell cycle arrest in prometaphase when 
failures occur (Wassmann et al., 2003).  SbcC is an ATPase involved in DNA 
repair (Hopfner et al., 2000; Lowe et al., 2001).  Function of DUF869 and 
COG2344 domains is unknown.  
 
Hypothetical protein MGC20806 was identified from band R11 and R13.  It 
contains LRR_RI, ERM, Smc and RNA1 domains.  ERM refers to 
Ezrin/radixin/moesin family.  This family of proteins contain a band 4.1 domain 
(pfam00373), at their amino terminus (Yonemura et al., 1998).  LRR_RI refers to 
Leucine-rich repeats (LRRs), ribonuclease inhibitor (RI)-like subfamily, which 
might involve in Ran GTPase activating (Kajava, 1998; Kobe & Kajava, 2001). 
RNA1 is Ran GTPase-activating protein involved in mRNA processing and 
transports.  Function of Smc domain has been described above. Band 4.1 is an 
erythrocyte membrane protein; therefore this protein was deduced as membrane 
or cytoplasmic location. 
 
IGHG1 protein, unknown protein for MGC: 20691, unnamed protein product 
(NCBI accession number gi34526063, gi34527739, gi34527430, gi21757082) 
and protein (Chain H, crystal structure of the intact human Igg B12 with broad 
and potent activity against primary Hiv-1 isolates: a template for Hiv vaccine 
design) were identified from band R12 and R13.  These are proteins contain IGc 
and IGv domains. Members of the IGc subfamily are components of 
immunoglobulins, T-cell receptors, CD1 cell surface glycoproteins, secretory 
glycoproteins A/C, and Major Histocompatibility Complex (MHC) class I/II 
molecules (Williams & Barclay, 1988; Bork et al., 1994; Brummendorf & Rathjen, 
1995; Halaby & Mornon, 1998; Halaby et al., 1999).  Members of the IGv 
subfamily are components of immunoglobulins and T-cell receptors (Chothia et 
al., 1998).  
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Tpr was identified from band R15. It contains V_ATPase_I, ERM, Smc and 
COG2344 domains.  V_ATPase_I refers to V-type ATPase 116 kDa subunit 
family. This subunit is a transmembrane glycoprotein with multiple putative 
transmembrane helices; it has a hydrophilic amino terminal and a hydrophobic 
carboxy terminal.  Functions of this subunit include proton transport and 
assembly of the V-type ATPase complex (Forgac, 1999a, 1999b).  COG2344 is 
uncharacterized conserved protein.  Functions of ERM and Smc domains have 
been described above.  Tpr was deduced as membrane or cytoplasmic in  
location. 
 
Hypothetical protein FLJ12649 was identified from band R19.  It contains 
COG5373 domain which is predicted membrane protein (PSI-BLAST NCBI 
website).  Hence the subcellular location of this hypothetical protein was deduced 
as the membrane. 
 
Group 2: Membrane associated proteins within AARBCs 
Membrane associated proteins include all proteins which have known interaction 
with membrane proteins and cytoskeletal proteins. 
 
Nebulin is a giant protein with MW varying 600-800 kDa.  It was reported as a 
component of cytoskeletal matrix that coexists with the thick and thin filaments 
within the sarcomeres of skeletal muscle (Ma et al., 2002, Politou et al., 2002). 
Hypothetical proteins with NCBI accession number gi30268247 (identified from 
band R2) and gi30348693 (identified from band R19) contain Nebulin repeats 
domain.  Therefore, together with nebulin-related anchoring protein, it was 
categorised into nebulin family.  These proteins were identified from bands R1, 
R4, R5, R8 to R19, R24, R27 and R28.  
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Kinesin family member 27, KIF27B and KIF27C were identified from band R2. 
Unnamed protein product (NCBI accession number gi14042584), myosin, heavy 
polypeptide 14, KIAA2034 protein, unnamed protein product (NCBI accession 
number gi10436039), Chromosome 6 open reading frame 60 were identified from 
band R4, R8, R22, R29 and R31.  All these proteins contain myosin related 
domains and are therefore categorized into the same classification.  These 
proteins were involved in cell motility (Wiemann et al., 2001; Strausberg et al., 
2002; Oduru et al., 2003; Ota et al., 2004; Golomb et al., 2004). 
 
Trabeculin-alpha with MW of 617,073 Da was identified from bands R2, R3 and 
R24.  This is a cytoskeletal giant protein and actin-binding protein; the 
corresponding gene encoding this protein exists in chromosome 1 (Sun et al., 
1999).  Plectin and desmoplakin belongs to plectin family (Green et al., 1990) 
were identified from band R2, R3, R11, R12 and R15.  Plectin is a giant protein 
which may be involved not only in the crosslinking and stabilization of cytoskeletal 
intermediate filaments network, but also in the regulation of their dynamics (Liu et 
al., 1996; McLean et al., 1996; Pulkkinen et al., 1996; Bauer et al., 2001; Koss-
Harnes et al., 2002).  Protein bands corresponding to these giant proteins might 
be the degradation product since coverage of amino acid sequence was 
distributed all along the whole sequence.  However, further confirmation is 
required for the real existence of these proteins in AARBCs. 
 
Filamin A interacting protein 1 was identified from bands R2, R7 and R8. It serves 
as an anchoring site for cell-ECM adhesion proteins and filamin-containing actin 
filaments.  It is implicated in cell shape modulation (spreading) and motility.  It 
may not only participate in the regulation of filamin-mediated cross-linking and 
stabilization of actin filaments, but also regulate the assembly of filamin-
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containing signaling complexes that control actin assembly (Tu et al., 2003; 
Takafuta et al., 2003).  
 
Envoplakin was identified from bands R3 and R24. Hypothetical protein 
KIAA0568, 195 KDa cornified envelope precursor and periplakin were identified 
from band R15.  These proteins belong to plakin family.  They are the component 
of the cornified envelope of keratinocytes.  It may link the cornified envelope to 
desmosomes and intermediate filaments (Ruhrberg et al., 1997; Marekov et al., 
1998; Aho et al., 1999; Risk et al., 1999). 
 
Microtubule-actin crosslinking factor 1 and KIAA0465 protein were identified from 
band R3.  The corresponding gene of microtubule-actin crosslinking factor1 is 
KIAA0465.  Therefore, these two proteins were categorized into same 
classification. Microfilament and actin crosslinker protein isoforms a, b were also 
identified from band R3. 
 
Pericentrin B was identified from bands R3, R11 and R24.  It is the structural 
constituent of cytoskeleton.  The protein binds to calmodulin and is expressed in 
the centrosome.  It is an integral component of the pericentriolar material (PCM) 
(Flory et al., 2000; Li et al., 2001). 
 
RGS isoform 2 and regulator of G protein signalling 9 were identified from band 
R6.  This protein inhibits signal transduction by increasing the GTPase activity of 
G protein alpha subunits thereby driving them into their inactive GDP-bound form 
(Granneman et al., 1998; Zhang K et al., 1999; Nishiguchi et al., 2004).  
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Dynein, axonimal, heavy polypeptide 8 was identified from band R6.  Major 
functions of this protein include axonemal motor activity and microtubule motor 
activity; nucleotide and ATP binding.  It also acts as adenosinetriphosphatase, 
cysteine-type endopeptidase and denein ATPase (Neesen et al., 1997; Chapelin 
et al., 1997).  
 
Rho-associated, coiled-coil containing protein kinase 1 and 2, KIAA0619 protein 
were identified from bands R10 and R11.  KIAA0619 protein is the synonym of 
Rho-associated, coiled-coil containing kinase 2.  These are protein kinases that 
phosphorylate a large number of important signalling proteins, and thereby 
regulate the assembly of the actin cytoskeleton.  They promote formation of 
stress fibers and of focal adhesion complexes.  They are associated with actin 
microfilaments and the plasma membrane (Ishikawa et al., 1998; Takahashi et al., 
1999). 
 
Unknown (protein for MGC: 75105), annexin A4, protein PP4-X and annexin IV 
were identified from band R22.  These proteins belong to annexin family. Annexin 
is a calcium phospholipids-binding protein which promotes membrane fusion and 
is involved in exocytosis (Ahn et al., 1998; Tait et al., 1988). 
 
Group 3: Cytoplasmic and nuclear proteins within AARBCs 
Cilliary rootlet coiled-coil, rootletin and KIAA0445 protein (identified from band R2 
and R3) contain Smc and Reo_sigma 1 domains, thus were categorised into 
same family.  Rootletin inhibits fibrinogen interaction with platelet receptors 
expressed on glycoprotein IIb-IIIa complex.  It also acts by binding to the 
glycoprotein IIb-IIIa receptor on the platelet surface and inhibits aggregation 
induced by ADP, thrombin, platelet-activating factor and collagen. It is a secreted 
protein highly expressed by the venom gland (Scarborough et al., 1993). 
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Reo_sigma 1 is the gene domain which is translated to revirus viral attachment 
protein—sigma 1 (glycoprotein).  This family consists of the reovirus sigma 
haemagglutinin, cell attachment protein (Dermody et al., 1990; Nibert et al., 1990; 
Duncan et al., 1990).  Function of Smc domain has already been described in the 
previous section 5.3.2.1. 
 
KIAA1275 protein and hypothetical protein (NCBI accession number gi30268231) 
were identified from bands R2, R4, R7, R8 and R12.  Both proteins contain MAD, 
HOOK and Smc domains.  HOOK protein is a cytoplasm protein (Walenta et al., 
2001; Mendoza-Lujambio et al., 2002).  Functions of MAD and Smc domains 
have already been described (section 5.3.2.1).  
 
Caspase recruitment domain protein 10 was identified from band R2.  It is a 
kinesin complex protein which has apoptosis regulator activity and receptor 
signalling complex scaffold activity (McAllister-Lucas et al., 2001; Wang et al., 
2001; Gaide et al., 2001). 
 
Golgin-245 (synonym: 256 kD golgin) was identified from bands R2, R8-R13, R17, 
R18, R22 and R24.  Golgin-245 is a novel Golgi complex protein containing a 
granin signature (Fritzler et al., 1995).  It may play a role in vesicular transport 
from the trans-Golgi (Erlich et al., 1996).  As it was established that mature red 
blood cell has no organelles (Pan et al., 1983; Johnstone et al., 1987; Darhell et 
al., 1990), identification of this organelle protein might be the residues of protein 
remain in the cell.  True existence of this identified organelle protein in AARBCs 
requires further confirmation. 
Protein (Asp (abnormal spindle)-like, microcephaly associated) was identified 
from band R3.  Subcellular location of this protein includes both plasmic and 
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nuclear.  It may play a role in mitotic spindle regulation and coordination of 
mitotic processes (Bond et al., 2002, 2003; Zhang, 2003). 
 
Unnamed protein product (NCBI accession number gi7023190), hypothetical 
protein (NCBI accession number gi31873894 and gi31874811), Grb10 interacting 
GYF protein 2 and KIAA0642 protein were identified from band R18.  All these 
proteins contain GYF domain.  The GYF domain is named because of the 
presence of Gly-Tyr-Phe residues.  The GYF domain is a proline-binding domain 
in intracellular CD2-binding protein (Nishizawa et al., 1998; Freund et al., 1999).  
 
Some of the proteins identified as cytoplasmic and nuclear proteins show 
similarity to proteins involved in bacterial cell cycle.  One such protein is 
KIAA0565 which was identified from band R19.  This hypothetical protein 
contains EzrA and Smc domains.  EzrA refers to septation ring formation 
regulator, which is a bacilli conserved domain.  During the bacterial cell cycle, the 
tubulin-like cell-division protein FtsZ polymerises into a ring structure that 
establishes the location of the nascent division site.  EzrA modulates the 
frequency and position of FtsZ ring formation (Levin et al., 1999).  Function of 
Smc domain has been described elsewhere. 
 
NLN protein was identified from band R19.  This hypothetical protein contains 
Peptidase_M3 and Dcp domains.  Peptidase_M3 refers to Peptidase family M3, 
which is the Thimet oligopeptidase family, a large family of mammalian and 
bacterial oligopeptidases that cleave medium sized peptides.  The group also 
contains mitochondrial intermediate peptidase which is encoded by nuclear DNA 
but functions within the mitochondria to remove the leader sequence (Rawlings & 
Barrett, 1995).  Dcp is Zn-dependent oligopeptidases which involves in amino 
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acid transport and metabolism (Rawlings & Barrett, 1995; Chen et al., 1998; 
Brown et al., 2001).  
  
TruB pseudouridine (psi) synthase homolog was identified from band R29.  Major 
function of this protein is pseudoouridylate synthase activity.  It is involved in 
translation, ribosomal structure and biogenesis (Strausberg et al., 2002). 
 
Centromere protein F and CENP-F kinetochore protein were identified from band 
R2; nuclear transcription factor, X-box binding 1 isoform 1 was identified from 
band R3; RAD50 protein was identified from bands R7 to R11, R13, R14, R18 
and R22; poly (ADP-ribose) synthetase was identified from band R11; multiple 
coiled-coil GABABR1-binding protein was identified from band R13; Possible 
global transcription activator SNF2L1 and global transcription activator 
homologous were identified from band R15; chromosome-associated protein C 
was identified from band R22; KIAA0542 gene product was identified from band 
R24.  These are all nuclear proteins or putative nuclear proteins. It was 
established that mature red blood cell has no nuclei (Pan et al., 1983; Johnstone 
et al., 1987; Darhell et al., 1990); these proteins might be the residual nuclear 
proteins retained within the cell during enucleation of RBCs.  
 
Group 4: Proteins with uncharacterised location within AARBCs 
Several proteins without putative conserved domains have been detected using 
PSI-BLAST search.  They are hypothetical protein (NCBI accession number 
gi21740028), CTLC tumor antigen HD-CL-01, KIAA0373 gene product, FLJ40198 
protein, similar to hypothetical protein FLJ36144 and LOC375251 protein.  
 
• FNRBC membrane protein identification   
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embrane protein bands from SDS-PAGE (8%, 16 cm gel) 
  Silver stain was used to resolve protein bands.  Membrane 
ed from 4.41 x 106 FNRBCs (purity was about 95%) and 
to lane 1-4.  28 distinct bands (accumulated by 4 lanes of 
-gel digestion and MALDI-TOF/TOF (indicated by arrow).  
 were excised from SDS-PAGE (Figure 5.8, N1-N28) and 
igestion. 58 different proteins were identified using MALDI 
OT database search. Data obtained from MALDI analysis 
ndix B (Table B5.2).  The number of peptides identified, the 
erage and the MS/MS ion score gave an indication of the 
tion.  Furthermore, only proteins with statistically significant 
ts (p < 0.05) are tabulated in Table B5.2.   
W proteins from the high MW region of the gel could be due 
ional modification that could alter the MW, or the formation 
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of dimers/trimers/tetramers and polymers (Herbert et al., 2001; Vitorino et al., 
2004).  In order to increase the specificity of identification, low MW proteins 
identified from high MW region were not included in Table B5.2.  The only 
exception to this was the globin chain, which was reported by Herbert et al. (2001) 
to form dimers, trimers and tetramers in SDS-PAGE gels.  In contrast, it is 
reasonable to expect high MW proteins in the low MW region due to degradation 
of high MW proteins in SDS-PAGE (Low et al., 2002).  All high MW proteins 
identified in low MW regions were included in subsequent analysis.   
 
All 58 distinct FNRBC proteins identified were categorised into 32 classes (Table 
5.5).  These proteins were also categorised according to their subcellular location 
into 4 major groups: (1) membrane proteins, (2) membrane associated proteins, 
(3) cytoplasmic and nuclear proteins, and (4) location uncharacterised proteins.  It 
is known that many of the proteins identified here can exist in multiple cell 
locations, but only those that are known to have some association with cellular 
membranes have been included in Table 5.5.  Only these would be relevant to 









Table 5.5 Classification of identified proteins from FNRBC membrane pellet 
fraction. (p) Denotes putative subcellular location deduced from functional 
domains or cited in literature. 
 
Protein Classification Identified from bands Subcellular location 
Spectrin alpha and beta chain N1, N2 Membrane 
Ankyrin N2 Membrane 
Actin, gamma1 polypeptide; 
ACTB protein; unknown 
(protein for IMAGE:3538275); 
actin beta;  
N17 Membrane 
N-ethylmaleimide-sensitive 
factor attachment protein, 
alpha 
N23 Membrane 
bA255A11.3 (novel protein 
similar to KIAA1074) 
N5, N6, N22, N28 Membrane (p) 
Domain: ACR_tran, 
ANK, Arp, HAP1_N 
Heat shock 90 kDa protein1, 
alpha and beta; HSPCA 
protein; HSPCB protein; 
Hypothetical protein 
DKFZp761K0511.1 
N9 Membrane (p) and 
Cytoplasm  
Heat shock 70 kDa protein 8 
isoform 1; HSPA8 protein 
N11 Membrane (p) and 
Cytoplasm  
Plectin 1; plectin 1 isoform 6; 
plectin 1 isoform 7; plectin 1 
isoform 8 
N2, N7 Membrane associated 
Myosin heavy polypeptide 13; 
similar to CG5882-PA; 
unnamed protein product 
(gi10438291); similar to 
superfast myosin heavy chain; 
myosin IXA; myosin heavy 
polypeptide 14; myosin heavy 
chain (MHY11) (5’ partial) 






gi34364971, gi34364735 and 
gi30268204) 
N7, N12,  N17 Membrane associated 
Domain: NEBU 
Hypothetical protein FLJ22037 N13 Membrane associated 
Domain: NEBU, 
MYSc, myosin_tail_1 
Macrophin 1 isoform 4 N14 Membrane associated 
Asonemal heavy chain dynein 
type 3 
N14 Membrane associated 
Beta 5-tubulin N14 Membrane associated 
 134
Eukaryotic translation 
elongation factor 2; translation 
elongation factor 1 alpha 1; 
translation elongation factor 1 
alpha 2; unnamed protein 
(gi31092); glucocorticoid 
receptor AF-1 specific 
elongation factor 
N8, N15 Cytoplasm  
Hypothetical protein FLJ12735 N9 Cytoplasm (p)  
Domain: AAA, Rad17 
ATP synthase, H+ transporting, 
itochondrial F1 complex, beta 
polypeptide 
N14 cytoplasm 
dJ37C10.5 (KIAA0445) N20 Cytoplasm (p) 
Domain: Smc, 
Reo_sigma1 
Hemoglobin Gower 2 epsilon; 
chain E, Human embryonic 
Gower Ii carbonmonoxy 
hemoglobin 
N22, N23, N25, N26, 
N27 
Cytoplasm 
Desmuslin  N22 Cytoplasm 
RABEP1 protein N23 Cytoplasm 
Hypothetical protein 
DKFZp434P011.1 
N24 Cytoplasm (p) 
Domain: TPR, 
COG5191, COG4783 
RAD50 homologue hsRAD; 
RAD50 homolog isoform 1; 
RAD50 homolog isoform 2 
N1, N7, N13 Nuclear 




Unnamed protein product 
(gi21755884); unknown 
protein (gi1196432) 
N9 Nuclear (p)  
Domain: RVT 





bB125O15.1 N24 Nuclear 
dJ398G3.1.1 (novel protein 
containing CH (Calponin 
homology) domains (contains 
KIAA1756), variant 1) 
N16 No putative conserved 
domains have been 
detected 
Hypothetical protein FLJ36144 N18 No putative conserved 
domains have been 
detected 
NAPA protein  N23 No putative conserved 




N28 No putative conserved 




Group 1: Membrane proteins within FNRBCs 
Spectrin α-chain and β-chain were identified from bands N1 and N2.  Ankyrin was 
identified from band N2.  Actin, ACTB protein and unknown protein for 
IMAGE:3538275 were identified from band N17.  These are the same membrane 
proteins identified in AARBCs. 
 
bA255A11.3 (novel protein similar to KIAA1074) was identified from bands N5, 
N6, N22 and N28.  This hypothetical protein contains ACR_tran, ANK, Arp and 
HAP1_N domains.  ACR_tran domain refers to AcrB/AcrD/AcrF family.  Members 
of this family are integral membrane proteins and some are involved in drug 
resistance.  AcrB cooperates with a membrane fusion protein, AcrA, and an outer 
membrane channel TolC.  The structure shows the AcrB forms a homotrimer. 
ANK and Arp domains are ankyrin repeats.  HAP1_N domain refers to HAP1 N-
terminal conserved region.  This family represents an N-terminal conserved 
region found in several huntingtin-associated protein 1 (HAP1) homologues. 
HAP1 binds to huntingtin in a polyglutamine repeat-length-dependent manner. 
However, its possible role in the pathogenesis of Huntington's disease is unclear. 
Based on the functional domains detected, this protein was deduced as 
membrane protein. 
 
Interestingly, heat shock proteins were identified in FNRBC membrane 
preparations.  Heat shock 90 kDa protein 1, alpha and beta; HSPCA and HSPCB 
protein; and hypothetical protein DKFZp761K0511.1 were identified from band N9. 
All of them belong to heat shock protein 90 superfamily.  Heat shock protein 90 
acts as molecular chaperone and has ATPase activity (Soeda et al., 1989; 
Obermann et al., 1998; Hernandez et al., 2002; Lotz et al., 2003; Yoshida et al., 
2003; Brychzy et al., 2003). 
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Heat shock 70 kDa protein 8 isoform 1 and HSPA8 protein were identified from 
band N11.  Both of these proteins belong to Heat shock 70 kDa protein (Hsp 70 
protein) family.  Hsp 70 protein binds to nascent polypeptides to facilitate correct 
folding.  It also serves as an ATPase in the disassembly of clathrin-coated 
vesicles during transport of membrane components through the cell (Noessner et 
al., 2002; Shin et al., 2003). 
 
Heat shock proteins were originally identified as being either cytoplasmic (Ellis, 
1993; Welch, 1993) or endoplasmic reticulum (Jolly & Morimoto, 2000) proteins. 
However, it has recently been demonstrated that heat shock 70 kDa protein does 
occur on the surface of a number of cell types (Di Cesare et al., 1992; Ferrairini et 
al., 1992; Poccia et al., 1996; Ishiyama et al., 1996; Botzler et al., 1996, 1998a, 
1998b; Multhoff et al., 1995, 1997; Asea et al., 2000; Hantschel et al., 2000; 
Sapozhnikov et al., 2002).  It has also been shown that a signalling complex of 
receptors, comprising heat-shock proteins 70 and 90, chemokine receptor 4 
(CXCR4), and growth differentiation factor 5, is formed during immune system 
recognition of bacterial lipopolysaccharide (Triantafilou  & Triantafiou, 2002). 
Thus, it has been demonstrated that heat-shock proteins and some receptors 
interact at the cell surface to stimulate receptor-mediated functions.  It is also 
interesting to note that recent data have implicated the endoplasmic reticulum 
(ER) as a membrane source.  Fusion of the ER with the macrophage 
plasmalemma underneath phagocytic (Harada et al., 1998) cups has been found 
to be a source of membrane for phagosome formation in macrophages (Gagnon 
et al., 2002).  Heat-shock proteins 90 and 70 were identified from FNRBC 
membrane pellet fraction, although there is not sufficient proof such as biotin-
directed affinity purification method to confirm the existence of heat shock 
proteins on cell surface membrane, it is still reasonable to postulate their surface 
membrane expression based on the literature evidence stated above. 
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N-ethylmaleimide-sensitive factor attachment protein alpha was identified from 
band N23.  This is a peripheral membrane protein which belongs to SNAP family. 
It is required for vesicular transport between the endoplasmic reticulum and the 
Golgi apparatus (Lemons et al., 1997; Strausberg et al., 2002).  
 
Group 2: Membrane associated proteins within FNRBCs 
Plectin 1, a giant protein with MW of about 533 kDa, was identified from band N2, 
and its isoform 6, 7 and 8 were identified from band N7.  Major function of this 
protein is to interlink intermediate filaments with microtubules and microfilaments 
and to anchor intermediate filaments to desmosomes or hemidesmosomes.  It 
could also bind muscle proteins such as actin to membrane complexes in muscle. 
It may be involved not only in the crosslinking and stabilization of cytoskeletal 
intermediate filaments network, but also in the regulation of their dynamics (Liu et 
al., 1996; McLean et al., 1996; Pulkkinen et al., 1996; Bauer et al., 2001; Koss-
Harnes et al., 2002). 
 
Myosin heavy polypeptide 13 was identified from band N3.  Protein similar to 
superfast myosin heavy chain was identified from band N13.  Myosin IXA was 
identified from band N14.  Myosin heavy polypeptide 14 was identified from band 
N19.  Myosin heavy chain (MHY11) (5'partial) was identified from band N28 
(indicates degradation in band N13, N14, N19 and N28).  Protein similar to 
superfast myosin and Myosin heavy chain (MHY11) (5'partial) are predicted by 
automated computational analysis (Loftus et al., 1999).  The corresponding gene 
of myosin heavy polypeptide 13 is located in chromosome 17 (Winters et al., 
1998).  Myosin IXA was cloned from chromosome 15 (Gorman et al., 1999); 
myosin heavy polypeptide 14 was cloned from chromosome 19 (Leal et al., 2003; 
Golomb et al., 2004).  Myosin is a cytoskeletal protein which binds to actin, ATP 
and calmodulin binding, and functioned in microfilament motor activity (Winters et 
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al., 1998).  As the above myosin related proteins share similarities of amino acid 
sequences, the identity of the dominant one in FNRBCs needs further 
experimental confirmation. 
 
Nebulin was identified from bands N7 and N17.  Nebulin-related anchoring 
protein and hypothetical protein (NCBI accession number gi34364818, 
gi21732890, gi34364971, gi34364735 and gi30268204) were identified from band 
R12.  All of these proteins contain nebulin repeats domain and were therefore 
categorised into the same classification. 
 
Hypothetical protein FLJ22037 was identified from band N13.  This protein 
contains NEBU, MYSc and myosin_tail_1 domains and was thus categorised into 
membrane associated protein. 
 
Macrophin 1 isoform 4 was identified from band N14.  It may play a role in cross-
linking cytoskeletal proteins by binding intermediate filaments to the N-terminal 
plectin repeats and microtubules to the C-terminus (Gong et al., 2001). 
 
Beta 5-tubulin was identified from band N14.  Tubulin is the major constituent of 
microtubules.  It binds two moles of GTP, one at an exchangeable site on the 
beta chain and the other at a nonexchangeable site on the alpha-chain (Lewis et 
al., 1985; Wang et al., 1986). 
 
Asonemal heavy chain dynein type 3 was identified from band N14.  This 
hypothetical protein is part of the dynein complex.  Major functions include ATP 
and nucleotide binding; axonemal and microtubule motor activity; dynein ATPase 
activity and adenosinetriphosphatase activity (Chapelin et al., 1997; Milisav, 1998; 
Loftus et al., 1999).  
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Desmuslin was identified from band N22.  It is a type-VI intermediate filament 
which may function as a mechanical support to the muscle fibers by making a 
linkage between the extracellular matrix via the dystrophin-associated protein 
complex (DAPC) and the Z-disk (Nagase et al., 1997; Mizuno et al., 2001a, 
2001b).  
 
Group 3: Cytoplasmic and nuclear proteins within FNRBCs 
Eukaryotic translation elongation factor 2, translation elongation factor 1 alpha 1 
and alpha 2, unnamed protein (NCBI accession number gi31092) and 
glucocorticoid receptor AF-1 specific elongation factor were identified from bands 
N8 and N15.  Unnamed protein (NCBI accession number gi31029) is actually 
translation elongation factor 1 alpha 1 (from swissprot database). Translation 
elongation factor 1 promotes the GTP-dependent binding of aminoacyl-tRNA to 
the A-site of ribosomes during protein biosynthesis (Dever et al., 1989; 
Whiteheart et al., 1989).  Translation elongation factor 2 promotes the GTP-
dependent translocation of the nascent protein chain from the A-site to the P-site 
of the ribosome (Rapp et al., 1988, 1989).  Glucocorticoid receptor AF-1 specific 
elongation factor contains the same domains (GTP_EFTU, GTP_EFTU_D2, 
GTP_EFTU_D3 and TEF1) as translation elongation factor, and thus is 
categorised into the same classification. 
 
Hypothetical protein FLJ12735 was identified from band N9.  It contains AAA and 
Rad17 domains.  AAA refers to ATPase family associated with various cellular 
activities (AAA).  AAA family proteins often perform chaperone-like functions that 
assist in the assembly, operation, or disassembly of protein complexes 
(Confalonieri & Duguet, 1995; Neuwald et al., 1999). Rad17 is a cell cycle 
checkpoint protein (Li et al., 1999). 
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ATP synthase-H+ transporting-mitochondrial F1 complex-beta polypeptide was 
identified from band N14.  This protein produces ATP from ADP in the presence 
of a proton gradient across the membrane.  The beta chain is the catalytic subunit. 
It is located in the mitochondria (Ohta & Kagawa, 1986; Wallace et al., 1987; 
Ohta et al., 1988; Neckelmann et al., 1989). 
 
dJ37D10.5 (KIAA0445) was identified from band N20.  It contains Smc and 
Reo_sigma 1 domains and was therefore deduced as cytoplasm location. 
 
Haemoglobin Gower 2 epsilon was identified from bands N22, N23, N25, N26 
and N27.  Haemoglobin Gower 2 (α2ε2) is human embryonic haemoglobin.  Yolk 
sac erythroblasts synthesise ε-, ζ-, γ-, and α-globins.  These combine to form the 
embryonic haemoglobins Gower I (ζ2ε2) (Huehns & Faroqui, 1975), Gower II (α2ε2) 
(Gale et al., 1979), Portland I (ζ2γ2) (Capp et al., 1967) and Portland II (ζ2β2) 
(Randhawa et al., 1984).  
  
RABEP1 (Rab GTPase binding effector protein 1) protein was identified from 
band N23.  It acts as linker between gamma-adaptin, RAB4A and RAB5A and is 
involved in endocytic membrane fusion and membrane trafficking of recycling 
endosomes (Stenmark et al., 1995; Horiuchi et al., 1997; Nagelkerken et al., 2000; 
Lippe et al., 2001; Mattera et al., 2003; Deneka et al., 2003).   
 
Hypothetical protein DKFZp434P011.1 was identified from band N24.  It contains 
TPR, COG5191 and COG4783 domains.  Tetratricopeptide repeat (TPR) domain 
is involved in a variety of functions including protein-protein interactions, but 
common features in the interaction partners have not been defined; It is also 
involved in chaperone, cell-cycle, transcription, and protein transport complexes 
(Sikorski et al., 1990; Goebl & Yanagida, 1991; Lamb et al., 1995; Das et al., 
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1998; Blatch & Lassle, 1999).  COG4783 is a putative Zn-dependent protease 
containing TPR repeats while the function of COG5191 is unknown.  
 
RAD50 homologue hsRAD50, RAD50 homolog isoform 1 and isoform 2 were 
identified from bands N1, N7 and N13.  Major function of RAD50 homologue 
hsRAD50 involves DNA repair and recombination.  RAD50 homolog isoform 1 
involves not only in DNA repair, but also in cell division and chromosome 
partitioning which it acts as membrane-bound metallopeptidase.  In addition, it 
plays a role in inorganic ion transport (ABC-type cobalt transport system) and 
metabolism (ATPase component).  RAD50 homolog isoform 2 forms a complex 
with MRE11 and NBS1.  The protein complex binds to DNA and displays 
numerous enzymatic activities that are required for nonhomologous joining of 
DNA ends.  This protein, cooperating with its partners, is important for DNA 
double-strand break repair, cell cycle checkpoint activation, telomere 
maintenance, and meiotic recombination (Grenon et al., 2001; Huang et al., 2002; 
Stracker et al., 2002; Furuta et al 2003).  
 
Putative p150 was identified from band N9.  This hypothetical protein contains 
Exo_endo_phos, Smc, RVT, Xtha and EIsH domains. Exo_endo_phos refers to 
endonuclease/Exonuclease/phosphatase family.  This large family of proteins 
includes magnesium dependent endonucleases and a large number of 
phosphatases involved in intracellular signalling (Lahm & Suck, 1991; Mol et al., 
1995; Dlakic, 2000).  RVT refers to reverse transcriptase (RNA-dependent DNA 
polymerase).  XthA is exonuclease III which involves in DNA replication, 
recombination, and repair.  EIsH refers to metal-dependent hydrolase.  Function 
of Smc domain has already been described.  Therefore, this hypothetical protein 
was deduced as nuclear location. 
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Unnamed protein product (NCBI accession number gi21755884) and unknown 
protein (NCBI accession number gi1196432) were identified from band N9.  Both 
of these proteins contain RVT domain and were deduced as nuclear location. 
FLJ36760 protein was identified from band N17.  This is a nuclear protein 
containing COG1204 and SEC63 domains.  COG1204 refers to superfamily II 
helicase, which is predicted to be involved in RNA processing and modification 
(Isogai & Yamamoto, 2002).  Function of SEC63 is unknown. 
 
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 was identified from 
band N21.  This protein is the component of ribonucleosomes.  It is associated 
with pre-mRNAs in the nucleus and appears to influence pre-mRNA processing 
and other aspects of mRNA metabolism and transport (Kumar et al., 1986; Kozu 
et al., 1995).  Interestingly, this protein could shuttle between the nucleus and the 
cytoplasm (Brumwell et al., 2002) 
 
bB152 O15.1 was identified from band N24.  This is a nuclear protein, which 
involved in pre-mRNA splicing.  It may act in the tri-snRNP complex as a bridging 
factor between U5 and U4/U6 snRNPs in the late step of spliceosome assembly 
(Nishikimi et al., 1999; Makarov et al., 2000; Yuryev et al., 2000).  
 
Group 4: Proteins with uncharacterised location within FNRBCs 
Four hypothetical proteins in which no conserved domains have been detected 
are dJ398G3.1.1, Hypothetical protein FLJ36144, NAPA protein and Hypothetical 






Interpretation.  It is interesting and important that the MS/MS study identified 
epsilon-globin chains in the membrane fractions of FNRBC samples (Appendix B, 
Table B5.2).  Finding these globin chains in the membrane fractions supports my 
suspicion that the 31.2 kDa proteins found using NP20, Cu2+, and Mg2+ 
ProteinChip arrays were likely to be haemoglobin contaminants in the FNRBC 
samples (section 3.4).  More importantly, the presence of these proteins give 
credence to the source of the membrane proteins studied i.e. fetal primitive 
erythroblasts.  These embryonic globins are present only during the first trimester 
of human pregnancy, and their presence here acts as an internal positive control.  
Also as an internal control of the investigative procedure is the fact that the 
AARBC membrane proteome determined using my protocol matched closely 
observations by other investigations and published reports (Low et al., 2002).   
 
Of the 114 AARBC proteins identified, membrane proteins and membrane-
associated proteins constituted 31% and 27% of the membrane proteome 
respectively (Figure 5.9).  Similarly, of the 58 FNRBC proteins identified, 
membrane proteins and membrane-associated proteins constituted 28% and 
31% of the membrane proteome respectively (Figure 5.11).  The locations of 
uncharacterised hypothetical proteins were assigned based upon their domain 
functions.  Pertinent to this study, 18 proteins unique to AARBCs, and 4 proteins 




















Figure 5.9 Categorization of proteins identified from AARBC membrane 















Figure 5.10 Categorization of proteins identified from FNRBC membrane 




5.4 Comparison of FNRBC and AARBC membrane proteins 
Aim.   To compare the identified FNRBC and AARBC membrane proteins. 
 
Investigation.  Membrane proteins common to both FNRBC and AARBC, and 
those unique to each cell type were identified and selected out from amongst the 
identified proteins.  
 
Results.  Three membrane proteins, spectrin (alpha and beta chain), ankyrin, and 
actin (beta and gamma) were identified as common to both FNRBCs and 
AARBCs.  4 proteins were found unique to FNRBCs, and 18 proteins unique to 
AARBCs (Table 5.6).  My results of the AARBC membrane proteins closely 
match those previously described by other investigators (Low et al., 2002; 
Kakniashvill et al., 2004).  A comparative classification of the membrane proteins 




















Figure 5.11 Comparison of subcellular distribution of membrane pellet fractions 
between AARBC and FNRBC. 
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Table 5.6 Comparison of AARBC and FNRBC membrane proteins (including 
putative subcellular location proteins) 
 
A. Membrane proteins common to both FNRBCs and AARBCs 
1. Spectrin: alpha and beta chain 
2. Ankyrin 
3. Actin: beta and gamma 
 
B. Membrane proteins unique to FNRBCs 
1. N-ethylmaleimide-sensitive factor attachment protein, alpha 
2. bA255A11.3 (novel protein similar to KIAA1074) (p) 
3. Heat shock 90 kDa protein 1 (p) 
4. Heat shock 70 kDa protein 8 (p) 
 
C. Membrane proteins unique to AARBCs 
1. Erythrocyte membrane protein band 3 
2. Erythrocyte membrane protein 4.1 
3. Erythrocyte membrane protein 4.2 
4. Erythrocyte membrane protein p55 
5. Flotillin 1 
6. Flotillin 2 
7. Tropomodulin 1 
8. Aldolase A 
9. Glyceraldehyde-3-phosphate dehydrogenase 
10. Uracil DNA glycosylase 
11. Erythrocyte membrane protein 7.2b (stomatin) 
12. Dystrophin Dp4271 isoform (p) 
13. Hypothetical protein (gi31874640) (p) 
14. Unnamed protein product (gi34536017) (p) 
15. Hypothetical protein MGC20806 (p) 
16. IGHG1 protein (p) 
17. Tpr (p) 
18. Hypothetical protein FLJ112649 (p) 
 
 
Known proteins are highlighted; (p) Denotes putative subcellular location 





Table 5.7 Functional classification of identified FNRBC and AARBC membrane 
proteins 
 
Protein groups AARBC FNRBC 
Membrane 
skeletal proteins 
Spectrin alpha and beta 
chain; ankyrin; ankyrin 
repeat domain; similar to 
hypothetical protein 
DKFZp434A171; 
KIAA1561 protein; actin 
beta and gamma; actin 
binding protein ABP620; 
ACTB protein; similar to 
FKSG30;  erythrocyte 
band 4.1 and 4.2; 
tropomodulin 
Spectrin alpha and beta 
chain; ankyrin; actin beta and 
gamma; ACTB protein; 
unknown (protein for 
IMAGE:3538275); N-
ethylmaleimide-sensitive 





protein band 3 
 
Protein of lipid 
rafts 
Flotilin 1 and 2; erythrocyte 










Kinases erythrocyte membrane 
protein p55 
 
Chaperones  Heat shock 90 kDa protein 1, 
alpha and beta; HSPCA 
protein; HSPCB protein; 
hypothetical protein 
DKFZp761K0511.1; heat 
shock 70 kDa protein 8 










IGHG1 protein; Unknown 
(protein for MGC: 20691); 
unnamed protein product 
(gi34526063, gi34527739, 
gi34527430, gi21757082); 
Chain H, crystal structure 
of the intact human Igg 
B12 with broad and potent 
activity against primary 
Hiv-1 isolates: a template 
for Hiv vaccine design; 
Tpr; Hypothetical protein 
FLJ12649 
bA255A11.3 (novel protein 
similar to KIAA1074);  
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Interpretation.   Predominant membrane structural proteins (spectrin, ankryin and 
actin) are common to both cell species, and this is not surprising.  It is surprising 
however that very few membrane proteins are unique to FNRBCs.  Of the 4 found 
(Table 5.6), three are putative proteins.  Only one is a known protein, but α-N-
ethylmaleimide-sensitive factor attachment protein is an intracellular peripheral 
membrane protein that does not interact with the lipid bilayer, and presumably 
does not have a surface domain (or epitopes) for antibody attachment.  As such, 
this protein would not be a useful target for non-invasive prenatal diagnosis.   
 
Comparing FNRBC membrane proteins identified using MS/MS technique with 
the unique FNRBC protein peaks identified using SELDI-TOF-MS analysis 
(Section 4.5) yield interesting results.  The mass spectrophotometry data showed 
that FNRBC proteins with MW of 47, 62 and 78 kDa were all unique to FNRBC, 
and not present on AARBCs.  While this confirmed the SELDI data, none of the 
14 proteins (highlighted in Appendix B, Table B5.2) were membrane or 
membrane-associated proteins.  This difference could be due to either (1) the 
quantities of the specific membrane proteins loaded on SDS-PAGE were not 
enough to be separated and identified using the MS/MS technique, (2) the 
membrane proteins might not have entered the gel as they could not be 
solubilised while loading in the SDS-PAGE gel, or most likely (3) these 14 nuclear 
and cytoplasmic proteins had contaminated the FNRBC membrane protein 
fractions (sections 3.4 and 4.6).   
 
Fetal erythroblasts can be separated from maternal anucleate red blood cells by 
unique surface antigens on the FNRBC surface (positive selection), or equally 
effectively by unique surface antigens present on AARBC plasma membranes 
(negative selection).  Eighteen unique, differentially expressed membrane 
proteins were identified in the AARBC membrane fraction by the MS/MS 
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technique.  Of these, 7 were putative proteins (Table 5.6).  Aldolase A, 
glyceraldehyde-3-phosphate dehydrogenase, and uracil DNA glycosylase are 
metabolic enzymes, and erythrocyte membrane protein p55 is a kinase; these 
enzymatic proteins are thought to be intracellular.  Flotillin 1 and 2, and 
erythrocyte membrane protein 7.2b are lipid raft proteins, and thought not to have 
an external surface domain.  Of the integral membrane proteins erythrocyte 
membrane protein bands 3, 4.1, 4.2 and tropomodulin 1, only erythrocyte 
membrane protein band 3 is known to be a transmembrane protein with external 
surface domains and epitopes.  Although all potential targets should be 
investigated further by experimentation, my results and literature review suggest 
that erythrocyte membrane protein band 3 is the most attractive target for 
enrichment of FNRBCs by negative selection i.e. depletion of maternal AARBCs.  
If successful, this would represent the most direct replacement of density gradient 
centrifugation: a physical properties-based depletion strategy replaced by an 
immunosorting depletion strategy. 
 
5.5 Conclusions  
The main aim of this research was to find potential targets for the 
immunoseparation of FNRBCs from maternal AARBCs, for non-invasive prenatal 
diagnosis.  Earlier efforts to investigate known antigenic differences between 
these two cells types did not yield any differences that could be exploited 
(Choolani et al., 2003).  I used a broader strategy to first identify any differences 
in the surface membrane protein profiles of these two cell types, with the longer-
term aim to further explore the differences that I find by Western blotting, 
immunocytochemistry and MACS/FACS. 
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First, I obtained relatively pure samples of FNRBC and AARBC membrane 
proteins (Chapter 3).  Next, I explored if any differences could be identified 
between the two cell types using SELDI technology (Chapter 4).  Promising 
results at both these stages led me to develop a strategy to isolate and identify 
the protein differences that exist between these two cell types.  I used gel 
electrophoresis to separate the proteins, and mass spectrophotometry to identify 
the individual proteins.  Interestingly, the differences noted using SELDI were 
confirmed by protein identification, but these proteins were not suitable for the 
main aim of my project as they were not membrane or membrane associated 
proteins.  Instead, other proteins differentially expressed on the two target cell 
types were identified.  Of these, only those on the AARBCs are likely to be 
suitable targets for non-invasive prenatal diagnosis; they represent a negative 
selection strategy by depletion of maternal AARBCs, and band 3 appears to be 
the most promising target.   
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Additional notes on Erythrocyte membrane band 3: 
Band 3 anion exchanger (AE1) is the major integral protein of the AARBC 
membrane.  This multiple function protein has 3 domains, a membrane-spanning 
domain that carries out chloride/bicarbonate exchange, a short C-terminal 
cytoplamic domain, and a large N-terminal cytoplasmic domain (Tanner, 1997, 
2002).  Based on hydropathy analyses and the wealth of available topographical 
and functional data, it is proposed the protein protrudes the membrane 14 times 
(Lux et al., 1989).  The C-terminal cytoplasmic domain of band 3 binds carbonic 
anhydrase II (CAII), forming a metabolon that channels HCO3- at the cytoplasmic 
face of band 3 and facilitates its interaction with CAII and band 3 (Sterling et al., 
2001).  The N-terminal cytoplasmic domain of band 3 binds glycolytic enzymes, 
haemoglobin, and hemichromes that may induce the aggregation of band 3 and 
cell turnover (Zhang et al., 2000).  However, a major function of the N-terminal 
domain of band 3 is to anchor the RBC membrane to the underlying cytoskeleton 
(Lux & Palek, 1995).  Band 3 exists in the RBC membrane as dimers (60%) and 
tetramers (40%).  The tetrameric form binds ankyrin (Michaely et al., 1995) and 
protein 4.2 (Rybicki et al., 1996), and is the major attachment site of the RBC 
membrane to the cytoskeleton.  A second site of attachment through the 
glycophorin C complex (glycophorin C [GPC], protein 4.1, and erythrocyte 
membrane protein p55) is thought to be of lesser importance (Chang & Low, 
2001).  Thus, the band 3 complex (band 3, GPA, protein 4.2, ankyrin, CAII, 
glycolytic enzymes, and Hb) is important for organising the structure of the RBC 
membrane and its attachment to the cytoskeleton. 
 
Band 3 failed to be detected in the FNRBC membrane pellet fraction, indicating 
that FNRBC contain little or no plasma-membrane band 3.  There are several 
assumptions and animal experiment evidence to address this phenomenon.  One 
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study using rabbit model found that bone-marrow-bound nucleated erythroid cells 
have a unique set of membrane surface components which are completely 
different from those found on circulating cells (Tanner & Light, 1976).  Rabbit 
erythrocyte polypeptide 3 was shown to be strikingly similar to that of the 
equivalent human erythrocyte-membrane protein.  It was evidenced that 
polypeptide 3 may be absent or present in only small quantities in the plasma 
membranes of the nucleated erythroid cells.  As polypeptide 3 is involved in the 
transporter of anions across the erythrocyte membrane, it was postulated that 
bone-marrow-bound nucleated erythroid cells are unlikely to need to equilibrate 
anions at a rate as fast as erythrocytes.  In addition, it was suggested that 
maturation of the erythroid cell involves a complete change in the membrane 
proteins and glycoproteins by the time the circulating stage of the cell is reached.  
 
As mentioned earlier, band 3 exists in the membrane as a mixture of dimers (B3D) 
and tetramers (B3T).  In one mouse model study (Hanspal et al., 1998), it was 
revealed that at the early erythroblast stage, the newly synthesized band 3 is 
predominantly as tetramers, whereas at the late stage of erythroid maturation, it 
is present exclusively as dimers.  This study also found that band 3 tetramer-
ankyrin complexes are unattached to the membrane skeleton in early 
erythroblasts and that the membrane skeleton has yet to become tightly 
organised in late erythroblasts (Hanspal et al., 1998).  
 
The animal models mentioned above only examined adult nucleated erythrocytes 
which would develop into mature anucleate erythrocytes.  However, the fetal 
nucleated erythrocytes do not have the property to develop into mature anucleate 
erythrocytes and remain nucleated through their functional lives (Forestier et al., 
1991).  The failure to detect band 3 from FNRBC membrane pellet fraction 
suggested that this protein may be absent or present in only small quantities in 
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the plasma membranes of fetal nucleated erythrocytes.  It could be postulated 
that anion equilibration function may not be necessary for fetal nucleated 
erythrocytes or at least during first trimester of gestation when primitive 











Chapter 6: General Discussion 
The key limitation preventing non-invasive prenatal diagnosis to be applicable for 
routine clinical use is the technical difficulty in enriching/isolating fetal cells from 
maternal blood, in particular separating fetal primitive erythroblasts from maternal 
anucleate red blood cells.  The identification of a unique cell surface marker could 
result in the efficient enrichment of fetal cells from maternal blood, thus reducing the 
risk of fetal loss from invasive methods such as amniocentesis.  
 
The aim of this thesis was to identify several unique, differentially expressed cell 
surface membrane proteins that could be further explored as potential targets for 
antibody selection/development, for non-invasive prenatal diagnosis.  The candidate 
target approach has been shown to be unsuccessful (Choolani et al., 2003), and 
therefore the strategy chosen here was to identify any difference between the 
membrane proteome of the two cell types.  I was searching for a clear difference i.e. 
the presence/absence of specific proteins; these absolute differences represent an 
“on/off switch” and can be exploited in an immunosorting strategy as GPA and CD45 
have been used successfully (Choolani et al., 2003).   
 
In this chapter, I examine if the hypotheses put forward (section 1.7.1) can be 
accepted or must be rejected, assess the clinical implications of these results with in 
the field of non-invasive prenatal diagnosis, critically evaluate the limitations of these 





Hypothesis 1: Membrane protein purification from first trimester fetal primitive 
erythroblasts is possible despite the small number of cells obtainable from this 
unique cell type present only during the first 14 weeks of human pregnancy.   
 
This is the first report of membrane protein extraction from fetal primitive 
erythroblasts.  The major limitation I faced was the small number of fetal cells 
available for membrane extraction (c.106 FNRBCs/sample), after these cells had 
been separated from placental tissue obtained from elective termination of 
pregnancy.  In order to recover the maximum possible amount of membrane proteins 
(only 30% of total proteins constitute membrane proteins), several different 
membrane extraction methods were tested.  The freeze-thawing-Dounce 
homogenisation method proved to be the most effective in extracting membrane 
proteins from these limited numbers of FNRBCs, and the extract was thought 
suitable for further downstream analysis  by SELDI and MALDI-TOF/TOF (Chapter 
3).  Thus, Hypothesis 1 was accepted. 
 
Hypothesis 2:  Membrane protein profiles of fetal nucleated red blood cells and adult 
anucleate erythrocytes differ. 
 
Profiling proteins using SELDI-TOF-MS is a novel approach that examines several 
hundreds of proteins simultaneously.  This is the first report that uses ProteinChip 
arrays to compare similarities and differences of the membrane proteome of two 
distinct cell types.  Membrane protein profiling of FNRBCs and AARBCs 
demonstrated more similarities than differences; this is interesting considering 
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anucleate erythrocytes are considered to be terminally differentiated cells.  
Haemoglobin dimers (putative) were noted in FNRBC samples, and these were 
accountable for by the identification of ε-globin using MALDI-TOF/TOF-MS.  In 
contrast, unique, differentially expressed iron-binding proteins were found on the 
FNRBC samples that were absent in AARBC preparations (Chapter 4).  Mass 
spectrophotometry confirmed this difference in the proteins, but unfortunately these 
proteins were nuclear and cytosol contaminants rather than membrane proteins.  
Although the results of the differences found were not applicable for the ultimate 
purpose of my research, Hypothesis 2 must be accepted: membrane protein profiles 
of FNRBCs and AARBCs do differ. 
 
Hypothesis 3:  Unique surface antigen proteins that are differentially expressed 
between fetal nucleated red blood cells and adult anucleate erythrocytes can be 
identified.   
 
This is the first report detailing the membrane proteome of a unique human cell type, 
the fetal primitive erythroblast; and the comparison of its membrane proteome to that 
of the adult anucleate erythrocyte.  Using MALDI-TOF/TOF-MS, membrane proteins 
unique to both cell types were identified: 4 uniquely expressed in FNRBCs, and 18 
unique to AARBCs (Chapter 5).  Of the 4 differentially expressed in FNRBCs, three 
were putative with regards their membrane localisation, and only 1 was a known 
membrane peripheral protein.  Unfortunately, it is an intracellular protein and not 
suitable for my purpose of cell sorting for non-invasive prenatal diagnosis.  In 
contrast, of the 18 AARBC unique proteins identified, four are known to be 
membrane integral proteins and possible candidates for antibody recognition and cell 
sorting.  Band 3 however appears to be the most promising target.  It is a well 
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characterised protein (see Chapter 5, Additional Notes on Band 3), with known 
extracellular domains and antigenic epitopes.  It should be further evaluated as a 
potential target for AARBC depletion (negative selection of FNRBCs) and as a 
replacement for density gradient centrifugation during the initial steps of non-invasive 
prenatal diagnosis.  The results of Chapter 5 confirm that unique, differentially 
expressed surface antigen proteins present on either FNRBC or AARBC can be 
characterised.  Thus, Hypothesis 3 is accepted.   
 
6.2 Implication of results in context of non-invasive prenatal 
diagnosis 
 
Non-invasive testing is the Holy Grail of prenatal diagnosis, and it is clear that 
women prefer antenatal testing in the first trimester (Chapter 1).  Whereas 
downstream processing of fetal cell identification (by ε-globin) and diagnosis (by 
cFISH) has been resolved (Choolani et al., 2001), fetal cell enrichment remains a 
challenge amongst investigators in this field worldwide.   
 
The one step during the enrichment process that is associated with the greatest cell 
loss is density gradient centrifugation (Choolani et al., 2003).  It is recognised that 
elimination of this mechanical step and replacement by an immunsorting strategy 
would enhance fetal rare cell recovery.  Thus, identification of unique, differentially 
expressed surface membrane proteins and antigens is the key to improved 
enrichment protocols.  Although my research did not reveal any suitable surface 
membrane proteins that could be exploited for the positive selection of FRNBCs from 
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maternal blood, it did show that there are potential targets for depletion (negative 
selection) of AARBCs.  This would represent a direct replacement of the density 
gradient centrifugation step in the overall enrichment protocol for fetal erythroblasts 
from first trimester maternal blood.   
 
6.3 Limitations of this research 
Membrane sample preparations were limited by the small numbers of cells available 
after isolation from trophoblast tissue obtained at elective termination of pregnancy.  
FNRBC cell numbers could be increased if more invasive techniques such as direct 
intracardiac puncture were performed under ultrasound guidance during TOP 
(Choolani et al., 2001).  It is not clear if this fetal cell collection method would be 
acceptable in Singapore.    
 
Other proteomics approaches such as 2-dimensional gel electrophoresis and liquid 
phase separation methods could be explored to increase the number of membrane 
proteins identified possibly to several hundreds.  It is unclear if this would make data 
analysis and target membrane protein identification easier, or more difficult.   
 
6.4 Directions for future research 
Enrichment of primitive erythroblasts derived from first trimester maternal blood is the 
key to make non-invasive prenatal diagnosis a clinical reality.  Potential targets have 
been identified during the course of this study.  We have verified one of the targets 
(Band 3; Note:  this investigation was carried out as an independent study by another 
student as part of this PhD) using immunoblotting studies and immunocytochemistry 
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(Figure 6.1 a,b).  In his study, FNRBC and AARBC membrane proteins were 
extracted as per my protocol.  Immunoblotting studies (Western blot) showed an 
absence of Band 3 in FNRBC membrane extracts, but Band 3 was present in 
AARBCs.  Using immunocytochemistry, Band 3 was found to be present in FNRBC 
samples, but in a significantly lower expression level than in AARBCs.  This 
contrasting result could be due to (1) false positive staining in the FNRBC samples, 
(2) presence of Band 3 intracellularly, or (3) a low level expression detectable in situ, 
but not in extracted membrane samples.   



























Figure 6.1a. Immunoblotting studies (western blotting) on AARBC and FNRBC 
membrane proteins.  Lanes 1 and 2 correspond to AARBC and FNRBC membrane 
proteins extracted using Freeze-thawing-Dounce homogenisation method and 
separated on 10% SDS-PAGE gel (bands were detected using silver stain).  Lanes 3 
and 4 correspond to immunoblotting studies carried out on nitrocellulose membrane 
using anti-band 3 monoclonal antibody on AARBC and FNRBC samples respectively.  
The above study confirmed the presence of band 3 protein in AARBC (indicated by 
arrow in the figure) while the same is absent in FNRBC membrane protein gels. The 
above results confirmed the results observed using MS studies.  (Figure courtesy of 
Mr Zhang Huo Ming) 
 
Further work (e.g. immunoblotting and immunocytochemistry) could be done to 
validate other proteins (4 uniquely expressed in FNRBCs, and 18 unique to AARBCs, 
























Figure 6.1b. Immunocytochemistry studies using mouse anti-human band 3 (CD233) 
monoclonal antibody; AARBC and lymphocyte served as positive and negative 
controls respectively; FNRBC (top right) is internal negative control (no primary 
antibody was added to this sample, rest of the procedure is the same). AARBCs 
were deeply stained while FNRBC absorbed only a very little stain during the 
process.  (Figure courtesy of Mr Zhang Huo Ming) 
 
It is anticipated that after all the potential targets have been investigated, antibodies 
to the most promising surface antigens would be conjugated to MACS beads for in 
vitro model mixture testing of the enrichment/depletion efficiency of selected antigens.  
If effective, these would then be used for testing in clinical samples to enrich fetal 
primitive erythroblasts from first trimester maternal blood for non-invasive prenatal 
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Appendix A: Appendix to Chapter 4 
Figure A4.1 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on a normal phase (NP20) chip surface. (a) (b) (c) 
illustrate protein mass spectra at different laser intensity, 240, 260 and 295, 
respectively. +H denotes that the respective peak is singly charged. +2H denotes 
that the respective peak is doubly charged and this peak is not taken into 
consideration for comparison. 
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Figure A4.2 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on a reversed phase (H4) chip surface. (a) (b) (c) 
illustrate protein mass spectra at different laser intensity, 240, 260 and 295, 
respectively. +H denotes that the respective peak is singly charged. +2H denotes 
that the respective peak is doubly charged and this peak is not taken into 
consideration for comparison. Peaks were detected only at laser intensity 295 for 
the second FNRBC membrane protein sample, as shown in (c). 
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Figure A4.3 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on a strong anion exchange (SAX2) chip surface. 
(a) (b) (c) illustrate protein mass spectra at different laser intensity, 240, 260 and 
295, respectively. +H denotes that the respective peak is singly charged. 
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(b) Laser intensity at 260 
20000 30000 40000 50000 60000





























 (c) Laser intensity at 295 
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Figure A4.4 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on a weak cation exchange (WCX2) chip surface. 
(a) (b) (c) illustrate protein mass spectra at different laser intensity, 240, 260 and 
295, respectively. +H denotes that the respective peak is singly charged. 
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(b) Laser intensity at 260 
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(c) Laser intensity at 295 
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Figure A4.5 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on an immobilized metal affinity capture (IMAC 
Cu2+) chip surface. (a) (b) (c) illustrate protein mass spectra at different laser 
intensity, 240, 260 and 295, respectively. +H denotes that the respective peak is 
singly charged. +2H denotes that the respective peak is doubly charged and this 
peak is not taken into consideration for comparison. 
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(c) Laser intensity at 295 
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Figure A4.6 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on an immobilized metal affinity capture (IMAC 
Mn2+) chip surface. (a) (b) (c) illustrate protein mass spectra at different laser 
intensity, 240, 260 and 295, respectively. +H denotes that the respective peak is 
singly charged.  
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Figure A4.7 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on an immobilized metal affinity capture (IMAC 
Ni3+) chip surface. (a) (b) (c) illustrate protein mass spectra at different laser 
intensity, 240, 260 and 295, respectively. +H denotes that the respective peak is 
singly charged. +2H denotes that the respective peak is doubly charged and this 
peak is not taken into consideration for comparison. 
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(c) Laser intensity at 295 
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Figure A4.8 Representative protein mass spectra of AARBC membrane and 
FNRBC membrane processed on an immobilized metal affinity capture (IMAC 
Mg2+) chip surface. (a) (b) (c) illustrate protein mass spectra at different laser 
intensity, 240, 260 and 295, respectively. +H denotes that the respective peak is 
singly charged. +2H denotes that the respective peak is doubly charged and this 
peak is not taken into consideration for comparison. 
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(c) Laser intensity at 295 
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Appendix B: Appendix to Chapter 5 
Table B5.1 Proteins identified from anucleate RBC membrane pellet fraction by 
SDS-PAGE and MALDI-TOF/TOF 
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9
















16 22 0 











15 21 0 
R14* gi|4758794 775749 nebulin [Homo 
sapiens] 
5 40 0 
R15 gi|5114049 47531 flotillin [Homo 
sapiens] 
36 16 6 
R15 gi|5031699 47554 flotillin 1 [Homo 
sapiens] 
36 16 6 
R15* gi|4758794 775749 nebulin [Homo 
sapiens] 
6 45 0 





13 19 1 




15 16 0 
R15* gi|4265638
3





20 14 1 
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sapiens] 






13 16 1 




8 25 1 





11 20 1 
R15* gi|2992541 205150 periplakin 
[Homo sapiens] 
11 20 1 
R15* gi|1419500
5








11 20 1 
R15* gi|2134996 311793 desmoplakin I – 
human 
8 24 1 
R15* gi|627367 312580 desmoyokin - 
human 
(fragments) 



















sequence            
[Homo sapiens] 
13 16 0 
R15* gi|37258 84042 Tpr [Homo 
sapiens] 
17 14 0 







52 22 4 
R16 gi|1527750
3
40536 ACTB protein 
[Homo sapiens] 












41321 actin, beta 
[Homo sapiens] 
49 20 3 




48 20 3 




24 13 2 
R16* gi|4265643
1
60787   similar to 
FKSG30 
[Homo sapiens] 
16 8 2 
R17 gi|4507553 40658 tropomodulin 1 
[Homo sapiens] 
37 12 4 
R17 gi|1280365
1
40657 Tropomodulin 1 
[Homo sapiens] 
32 11 4 
R17 gi|1427773
9









19 8 4 
R17 gi|4507021 102013 solute carrier 












11 11 4 
R17* gi|1173565 245291 golgin-245 
[Homo sapiens] 
11 24 0 
R17* gi|1236759 256666 256 kD golgin 
[Homo sapiens] 
9 23 0 
R17* gi|4758794 775749 nebulin [Homo 
sapiens] 






19 13 0 
R17* gi|4266066
5





17 13 0 
R18 gi|1427773
9











R18 gi|4507021 102013 solute carrier 












10 10 5 








37 13 1 
R18 gi|28614 39706 aldolase A 
[Homo sapiens] 
37 13 1 
R18 gi|229674 39720 Aldolase A 
(E.C.4.1.2.13) 







15 22 0 











14 22 0 
R18* gi|4758794 775749 nebulin [Homo 
sapiens] 
5 40 1 
R18* gi|1173565 245291 golgin-245 
[Homo sapiens] 






18 14 0 
R18* gi|4266066
5





18 14 0 
R18* gi|7023190 127497 unnamed 
protein product 
[Homo sapiens] 























12 18 0 
R18* gi|1236759 256666 256 kD golgin 
[Homo sapiens] 
11 23 0 
R18* gi|2052111
7
153856  KIAA0642 
protein [Homo 
sapiens] 
12 18 0 
R19 gi|4507021 102013 solute carrier 












16 16 5 
R19 gi|1427773
9









20 9 5 
R19 gi|1094704
0






10 18 2 
R19 gi|105337 207138 ankyrin 1, 
erythrocyte 
splice form 2 – 
human 
10 18 2 
R19 gi|1845265 204538 ankyrin [Homo 
sapiens] 
9 17 2 
R19 gi|1360744 204518 ankyrin 1, 
erythrocyte 
splice form 3 – 
human 
9 17 2 
R19 gi|1094703
6






9 17 2 
R19 gi|1094703 207346 ankyrin 1 9 17 2 
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24 12 0 
R19* gi|4758794 775749 nebulin [Homo 
sapiens] 
5 40 0 
R19* gi|6683717 76358 KIAA0565 
protein [Homo 
sapiens] 






12 18 1 
R19* gi|1280447
3
71171 NLN protein 
[Homo sapiens] 
17 13 0 




39 12 7 




39 12 6 
R20 gi|35053 35698 uracil DNA 
glycosylase 
[Homo sapiens] 
34 9 5 
R21 gi|4507021 102013 solute carrier 












12 7 2 
R21 gi|1427773
9








14 4 2 
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Band-3 Protein 




24 6 2 




24 6 2 
R21 gi|35053 35698 uracil DNA 
glycosylase 
[Homo sapiens] 
20 5 2 
R22 gi|181184 31860 stomatin 
peptide 










37 13 6 
R22 gi|1103842 32741 band 7.2b 
stomatin 













36 11 1 














binding protein    
P33/P41)(P33/
41) 
33 11 1 
R22 gi|189617 36262 protein PP4-X 
 
33 11 1 









33 11 1 
R22* gi|3851586 138662 chromosome-
associated 












chain 14 [Homo 
sapiens] 
11 24 0 
R22* gi|1236759 256666 256 kD golgin 
[Homo sapiens] 






13 21 0 
R22* gi|1173565 245291   golgin-245 
[Homo sapiens] 
10 25 0 


















13 19 0 
R23 gi|181184 31860 stomatin 
peptide 










40 17 5 
R23 gi|1103842 32741 band 7.2b 
stomatin 






35 15 5 
R23 gi|2168699
5







10 3 1 
R24 gi|181184 31860 stomatin 
peptide 










48 14 1 
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R24 gi|1103842 32741 band 7.2b 
stomatin 

















7 37 0 
R24* gi|4266246
0
145199 KIAA0542 gene 
product [Homo 
sapiens] 





antigen 1 eA 
[Homo sapiens] 
6 36 0 
R24* gi|1173565 245291 golgin-245 
[Homo sapiens] 
110 24 0 
R24* gi|1236759 256666 256 kD golgin 
[Homo sapiens] 

















6 35 0 
R24* gi|1205991 350062 Nebulin 8 26 0 
R24* gi|2203567
4














with coiled coil 
domains and 
ankyrin repeats   
[Homo sapiens] 






12 19 0 
R24* gi|4503613 232789 envoplakin 
[Homo sapiens] 
10 23 0 












29 8 4 
R25 gi|1103842 32741 band 7.2b 
stomatin 






24 7 4 
R26 gi|181184 31860 stomatin 
peptide 










27 9 5 
R26 gi|1103842 32741 band 7.2b 
stomatin 






21 7 5 
R27* gi|4758794 775749 nebulin [Homo 
sapiens] 
7 40 0 
R28* gi|4758794 775749 nebulin [Homo 
sapiens] 














35 10 0 
R30 gi|181184 31860 stomatin 
peptide 










33 8 1 
R30 gi|1103842 32741 band 7.2b 
stomatin 
32 8 1 
R31* gi|4025514
3




19 17 0 
 
Protein bands with * are those identified with significant score but the MW of the 
proteins are larger than the range of the gel bands. 
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Table B5.2 Proteins identified from FNRBC membrane pellet fraction by SDS-
PAGE and MALDI-TOF/TOF 



















N1 gi|19924129 154823 RAD50 homolog 
isoform 1 [Homo 
sapiens] 
18 20 0 
N1 gi|1174412 280884 Spectrin alpha chain, 
erythrocyte (Erythroid 
alpha-spectrin) 
13 25 0 






12 24 0 
N1 gi|19924131 139145 RAD50 homolog 
isoform 2 [Homo 
sapiens] 
17 17 0 
N2 gi|338440 243419 spectrin Rouen (beta-
220-218) mutant 
coding sequence 
13 24 0 
N2 gi|134798 247025 Spectrin beta chain, 
erythrocyte (Beta-I 
spectrin) 
13 24 0 
N2 gi|27413156 247026 spectrin, beta, 
erythrocytic (includes 
spherocytosis, clinical 
type I); Spectrin, 
beta, erythrocytic; 
spectrin, beta, 
erythrocytic            
(includes 
sperocytosis, clinical 
type I) [Homo 
sapiens]. 
13 24 0 
N2* gi|14195007 533408 Plectin 1 (PLTN) 
(PCN) 
(Hemidesmosomal 
protein 1) (HD1) 
8 32 0 
N2 gi|1845265 204538 ankyrin [Homo 
sapiens] 
13 20 0 
N2 gi|1360744 204518 ankyrin 1, erythrocyte 
splice form 3 – 
human 
13 20 0 
N2 gi|10947036 204488 ankyrin 1 isoform 4; 
ankyrin-1, 
erythrocytic; ankyrin-
R [Homo sapiens] 
13 20 0 
N2 gi|178646 207138 ankyrin 13 20 0 
N2 gi|10947040 207108 ankyrin 1 isoform 3; 
ankyrin-1, 
erythrocytic; ankyrin-
R [Homo sapiens] 
13 20 0 
N2 gi|105337 207138 ankyrin 1, erythrocyte 13 20 0 
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splice form 2 – 
human 
N2 gi|10947038 207346 ankyrin 1 isoform 1; 
ankyrin-1, 
erythrocytic; ankyrin-
R [Homo sapiens] 
13 20 0 
N2 gi|226788 207332 erythrocyte ankyrin 13 20 0 
N2 gi|10947042 189977 ankyrin 1 isoform 2; 
ankyrin-1, 
erythrocytic; ankyrin-
R [Homo sapiens] 
14 19 0 




myosin heavy chain 
[Homo sapiens] 
14 26 0 
N3 gi|27498927 103525 similar to CG5882-PA 
[Homo sapiens] 
18 17 1 
N5 gi|12314195 131630 bA255A11.3 (novel 
protein similar to 
KIAA1074) [Homo 
sapiens] 
14 16 1 
N6 gi|12314195 131630 bA255A11.3 (novel 
protein similar to 
KIAA1074) [Homo 
sapiens] 
16 16 0 
N7 gi|2687853 155341 RAD50 homologue 
hsRAD50 [Homo 
sapiens] 
17 22 0 
N7 gi|19924129 154823 RAD50 homolog 
isoform 1 [Homo 
sapiens] 
15 20 0 
N7 gi|19924131 139145 RAD50 homolog 
isoform 2 [Homo 
sapiens] 
15 19 0 
N7* gi|1205991 350062 Nebulin 10 26 0 




simplex 1 (Ogna) 
[Homo sapiens] 
7 33 0 




simplex 1 (Ogna) 
[Homo sapiens] 
7 33 0 




simplex 1 (Ogna) 
[Homo sapiens] 
7 33 0 
N8 gi|4503483 96246 eukaryotic translation 
elongation factor 2; 
polypeptidyl-tRNA 
translocase [Homo 
9 9 2 
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sapiens] 
N9 gi|40254816 85020 heat shock 90kDa 
protein 1, alpha; heat 
shock 90kD protein 1, 
alpha [Homo sapiens] 
23 18 0 
N9 gi|72219 85006 heat shock protein 
90-alpha – human 
23 18 0 
N9 gi|20149594 83554 heat shock 90kDa 
protein 1, beta; heat 
shock 90kD protein 1, 
beta; Heat-shock 
90kD protein-1, beta 
[Homo sapiens] 
24 18 0 
N9 gi|72222 83584 heat shock protein 
90-beta [validated] – 
human 
24 18 0 
N9 gi|11277141 85189 hypothetical protein 
DKFZp761K0511.1 – 
human 
24 18 0 
N9 gi|18605741 73952 HSPCA protein 
[Homo sapiens] 
22 17 0 
N9 gi|39644662 75088 HSPCB protein 
[Homo sapiens] 
24 16 0 
N9* gi|2072972 150044 putative p150 [Homo 
sapiens] 
15 19 0 
N9* gi|2072953 149997 putative p150 [Homo 
sapiens] 
14 18 0 
N9 gi|21755884 76398   unnamed protein 
product [Homo 
sapiens] 
22 14 0 
N9* gi|1196432 140501 unknown protein 14 17 0 
N9* gi|26080431 209494 hypothetical protein 
FLJ12735 [Homo 
sapiens] 
12 21 0 
N11 gi|5729877 71082 heat shock 70kDa 
protein 8 isoform 1; 
heat shock cognate 
protein, 71-kDa; heat 
shock 70kd protein 1 
30 17 1 
N11 gi|13938297 64733 HSPA8 protein 
[Homo sapiens] 
26 13 0 
N12* gi|34364818 197943 hypothetical protein 
[Homo sapiens] 
12 21 0 
N12* gi|21732890 198004 hypothetical protein 
[Homo sapiens] 
13 20 0 
N12* gi|34364971 197966 hypothetical protein 
[Homo sapiens] 
13 19 0 
N12* gi|22267939 193847 nebulin-related 
anchoring protein 
[Homo sapiens] 
12 19 0 
N12* gi|34364735 197961 hypothetical protein 
[Homo sapiens] 
12 19 0 
N12* gi|30268204 197897 hypothetical protein 
[Homo sapiens] 
12 19 0 
N13 gi|10438291 87054 unnamed protein 
product [Homo 
sapiens] 
18 17 0 
N13* gi|42658517 221954 similar to superfast 
myosin heavy chain 
12 24 0 
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[Homo sapiens] 
N13* gi|42658064 221966 hypothetical protein 
FLJ22037 [Homo 
sapiens] 
12 24 0 
N13* gi|19924129 154823 RAD50 homolog 
isoform 1 [Homo 
sapiens] 
14 19 1 
N14 gi|18088719 50096 Beta 5-tubulin [Homo 
sapiens] 
26 13 1 
N14* gi|17426161 603087 macrophin 1 isoform 
4 [Homo sapiens] 
7 32 0 
N14* gi|24308169 473776 axonemal heavy 
chain dynein type 3 
[Homo sapiens] 
7 29 0 






29 13 0 
N14* gi|5902012 294918 myosin IXA [Homo 
sapiens] 
10 25 0 
N14 gi|2119276 49362 beta-tubulin - human 
(fragment) 
23 12 0 
N14 gi|135470 50055 Tubulin beta-5 chain 
(Tubulin 5 beta) 
23 11 0 
N15 gi|15277711 43282 translation elongation 
factor 1 alpha 1-like 
14 [Homo sapiens] 
16 8 2 
N15 gi|4503471 50451 eukaryotic translation 
elongation factor 1 
alpha 1; eukaryotic 
translation elongation 
factor 1 alpha 1-like 
14; CTCL tumor 
antigen; translation 
elongation factor 1 
alpha 1-like 14; 
prostate tumor-
inducing protein 1; 
EF1a-like protein; 




factor            1-alpha; 
elongation factor 1 
alpha subunit; 
elongation factor Tu      
[Homo sapiens] 
14 8 2 
N15 
 
gi|31092 50437 unnamed protein 
product [Homo 
sapiens] 
14 8 2 





12 6 2 
N15 gi|4503475 50780 eukaryotic translation 
elongation factor 1 
9 5 2 
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alpha 2; elongation       
factor-1 alpha; statin 
S1; elongation factor 
1-alpha 2 [Homo           
sapiens]. 
N15 gi|1220311 47768 elongation factor-1 
alpha 
7 3 2 
N16* gi|5911842 80795 dJ398G3.1.1 (novel 
protein containing CH 
(Calponin homology)    
domains (contains 
KIAA1756), variant 1) 
[Homo sapiens]. 
20 15 0 
N17 gi|4501887 42108 actin, gamma 1 
propeptide; actin, 
cytoplasmic 2; 




20;         cytoskeletal 
gamma-actin [Homo 
sapiens]  
32 14 0 
N17* gi|38348386 63585 FLJ36760 protein 
[Homo sapiens] 
21 13 0 
N17* gi|4758794 775749 nebulin [Homo 
sapiens] 
6 40 0 
N17 gi|15277503 40536 ACTB protein [Homo 
sapiens] 
28 12 0 
N17 gi|16924319 40819 Unknown (protein for 
IMAGE:3538275) 
[Homo sapiens] 
28 12 0 
N17 gi|14250401 41321 actin, beta [Homo 
sapiens] 
28 12 0 
N17 gi|4501885 42052 beta actin; beta 
cytoskeletal actin 
[Homo sapiens] 
27 12 0 
N17 gi|16359158 42078 Beta actin [Homo 
sapiens] 
27 12 0 
N18* gi|32698944 79532 hypothetical protein 
FLJ36144 [Homo 
sapiens] 
23 15 0 
N19* gi|33563340 228889 myosin, heavy 
polypeptide 14; 
nonmuscle myosin 
heavy chain II-C; 
myosin heavy chain 
14 [Homo sapien] 
12 23 0 
N20* gi|8979803 148339 dJ37C10.5 
(KIAA0445) [Homo 
sapiens] 
13 17 1 
N21 gi|14043072 37464 heterogeneous 
nuclear 
ribonucleoprotein 




nuclear            
ribonucleoprotein 
26 10 1 
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particle A2 protein 
[Homo sapiens] 
N22** gi|223114 15435 hemoglobin Gower 2 
epsilon 
55 8 1 
N22* gi|14211720 140278 desmuslin [Homo 
sapiens] 
14 17 0 
N22* gi|12314195 131630 bA255A11.3 (novel 
protein similar to 
KIAA1074) [Homo 
sapiens] 
13 16 0 
N23 gi|12654655 33667 NAPA protein [Homo 
sapiens] 
39 12 1 





39 12 1 
N23** gi|223114 15435 hemoglobin Gower 2 
epsilon 
55 8 1 
N23 gi|7459532 33837 alpha SNAP – human 36 11 0 
N23 gi|33873882 26401 RABEP1 protein 
[Homo sapiens] 
40 9 0 
N23** gi|34533027 16026 unnamed protein 
product [Homo 
sapiens] 
48 7 1 
N24* gi|11360156 62664 hypothetical protein 
DKFZp434P011.1 - 
human (fragment) 
27 14 0 
N24* gi|11229138 63240 bB152O15.1 (TOM 
(putative 
mitochondrial outer 
membrane protein        
import receptor 
(similar to yeast pre-
mRNA splicing 
factors            
Prp1/Zer1 and Prp6)) 
[Homo sapiens] 
27 14 0 
N25** gi|223114 15435 hemoglobin Gower 2 
epsilon 
42 7 1 
N26** gi|3318949 16118 Chain E, Human 
Embryonic Gower Ii 
Carbonmonoxy 
Hemoglobin 
55 9 1 
N26** gi|4885393 16249 epsilon globin [Homo 
sapiens] 
55 9 1 
N26* gi|223114 15435 hemoglobin Gower 2 
epsilon 
37 7 1 
N27 gi|3318949 16118 Chain E, Human 
Embryonic Gower Ii 
Carbonmonoxy 
Hemoglobin 
55 9 1 
N27 gi|4885393 16249 epsilon globin [Homo 
sapiens] 
55 9 1 
N27 gi|223114 15435 hemoglobin Gower 2 
epsilon 
37 7 1 
N28 gi|3318949 16118 Chain E, Human 
Embryonic Gower Ii 
Carbonmonoxy 
57 9 2 
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Hemoglobin 
N28 gi|4885393 16249 epsilon globin [Homo 
sapiens] 
57 9 2 
N28 gi|223114 15435 hemoglobin Gower 2 
epsilon 
51 8 2 
N28* gi|12314195 131630 bA255A11.3 (novel 
protein similar to 
KIAA1074) [Homo 
sapiens] 
16 17 0 
N28* gi|2104553 215017 Myosin heavy chain 
(MHY11) (5'partial) 
[Homo sapiens] 
13 22 0 
N28 gi|7512576 21357 hypothetical protein 
DKFZp434F076.1 - 
human (fragment) 
38 9 0 
 
Protein bands with * are those identified with significant score but the MW of the 
proteins are larger than the range of the gel bands. Protein bands with ** are 
those identified with significant score but the MW of the proteins are smaller than 
the range of the gel bands (only haemoglobin is included). Mascot sequence 
query searching result for band N4 only hits one protein 60S ribosomal protein 
L36 with MW of 12,302 Da with p<0.05. As the MW of this protein is smaller than 
the range of the gel bands and there is no ion score supporting the identification, 
this result was not regarded as positive identification.  Highlighted proteins were 
those identified by SELDI. 
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